Metabolic analysis of neural tube defects. by Burren, K.A.
2809662241
REFERENCE ONLY
pVo
GHT
thesis accepted for a Higher Degree of the University of London. It is an 
ted typescript and the copyright is held by the author. All persons 
l this thesis must read and abide by the Copyright Declaration below.
HT DECLARATION
3 that the copyright of the above-described thesis rests with the author 
) quotation from it or information derived from it may be published without 
itten consent of the author.
iy not be lent to individuals, but the Senate House Library may lend a 
)roved libraries within the United Kingdom, for consultation solely on the 
f those libraries. Application should be made to: Inter-Library Loans, 
ise Library, Senate House, Malet Street, London WC1E 7HU.
CTION
of London theses may not be reproduced without explicit written 
from the Senate House Library. Enquiries should be addressed to the 
ution of the Library. Regulations concerning reproduction vary according 
of acceptance of the thesis and are listed below as guidelines.
3 1962. Permission granted only upon the prior written consent of the 
r. (The Senate House Library will provide addresses where possible).
1974. In many cases the author has agreed to permit copying upon 
etion of a Copyright Declaration.
1988. Most theses may be copied upon completion of a Copyright 
ration.
onwards. Most theses may be copied.
> com es within category D.
This copy has been deposited in the Library of v
This copy has been deposited in the Senate House Library,
Senate House, Malet Street, London WC1E 7HU.
Chilly
UNIVERSITY OF LONDON THESIS
Year "10 0 ^  Name of Author ^

Metabolic Analysis
of Neural Tube 
Defects
Katie Ann Burren
Neural Development 
Institute of Child Health 
University College London
May 2007
1
UMI Number: U591869
All rights reserved
INFORMATION TO ALL USERS  
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U591869
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition ©  ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
I, Katie Ann Burren, confirm that the work presented in this thesis is 
my own. Where information has been derived from other sources, I 
confirm that this has been indicated in the thesis.
Signature______________________________
Date
Abstract
Neural tube defects (NTDs), such as exencephaly and spina bifida, occur when the 
neural tube fails to close properly during embryonic development. Folic acid 
supplementation has been shown to effectively reduce the occurrence of NTDs and low 
folate is a known risk factor for human NTDs. However despite extensive research, the 
mechanism explaining how the folate status affects the incidence of NTDs remains 
unknown.
One effect of sub-optimal folate could be suppression of the methylation cycle, which is 
interlinked with the folate cycle. To explore this hypothesis, a method has been 
developed to quantitatively measure the substrate, S-Adenosylmethionine (SAM), and 
the product, S-Adenosylhomocysteine (SAH), of methylation reactions in neurulation- 
stage mouse embryos by Liquid Chromatography Tandem Mass Spectrometry (LC- 
MS/MS). To investigate the link between methylation perturbation and neural tube 
defects, the abundance of SAM and SAH has been quantified in a series of 
experimental models and human NTD cell lines.
Using a folate-deficient diet, this study also investigates folate deficiency using mouse 
models (splotch and curly tail) for NTDs. Results illustrate that folate deficiency, in both 
mouse models, caused an increase in the incidence of neural tube defects and, 
embryos were growth retarded. To examine the effect the folate deficient diet was 
having on endogenous folate metabolism, embryonic folate levels were analysed, in 
addition to maternal folate. Furthermore, using the established Ic-ms/ms method, the 
effect of folate deficiency on the abundance of SAM and SAH was determined.
Increasing evidence suggests that myo-inositol may prove effective in preventing 
NTDs, in conjunction with folic acid. Thus, a double-blind, randomised clinical trial has 
been designed to investigate this and, in order to monitor patient compliance an LC- 
MS/MS method has been developed to quantify myo-inositol in urine.
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CHAPTER 1
Introduction
1.1 Neurulation
Neurulation is a major developmental event of embryogenesis, that results in the 
formation of the neural tube; the embryonic precursor of the brain and spinal cord. 
Neural tube defects (NTDs), which occur due to failure of neurulation, result in life 
threatening and debilitating conditions which affect approximately 1 per 1000 births 
worldwide (Borman et al., 1986;Carter, 1974). Dietary supplementation with folic acid 
(FA) offers a major breakthrough in the prevention of NTDs, however the mechanism of 
prevention remains to be identified (Blom et al., 2006).
1.1.1 Primary and Secondary Neurulation
The process of neurulation is classically sub-divided into two parts; primary and 
secondary neurulation. Primary neurulation is the transformation of the flat ectodermal 
neural plate into the closed cylindrical neural tube (Figure 1.1). During gastrulation, 
cells that do not migrate through the node form the ectoderm layer, from which the 
neural plate is derived. Following induction of the neural plate, it elongates by cell 
division (Sausedo et al., 1997) and a process known as convergent extension whereby 
cells move towards the midline and extend along the body axis (Wallingford and 
Harland, 2002) (Figure 1.1).
The lateral borders of the ectodermal neural plate thicken and elevate to form neural 
folds (Figure 1.1), that subsequently bend towards the midline through the formation of 
median and/or dorsal-lateral hinge points (Carroll et al., 2003;Copp et al., 2003;Sadler,
2005). Fusion of the apposed neural folds then completes neural tube closure (Sadler, 
1978). During secondary neurulation, the mesenchymal tail bud cells coalesce and 
become epithelial reorganising around a lumen to form a neural tube continuous with 
the remainder of the neural tube formed by primary neurulation (Schoenwolf, 1979).
In mouse embryogenesis, primary neurulation initiates at embryonic day 8, when the 
embryo is at the 6 to 7 somite stage. The process begins at the boundary between the 
hindbrain and the cervical region, an initiation event known as closure 1 (Copp et al., 
2003;Greene and Copp, 2006). Closure spreads both rostrally into the hindbrain to 
initiate cranial neural tube closure and caudally into the spinal region to initiate spinal 
neural tube closure (Figure 1.2). The second point of de novo neural tube closure 
(closure 2) occurs at the forebrain-midbrain barrier around the 10-somite stage and a 
third closure site (closure 3) follows rapidly at the rostral extremity of the forebrain 
(Figure 1.2). Although the location of closure 1 and 3 is uniform, the exact location of 
closure 2 does vary between mouse strains (Fleming and Copp, 2000). Thus, strains
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with a more caudal location of closure 2 are relatively resistant to NTDs, whereas 
strains with a rostrally positioned closure 2 exhibit increased susceptibility to NTDs.
Figure 1.1. Primary neurulation. (A) A transverse view of neural tube closure. (B) Processes 
during primary neurulation. 1, the arrows in the neural groove indicate the narrowing and 
elongation, resulting in convergent extension; 2, elevation of the neural wall; 3, convergence of 
the neural fold; 4, fusion. MHP, medial hinge point; LHP, dorsolateral hinge point. Taken from 
(Van der Put et al., 2001).
Neural tube closure spreads from the initiation sites into neighbouring regions. Open 
regions are termed neuropores and these gradually shorten as closure proceeds. The 
completion of cranial neural tube closure occurs at the anterior neuropore and the 
hindbrain neuropore (Figure 1.2), around the 15 somite stage (embryonic day 9.5). As 
cranial neurulation is occurring, neural tube closure also progresses from closure 1 in a 
caudal direction, through the spinal region (Figure 1.2). Primary neurulation is 
completed by closure of the posterior neuropore (PNP) at embryonic day 10, at the 31 
to 33 somite stage. Secondary neurulation forms the remainder of the spinal cord, 
caudal to the lowest sacral level of primary neurulation.
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Figure 1.2. Neural tube closure in mouse embryos initiates at three distinct de novo 
closure sites. ‘ Closure 1 occurs initially at the cervical/hindbrain boundary, “ Closure 2 occurs 
at the forebrain/midbrain boundary, ‘ “ Closure 3 initiates at the rostral extremity of the forebrain. 
Failure of closure 2 to initiate, or disruption of closure at the anterior and hindbrain neuropore 
results in exencephaly. Failure of PNP closure results in spina bifida.
In human embryos, neural tube closure occurs during the fourth week of human 
embryonic development, before most women even know they are pregnant (Campbell 
et al.. 1986). Like mouse embryos, primary neurulation in human embryos appears to 
occur by a multi-site closure process. Although the exact location of the closure sites 
in human embryos remains to be definitively identified, the positions of the closure sites 
do appear to be different to mice (De Marco et al., 2006).
1.1.2 Neural Tube Defects (NTDs)
Neural tube defects (NTDs) occur when the neural tube fails to close. The most 
common type of NTD, and the focus of this study, occurs in the cranial region due to 
defective primary neurulation (De Marco et al., 2006). Cranial neural tube defects, 
referred to as exencephaly (EX; Figure 1.3), arise when the cranial neural tube fails to 
close in the developing brain, often as a result of failure of closure 2 (Copp, 2005). 
Exposure of cranial tissue to the amniotic fluid leads to neural degeneration, resulting 
in the condition anencephaly (Matsumoto et al., 2002). Unless terminated or 
miscarried, the pregnancy may be still born or the baby will die shortly after birth.
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Figure 1.3. Images of exencephaly in mouse embryos. CD1 non-mutant mouse embryo at 
embryonic day (E) 9.5 treated with the teratogenic agent, azacytidine, which causes 
exencephaly (A, side view of the embryo; B dorsal view of the neural tube at the cranial and 
upper sacral level). Curly tail mutant embryo at embryonic day (E) 15.5 with exencephaly and 
open spina bifida (Taken from (Copp et al., 2003)). Thin arrow in a, b and c, midbrain 
exencephaly; arrowhead in c, open spina bifida; thick arrow in c, curled tail.
Failure of primary neurulation in the spinal neural tube is known as myelomeningocele 
or, more commonly, spina bifida (Copp et al., 2003;Seller, 1981 ;Seller, 1994a). This 
arises when the caudal progression of neural tube closure fails to complete and the 
posterior neuropore remains open (Figure 1.3). Human fetuses with spina bifida are 
often viable. However, the individual will suffer from physical and developmental 
disabilities of varying severities, due to abnormal neural innervation below the lesion. 
Other types of NTDs include spina bifida occulta and craniorachischisis (Copp et al., 
2003).
1.2 Causes of NTDs in humans
NTDs have been the focus of much research but a common mechanism explaining 
how NTDs arise has yet to be described. In most cases, the underlying genetic 
predisposition is unknown and very few cases of multiple NTDs in large families have 
been described. When studied, they display complex inheritance patterns (Copp, 
1994). The cause of NTDs may involve a combination of various polymorphisms which 
can then be influenced by external environmental factors. Thus, some cases of NTD 
may occur by the summation and/or interaction of several predisposing factors which 
individually are insufficient to cause NTDs. Furthermore, the causes of NTDs which 
occur in association with other malformations or as part of a syndrome are likely to 
differ from the causes of NTDs that occur as isolated defects (Rasmussen and Frias,
2006).
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1.2.1 Genetic predisposition
Genetic studies of human NTDs have revealed but a few human NTD risk genes, while 
no single gene has been identified as a major independent cause of NTDs (Harris, 
2001). Nonetheless, there is evidence to support a genetic influence in the aetiology of 
NTDs. Investigations into familial cases have shown that there is an increased risk of 
an NTD pregnancy following a previous affected pregnancy, termed the recurrence 
risk. Studies conducted in several countries report recurrence risks ranging from 2.3 -  
4 % (Elwood et al., 1992; Czeizel and Metneki, 1984; Cowchock, S., 1980; Elwood and 
Elwood, 1980). Whilst, a study in the UK reported a 3% recurrence rate among women 
who were given dietary counselling before the pregnancy, compared to a 7% 
recurrence rate among uncounselled women (Laurence et al., 1980). After two or more 
affected pregnancies, the recurrence risk has been reported to be as high as 10% 
(Elwood et al., 1992;Elwood and Elwood, 1980). Thus analysis of recurrence risk 
provides evidence of a genetic influence, but factors such as geographical location and 
diet are also associated with variations in the incidence of NTDs. Further evidence to 
support a genetic predisposition comes from studies which have shown that the risks 
are higher for first-degree relatives (Toriello and Higgins, 1983) and monozygotic twins 
(Janerich and Piper, 1978). The prevalence of NTDs is also higher among females 
compared to males (Seller, 1987), yet the reason for this sex difference is unknown 
(Brook et al., 1994).
1.2.2 Environmental influences
In addition to genetic susceptibility, epidemiological studies have conclusively shown 
that environmental factors affect the prevalence rates of NTDs (Borman et al., 
1986;Carter, 1974). Many of the environmental factors that are believed to play a role 
in the aetiology of NTDs in humans could be related to maternal nutrition. These 
include seasonal trends, variations in geographic area, social class and the 
consumption of toxin-contaminated food products. The continued decline in NTD 
prevalence observed during the last five decades in both US and British populations 
may be due to improvements in maternal nutrition (Yen et al., 1992). Particular 
nutrients, such as folic acid (see section 1.4) and vitamin B12 have been shown to play 
a major role in the prevention of NTDs and consequently, much research has focused 
on elucidating the preventative mechanisms involved (Copp and Greene, 2000;Scott, 
1999;Van der Put et al., 2001).
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1.3 The mouse as an experimental model for NTDs
The benefits of the mouse for understanding the development of NTDs are, first, that 
neural folding and fusion to create a closed neural tube only occurs in higher 
vertebrates; second, the wealth of available mouse strains which exhibit NTDs; third, 
the ease of use as a laboratory animal for experimental studies and fourth, the genetics 
of the mouse are well-understood. Experimental studies are not permitted in humans 
for ethical reasons whilst epidemiology studies and clinical trials are often hampered by 
low numbers of NTD cases. Thus, mouse research is critical to address issues of 
molecular and cellular pathologies in NTDs, and to conduct experimental studies on the 
action of agents in preventing NTDs.
1.3.1 Range of NTDs exhibited by the mouse mutants
There are a large number of mutant mouse models with NTD phenotypes (Harris and 
Juriloff, 2006;Juriloff and Harris, 2000), including models that arose spontaneously and 
models that were generated experimentally. The majority of NTD mouse models 
develop exencephaly either alone, as seen in Cited-2 null mutants (Martinez-Barbera et 
al., 2002) or in combination with spina bifida as observed in the well-studied splotch 
and curly tail mutants (Auerbach, 1954;Van Straaten and Copp, 2001). Relatively few 
mouse mutants exhibit spina bifida alone, as seen in Vacuolated lens (vl) mice (Wilson 
and Wyatt, 1988). Delay of spinal closure can be seen as an enlarged posterior 
neuropore in embryos with 28-30 somites. Severe delay prevents neural tube closure, 
as in spina bifida, but a minor delay is compatible with posterior neuropore closure yet 
tail flexion defects are frequent, as seen in curly tail mutants (Van Straaten and Copp, 
2001).
1.3.2 Mechanisms underlying cranial neural tube closure as revealed by 
mouse mutants
1.3.2.1 Cytoskeleton
It is believed that ‘purse string’ contractions of actin microfilaments, located in the 
bending neural plate, are required for neural tube closure (Karfunkel, 1974;Sadler et 
al., 1982). Indeed, the application of cytochalasins that disassemble actin 
microfilaments disturbs cranial neural tube closure (Morriss-Kay and Tuckett, 
1985;Smedley and Stanisstreet, 1986). Gene targeting of cytoskeleton-related proteins 
has been shown to cause exencephaly in several mouse mutants, including the F-
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actin-associated protein shroom (Hildebrand and Soriano, 1999), the actin-binding 
protein vinculin (Xu et al., 1998), the protein kinase C target MARCKS, which cross­
links actin filaments (Stumpo et al., 1995) and the RhoGAP p190 regulator of the actin 
cytoskeleton (Brouns et al., 2000). Embryos doubly mutant for other cytoskeleton- 
related genes also develop exencephaly (Koleske et al., 1998;Lanier et al., 
1999;Menzies et al., 2004). Of interest, spinal neural tube closure occurs normally in 
all these mutants, with the exception of shroom where a proportion of embryos have 
spina bifida. Hence, a microfilament-based mechanism is crucial for cranial neural 
tube closure, but plays a less certain role in spinal neurulation.
1.3.2.2 Apoptosis
Studies of several knockout mouse strains have demonstrated that both increased and 
decreased apoptosis in the cranial neural tube disrupts cranial neurulation (Copp, 
2005), whilst inhibition of apoptosis using the peptide Zvad-fmk produces NTDs in the 
chick embryo (Weil et al., 1997). In the majority of cases, only cranial neurulation is 
affected whilst spinal neurulation occurs normally. In the cranial neural tube, apoptotic 
cells observed at the sites of dorsolateral bending of the neural plate are thought to 
enhance the conversion of neural fold morphology from convex to concave, whilst 
apoptosis at the tips of the neural folds is believed to play a role in tissue remodelling 
required for fusion of the apposed neural tips (Copp, 2005).
1.3.2.3 Cell Proliferation and differentiation
During neural tube closure, cells continue to proliferate and will only begin to exit the 
cell cycle and differentiate following completion of neurulation. Premature onset of 
neuronal differentiation in the neural plate appears to prevent cranial neural tube 
closure in mouse knockouts affecting the Notch and related signalling pathways 
(Ishibashi et al., 1995;Oka et al., 1995;Zhong et al., 2000). However, the exact 
mechanism underlying neural tube defects caused by premature differentiation through 
the disruption of the Notch pathway is unknown. Exencephaly has also been 
associated with excessive cell proliferation in some mouse mutants, for example over­
expression of Notch3 (Lardelli et al., 1996).
1.3.2.4 Convergent Extension
The most severe type of NTD is craniorachischisis, in which the neural tube is open 
throughout part of the cranial region as well as the whole of the spine. A small number
of mutants exhibit craniorachischisis, including loop-tail, circletail, and crash (Curtin et 
al., 2003;Hamblet et al., 2002;Murdoch et al., 2001b;Murdoch et al., 2001a). In these 
mutants the initial closure event, closure 1, fails thereby preventing further closure 
events in the midbrain, hindbrain and spinal neural tube (Greene et al., 1998). Analysis 
of the craniorachischisis mutants revealed that the neural folds at the cervical-hindbrain 
region are spaced widely apart and cannot appose at the midline to enable closure 1 to 
occur. Recent studies have implicated defects in non-canonical Wnt / planar cell 
pathway signalling in causation of craniorachischisis. Shaping of the neural plate 
occurs by a process termed convergent extension whereby mesodermal cells move 
medially and intercalate in the midline lengthening the body axis (Keller et al., 2000). 
Disruption of cellular polarity via the planar cell polarity (PCP) genes in Xenopus 
disrupts convergent extension yielding short, broad neural plates that fail to complete 
neural tube closure (Wallingford and Harland, 2002). Significantly, the genes mutated 
in loop-tail, circletail, crash and dishevelled-1/2 are homologues of the Drosophila PCP 
genes (Curtin et al., 2003;Murdoch et al., 2001a;Murdoch et al., 2003). Similarly, cell 
labelling studies reveal that convergent extension movements are defective in loop-tail 
mutant embryos (Ybot-Gonzalez et al., 2007). Hence, the use of mouse mutants has 
demonstrated that the PCP signalling pathway is required for shaping of the neural 
plate, a process vital for the initiation of neural tube closure.
1.3.3 Gene-gene, gene-background and gene-environment interactions 
identified in mouse mutants
Many of the mouse mutants only exhibit NTDs when the mutant allele is present in 
homozygous state, such that NTD phenotypes are rare amongst heterozygotes. In 
humans, abnormal gene dosage is a common cause of spontaneous abortion and birth 
defects, for example those caused by chromosomal trisomy such as Down syndrome 
(Fisher and Scambler, 1994). Thus, abnormal gene dosage may be common among 
human NTD cases. Furthermore, it may be gene-gene interactions that result in the 
development of NTDs as is known to occur in mouse mutants. For example, while ct/ct 
and Sp2H/Sp2H mutants develop spina bifida, a proportion of double heterozygotes (ct/+ 
; Sp2H/+) also have NTDs whilst ct/ct ; Sp2H/+ embryos exhibit severe spina bifida 
(Estibeiro et al., 1993).
The severity and frequency of NTDs is also affected by modifier genes that are present 
in the genetic background. Mouse inbred strains, which have identical genetic 
backgrounds, can be used to demonstrate the role of genetic background. The curly 
tail mutant gene, for example, when crossed onto different inbred mouse genetic
backgrounds gives rise to widely differing frequencies of spina bifida (Embury et al., 
1979;Neumann et al., 1994). Similarly, the frequency of exencephaly in splotch (Sp2H) 
is governed by genetic background whereby variations in the position of closure 2 
between inbred strains can enhance or hinder midbrain closure (Fleming and Copp, 
2000). The role of genetic background in humans has yet to be demonstrated but with 
its continuously varying genetic background, it provides enormous scope for 
background effects on NTD occurrence (Copp et al., 2006).
The gene-gene and gene-background interactions are further influenced by the 
environment in which the embryo develops. Many agents delivered to the developing 
embryo exhibit teratogenic effects which include neural tube defects. Mouse embryos 
are particularly useful to study the effects of exogenous agents on neural tube 
development as they can be maintained in vitro throughout the stages of neurulation 
using the method of whole embryo culture (Copp et al., 1993). Examples of agents 
which cause NTDs include drugs, (for example, valproic acid used to treat epilepsy 
(Trotz et al., 1987)), chemicals, (for example, methanol (Bolon et al., 1994)), molecules 
that may be present at abnormal levels, particularly in maternal disease conditions (for 
example, eievated glucose and ketone body concentrations, as found in diabetes 
(Sadler, 1980)) and heavy metals (for example, arsenic, cadmium, lead and mercury 
(Brender et al., 2006). These teratogenic agents can also interact directly with genetic 
mutant effects to affect the frequency of NTDs. For example, mitomycin C (an inhibitor 
of DNA synthesis) increases the incidence of exencephaly in curly tail mutants when 
administered on embryonic day 8, but decreases the incidence of spina bifida when 
administered on embryonic day 9 (Seller and Perkins, 1986).
1.3.4 Prevention of NTDs by vitamins
Amelioration of NTDs by exogenous agents highlights potential therapeutic agents for 
the prevention of NTDs. Folic acid has proved to be a very successful preventative 
agent for human NTDs, particularly since there are no teratogenic side effects, making 
it suitable for clinical use. Although the initial research highlighting folic acid as a 
preventative agent was established in human studies, folic acid is also capable of 
preventing NTDs in several mouse mutants (see section 1.4.5). Thus, folate 
prevention of NTDs in mouse mutants provides a means to study the underlying 
mechanisms of prevention which are as yet unknown.
There are however some mouse mutants which do not respond to folic acid, including 
curly tail, Axial defects, and the EphA7 (Essien and Wannberg, 1993;Holmberg et al.,
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2000;Seller, 1994b). This mirrors the situation in humans in which there appears to be 
a sub-set of cases which do not respond to folic acid as highlighted by the existence of 
NTD cases which occurred despite high folic acid intake in the MRC clinical trial (see 
section 1.4.4). Evidence from mouse studies is now accumulating to suggest that 
inositol may be a potentially useful therapeutic agent to be used in combination with 
folic acid to prevent more cases of NTDs (Greene et al., 1997; Cogram et al., 2002).
1.4 Folate-Sensitive Neural Tube Defects
1.4.1 Folates and Folic Acid
Folate is the generic term used to describe a group of molecules derived from 
tetrahydrofolate (THF), which consists of a pteridine ring, p-aminobenzoic acid and one 
to six glutamic acids (Lucock, 2000). THF can be reduced or oxidised, by the removal 
or addition of one-carbon units at the N-5 and/or N-10 position, to give the remaining 
folate species (Figure 1.4). A folate molecule conjugated to a single glutamate residue 
is referred to as a “monoglutamate” or “monoglutamylfolate” whilst a folate molecule 
conjugated to multiple glutamate residues is a “polyglutamate” or “polyglutamylfolate”. 
The addition of a polyglutamyl chain to folates, catalysed by folylpolyglutamate 
synthetase (FPGS) (EC 6.3.2.12), is important for cellular retention and polyglutamates 
are generally the preferred substrates for folate-utilising enzymes rather than 
monoglutamates (Shane, 1989).
Humans are not able to synthesise folate and therefore rely entirely on exogenous 
sources to provide it. The principal dietary sources of folate are Marmite, leafy green 
vegetables, legumes (beans, peas), citrus fruits and juices, liver and whole wheat 
bread (Locksmith and Duff, 1998;Lucock, 2000). Most naturally occurring folates, 
including those found in food, are present as polyglutamates which must be converted 
to the absorbable monoglutamate, 5-methyltetrahydrofolate, in the small intestine (Erbe 
and Wang, 1984).
Folic acid (pteroylmonoglutamate, FA) is a synthetic, stable monoglutamylfolate found 
in vitamin tablets and fortified foods. At low levels it can be efficiently metabolised to 5- 
MeTHF, yet the absorption and conversion to 5-MeTHF is saturable at doses between 
266-400 pg (Lucock et al., 1989). The recommended daily intake of folic acid for 
woman planning a pregnancy is 400 pg per day (Whitehead and Bates, 1997), thus it is 
not uncommon to find unmetabolised folic acid in the circulation. Upon entry into the 
cell, unmetabolised folic acid becomes incorporated in the folate cycle following
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reduction to D HF and subsequently forms TH F, whilst 5 -M eTH F  is converted to TH F  by 
methionine synthase (M S) (Figure 1.5).
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Figure 1.4. The chemical structure of Tetrahydrofolate, highlighting the N-5 and N-10 
positions and the oxidation states of the main folate species. The figure displays the 
diglutamate derivative with two glutamate residues attached. The major folate species are 
Tetrahydrofolate (THF), 5-Methyltetrahydrofolate (5-MeTHF), 5,10-Methylenetetrahydrofolate 
(5,10-MethyleneTHF), 10-Formyltetrahydrofolate (10-FormylTHF), Dihydrofolate (DHF), Folic 
Acid (FA) and 5-Formyltetrahydrofolate (5-FormylTHF).
1.4.2 Folate Receptors
There are two different categories of transporters which facilitate cellular uptake of 
folate: a) m em brane channels or carriers, such as the reduced folate carrier (R FC ), and 
b) cell surface molecules that facilitate uptake by vesicle endocytosis, collectively 
termed the folate receptors (FR ). The reduced folate carrier (R FC 1) is a facilitative 
anion-exchanger that m ediates folate delivery into a variety of cell types (Sierra and 
Goldm an, 1999;Sirotnak and Tolner, 1999). RFC1 has a high affinity for reduced  
folates, including the physiological substrate 5-M eTH F, and a low affinity for FA
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(Goldman, 1971). RFC1 is expressed during neurulation (E9.5-E11.5) in the placenta, 
yolk sac and throughout the embryo, with intense expression localised in the neural 
tube, forebrain, hindbrain, craniofacial regions, eye, limb buds, somites, tail bud and 
the heart (Maddox et al., 2003). RFC1 expression in adult tissues is localised to the 
liver, lung and small intestine (Chiao et al., 1997;Prasad et al., 1995). A recent 
publication reports the identification of a second carrier-mediated high affinity folate 
transporter (proton coupled folate transporter, PCFT) believed to be responsible for the 
absorption of folates in the acidic conditions of the small intestine (Qiu et al., 2006).
The folate receptors (FR) are attached to cell membranes through a 
glycosylphosphatidylinositol (GPI) anchor and transport folates by an endocytotic 
process (Anderson et al., 1992;Kamen et al., 1988). These receptors have a very high 
affinity for both FA and 5-MeTHF (Brigle et al., 1991;Wang et al., 1992). Four isoforms 
of the folate receptor (FR a, p, y  and 8) have been cloned in humans (Elwood, 
1989;Ratnam et al., 1989;Shen et al., 1995;Spiegelstein et al., 2000), whereas three 
isoforms (Folbpl, 2 and 3) have been identified in mice (Brigle et al., 1991 ;Spiegelstein 
et al., 2000). In the developing embryo, Folbpl (murine homologue of FRa) is highly 
expressed in the yolk sac, the neural folds and the neural tube (Barber et al., 
1999;Saitsu et al., 2003). Expression of Folbpl in adult tissues has been detected in 
choroids plexus, lung, thyroid, kidney, liver, lung and small intestine (Weitman et al., 
1992).
1.4.3 Folate Cycle
Once taken up into the cell, the role of folates is to act as acceptors and donors of one- 
carbon units in a series of cyclic reactions involving nucleotide and amino acid 
metabolism, collectively known as one-carbon metabolism (Figure 1.5). The principle 
origin of the one-carbon units is serine, provided by the action of serine 
hydroxylmethyltransferase (SHMT) which converts serine and tetrahydrofolate (THF) to 
5,10-methylene THF and glycine. Other sources of one-carbon units include 
formiminoglutamic acid, the mitochondrial glycine cleavage pathway, choline 
metabolism and formate. Folates have two important direct biological effects. First, via 
the folate cycle, they provide single carbon units for the synthesis of nucleotide bases 
required for DNA and RNA synthesis. Secondly, folates are the methyl-donors for the 
recycling of homocysteine to methionine, an essential step in the methylation cycle.
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Figure 1.5. A diagram of One-Carbon Metabolism. Blue numbered circles represent the 
following enzymes: (1) Methyltransferases (MT), (2) Methionine Synthase (MS), (3) 5,10- 
Methylenetetrahydrofolate Reductase (MTHFR), (4) Thymidylate Synthase (TS), (5) 
Dihydrofolate Reductase and (6) Folylpolyglutamate Synthetase (FPGS). For chemical 
structures of folate species refer to Fig. 1.4, and of S-Adenosylmethionine and S- 
Adenosylhomocysteine refer to Fig. 3.2.
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For the synthesis of DNA and RNA, folates are required for the de novo synthesis of 
both purines and pyrimidines. The cofactor 10-formyl THF donates its formyl groups to 
two enzymes involved in purine biosynthesis, both of which generate THF which can 
be re-used further in the folate cycle (Figure 1.5). The cofactor 5,10-methylene THF 
donates carbon units to deoxyuridine monophosphate (dUMP), in a reaction catalysed 
by thymidylate synthase (EC 2.1.1.45, TS), to produce deoxythymidine 
monophosphate (dTMP), for the synthesis of pyrimidines and thus the synthesis of 
DNA.
Glycine
Sarcosine
Dimethylglycine
©
Betaine
4
Choline
THF
P ^ ^ F o la te  
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Cystathionine
Cysteine
Figure 1.6. Pathways of Homocysteine Metabolism. 1, Betaine-homocysteine 
methyltransferase (BHMT); 2, Methionine Synthase (MS); 3, Cystathionine p Synthase (CBS). 
For chemical structures of folate species refer to Fig. 1.4, and of S-Adenosylmethionine and S- 
Adenosylhomocysteine refer to Fig. 3.2.
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The enzyme, 5,10-methylenetetrahydrofolate reductase (EC 1.7.99.5, MTHFR) 
converts 5,10-methyleneTHF to 5-MeTHF in an irreversible reaction (Figure 1.5). This 
step provides a means to channel single carbon units derived from amino acids such 
as serine, histidine, glycine and also formate, to participate in the methylation cycle. 
The methyl group of 5-MeTHF is used by methionine synthase (MS) to methylate 
homocysteine to methionine, which is subsequently converted to S- 
adenosylmethionine (SAM), the universal methyl donor in methylation reactions 
catalysed by methyltransferases (MT). There are 115 different MT enzymes that 
transfer the methyl group of SAM to a wide variety of compounds including DNA, RNA, 
proteins and lipids. The product of this reaction, S-Adenosylhomocysteine (SAH), is 
hydrolysed to homocysteine to complete the methylation cycle (discussed in chapter 3).
Adult cells are able to degrade excess homocysteine, via vitamin B6-dependent 
cystathionine (3 synthase (EC 4.2.1.22, CBS), to cystathionine and then to cysteine 
(Figure 1.6). However, CBS is not expressed until day 14 of gestation in the fetal liver 
(VanAerts et al., 1995) such that embryos do not have an alternative means of 
removing homocysteine other than by methylation. Another enzyme betaine- 
homocysteine methyltransferase (EC 2.1.1.5, BHMT) is also able to recycle 
homocysteine back to methionine, independent of folate, vitamin B6 and B12 (Figure 
1.6). BHMT is expressed in the liver and kidney in adults (McKeever et al., 1991), 
whilst BHMT is not expressed in either yolk sac or embryonic tissue until embryonic 
day 10, when neurulation is nearly complete (Fisher et al., 2002).
1.4.4 Prevention of Human NTDs by Folic Acid
Evidence implicating folate in the aetiology of human NTDs started to become apparent 
over fifty years ago, with a series of case reports linking the use of antifolates in 
pregnancy to NTD-affected pregnancies (Goetsch, 1962;Thiersch and Wash, 
1952;Warkany et al., 1959). Since then a number of other publications have described 
a correlative relationship between folate deficiency during pregnancy and NTDs (see 
section 1.3.1) (Kirke et al., 1993;Smithells et al., 1976). Thus it became apparent with 
time that folate appeared to play a distinct role in the pathogenesis of human NTDs. 
These findings ultimately prompted various study groups to begin trials involving the 
administration of folic acid to women planning a pregnancy (Czeizel and Dudas, 
1992;Kirke et al., 1992;Laurence et al., 1981 ;Smithells et al., 1981a;Smithells et al., 
1981b;Smithells et al., 1983;Smithells and Sheppard, 1980;Wald et al., 1991).
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The strongest evidence for the prevention of recurrent NTDs by folic acid came from 
the United Kingdom Medical Research Council Trial, a randomised, double-blind trial 
involving 1817 women with a history of a previous pregnancy affected by an NTD 
(Wald et al., 1991). Women were randomised into four groups: folic acid (4 mg/day) 
alone, folic acid (4 mg /day) plus multivitamins, multivitamins without folic acid, and 
placebo. Among 1195 completed pregnancies, there were six NTD recurrences among 
the 593 (1.0%) women who took folic acid compared with 21 among the 602 women 
(3.5%) who did not receive folic acid which represents a 72% protective effect. The 
multivitamin preparation without folic acid was found to have no protective effect. 
Around the same time, Czeizal and Dudas carried out a randomised double blind trial
comparing multivitamin preparations to test the effects of NTD prevention (Czeizel and
Dudas, 1992). Importantly, this trial studied the prevention of occurrence, rather than 
recurrence, of NTDs (women with no previous history of an NTD affected pregnancy) 
and the amount of folic acid used in this trial was at the lower level of 800 pg/day. 
Among the 2104 women receiving multivitamins including folic acid there were no NTD 
affected pregnancies compared to 6 NTD-affected pregnancies among 2052 women 
not receiving folic acid. While the numbers of affected pregnancies were lower than in
the MRC trial, the results were significant (p = 0.029).
Critics of the MRC clinical trial, the only trial to conclusively demonstrate the 
effectiveness of folic acid alone, argue that there was no pure placebo group since the 
placebo capsules contained iron and calcium, both of which can affect zinc status 
which has been linked to neural tube defects (Turner et al., 2001). Additionally, serum 
folate levels were exceptionally high among women randomised to receive folic acid 
alone or multi-vitamins containing folic acid which might suggest that some women 
took several previously missed capsules at the same time to “catch up” just before their 
blood test (Turner et al., 2001). Thus, women taking multiple doses in the multivitamin 
alone and multivitamins plus folic acid groups would have been exposed to very high 
doses of vitamin A which is known to cause NTDs. Critics point out that this could 
explain why the incidences were higher in the multivitamins alone and the multivitamins 
plus folic acid groups, compared to the low incidences reported in the folic acid alone 
group.
Despite the criticism, in the early 1990s, publication of the two clinical trials convinced 
many that if women take folic acid beginning before conception they will lower their risk 
of having a baby with a NTD. This was followed by a large public health campaign 
undertaken in China whereby women who reported having taken folic acid alone (0.4 
mg) during the periconceptual period had a lower prevalence of NTD affected
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pregnancies (Berry et al., 1999). However, critics believe that the evidence was 
weakened by the fact that women were required to purchase the tablets themselves. 
Thus women who could not afford to purchase the folic acid, such as farmers and 
factory workers, may have been exposed to different risk factors or diet (Turner et al.,
2001 ).
Recommendations are now in place in several countries to advise women planning 
their first pregnancy to supplement their diet with 0.4 mg/day of folic acid, whilst to 
prevent recurrence of NTDs women should take 4 mg/day of folic acid (Whitehead and 
Bates, 1997). Any risks associated with the use of high dose folic acid to treat 
recurrence are thought to be outweighed by the benefit, as such women have a 
recurrence risk of 4% (Scott et al., 1995). In the USA, millers have been required by 
law to fortify their flour with folic acid since 1998 to ensure women have an intake of 
100 pg/day (Food and Drug Administration, 1996). Fortification led to a threefold 
increase in the median serum folate concentration and a twofold increase in the 
median red blood cell folate concentration in women of child bearing age (Centers for 
Disease Control and Prevention., 2002). This coincided with an estimated decline in 
the number of NTD-affected pregnancies in the US from 4,000 in 1995-1996 to 3,000 in 
1999-2000 (Centers for Disease Control and Prevention., 2004;Centers for Disease 
Control and Prevention., 1999)). The main risk associated with folic acid fortification in 
a general population is that it may complicate the diagnosis of vitamin B12 deficiency 
which is common in the elderly, and can, if undetected, lead to pernicious anemia and 
neuropathy.
1.4.5 Folate prevents NTDs in mouse models
Among the numerous genetically manipulated mutant mouse strains which display a 
NTD mutant phenotype (Copp et al., 2003;Greene and Copp, 2005;Juriloff and Harris, 
2000), the preventative action of folic acid has been observed in several mouse models 
including splotch {Sp2H) and Crooked tail and the Cartl and Cited2 knockouts (Carter 
et al., 1999;Fleming and Copp, 1998;Martinez-Barbera et al., 2002;Zhao et al., 1996). 
These mouse models provide an experimental system to study the unknown 
mechanisms underlying the prevention of human NTDs by folic acid.
Homozygous mice for Cartl develop cranial NTDs believed to result from excessive 
cell death of the forebrain mesenchyme, which causes a reduction in cell number that 
is assumed to prevent the closure of the cranial neural folds (Zhao et al., 1996). Folic 
acid reduces the incidence of exencephaly by 60%, although it is not clear whether this
is through the prevention of apoptosis or a compensatory increase in cell number, 
perhaps by stimulation of proliferation. The development of exencephaly in Cited2 
homozygous null mice is also associated with excessive apoptosis at the forebrain- 
midbrain boundary (Martinez-Barbera et al., 2002). Treatment with folic acid 
significantly reduces the incidence of exencephaly, but there is no obvious amelioration 
of the excessive apoptosis. Cell proliferation in the neuroepithelium of Cited2 null 
embryos was comparable to that in wild-type litter mates but, unfortunately, it was not 
established whether folic acid treatment caused an up-regulation of cell proliferation to 
overcome the excessive apoptosis. The cellular mechanism of NTD in splotch has yet 
to be clarified (discussed further in chapter 5) but it has been suggested that failure of 
neural tube closure also occurs as a result of increased cell death (Pani et al., 2002).
In contrast to the previously mentioned studies in which FA was administered by 
maternal i.p. injections, the effect of maternal folate supplementation on the incidence 
of exencephaly in the Crooked tail mouse model was investigated using diets differing 
only in the concentration of folic acid. Embryonic lethality was prevalent among Cd/Cd 
embryos receiving a folate deficient diet (0 mg/kg), while on the 4 mg/kg diet, 
exencephaly became a more common outcome. On diets containing a higher FA 
content, most Cd/Cd embryos were viable and closed their neural tubes. Thus, low 
dose FA rescues lethality and high dose FA rescues NTDs. A recent report identified 
the Crooked tail gene as low density lipoprotein receptor 6 (Lrp6), a co-receptor 
required for Wnt signalling (Carter et al., 2005), but it remains to be investigated if 
folate affects this pathway.
Mouse
Model
Reference NTD Suggested
mechanism
Prevention by 
other agents?
Cartl -/- (Zhao et al., 1996) EX Excess
apoptosis
■ "1
Cited2-/- (Martinez-Barbera et al., 2002) EX Excess
apoptosis
Crooked tail (Carter et al., 1999) EX Canonical Wnt 
signalling
Splotch
i!
(Fleming and Copp, 1998) SB and 
EX
Excess
apoptosis
Thymidine
Table 1.1. Summary of Mouse Models in which NTDs are preventable by folic acid. EX,
exencephaly, SB, Spina bifida.
Using the dU suppression test (for details see Chapter 4) Cited2 null embryos have 
been shown to have apparently normal folate cycling whilst homozygous splotch 
mutant embryos do not. Moreover, a recent publication demonstrated that Crooked tail 
mutants appear to have an underlying defect in the utilisation of intracellular folate 
(Ernest et al., 2006). Thus, it appears that among the mutants in which folic acid is 
known to prevent NTDs, only the Cartl and Cited2 mutants do not have a folate-related 
defect, but further work may question this.
1.5 Mechanisms of prevention of NTDs by folic acid
Despite extensive research the mechanism explaining the preventative effect of folic 
acid on NTDs remains unclear. Several areas of research are described below.
1.5.1 Maternal folate deficiency
The original mechanism proposed that folic acid supplementation rescues maternal 
folate deficiency, arising from insufficient folate in the diet (Smithells et al., 1976). 
Thus, there have been numerous studies to date, using a variety of methods which 
attempted to definitively establish whether maternal folate status is linked to NTD risk 
(Table 1.2).
The main criticism of studies that determine folate status late in pregnancy or following 
delivery is that they would only be predictive of folate status at the critical time of neural 
tube closure if the mother kept to the same diet after pregnancy (Scott et al., 1995). 
However, retrospective analysis of this type may identify genetic disturbances which 
have long term effects. Analysis of maternal folate status in serum taken at the first 
antenatal clinic visit (two months after the neural tube has closed) attempted to 
overcome this potential drawback (Kirke et al., 1993;Mills et al., 1995;Molloy et al., 
1985). However, the results failed to conclusively demonstrate a correlation between 
maternal folate deficiency and the incidence of NTD (Table 1.2).
34
Ref. Maternal 
Sample Type
Time of study Difference in folate 
status between cases 
and controls?
Other findings
1 Serum Retrospective No difference -
2 Serum Retrospective No difference -
3 RCF & serum Early pregnancy Cases had lower RCF -
4 RCF & serum Retrospective More cases had a lower 
RCF
5 Serum 1st antenatal 
clinic visit
No difference No difference in 
vit. B12
6 RCF & serum Retrospective Cases had lower RCF -
7 Whole blood Mid-gestation No difference Amniotic fluid 
vit. B-I2 was lower 
in cases
8 Serum 8 weeks after 
neurulation
No difference No difference in 
vit. Bi2or retinol
9 RCF & plasma 1sl antenatal 
clinic visit
Cases had lower RCF & 
plasma folate
Cases had lower 
vit. B12
10 RCF & serum Retrospective Relationship between 
RCF & serum folate 
differs between cases 
and controls
No difference in 
vit. B12or vit. C
11 RCF & plasma 1st antenatal 
clinic visit
No difference Cases had higher 
homocysteine
12 RCF & serum Before & during 
pregnancy
Cases had lower RCF  
and serum folate
Cases had lower 
vit. B12
13
i
RCF & plasma Retrospective Cases had lower plasma 
folate. SB patients also 
had lower plasma folate.
SB patients & 
parents had higher 
homocysteine & 
subset had lower 
vit. B12
Table 1.2. Studies investigating differences in maternal folate status between cases and 
controls. Cases, mothers with an NTD-affected pregnancy; controls, mothers with a normal 
pregnancy. 1, (Emery et al., 1969); 2, (Hall, 1972); 3, (Smithells et al., 1976); 4, (Schorah et al., 
1983); 5, (Molloy et al., 1985); 6, (Yates et al., 1987); 7, (Economides et al., 1992); 8, (Mills et 
al., 1992); 9, (Kirke et al., 1993); 10, (Wild et al., 1993); 11, (Mills et al., 1995); 12, (Wald et al., 
1996); 13, (Van der P u te ta l., 1997b).
35
Sample type also has an effect on the outcome of studies in which folate is quantified. 
Red blood cell folate (RCF) estimations are believed to be a reliable method of 
assessing long-term folate status, due to the stable nature of red cell folate (Hoffbrand 
et al., 1966). Serum folate is dramatically altered by food intake, whereas red cell 
folate is only affected by long-term changes in dietary folate. Thus, sample type needs 
to be chosen depending on whether interest is in retrospective examination of the 
effects of genetic variations which cause long-term changes in folate status. 
Alternatively, the aim may be to quantify folate level at the time of neural tube closure, 
to determine if there is a transient folate deficiency (e.g. due to dietary folate 
deficiency) which leads to a NTD. Significantly lower maternal RCF levels were 
detected in NTD affected pregnancies, supporting the view that an inherited disorder of 
folate metabolism is involved in the etiology of NTDs (Smithells et al., 1976;Yates et al., 
1987). In addition, changes in serum and plasma folate during pregnancy also support 
the idea that transient folate deficiency may be related to NTD risk (Economides et al., 
1992;Kirke et al., 1993). However, low maternal folate levels associated with NTDs are 
not considered clinically folate deficient, thus maternal status appears to be sub- 
optimal but within the ‘normal range’ (Kalter, 2000).
Two studies using folate deficient diets concluded that folate deficiency does not 
produce NTDs in wild-type mice (discussed in section 5.1.1) (Burgoon et al., 2002;Heid 
et al., 1992). The level of dietary folate in a genetically predisposed mutant can affect 
the incidence of NTDs (Carter et al., 1999) such that a higher rate of exencephaly is 
observed with lower dietary content of folic acid (see section 1.4.5). Overall, sub- 
optimal folate status does appear to be involved in the pathogenesis of NTD but the 
findings to date are inconclusive and further work is needed for clarification.
1.5.2. Insufficient uptake of folate due to defective intracellular transport
Folic acid supplementation may act to overcome defective intracellular uptake of folate. 
For example, insufficient maternal uptake could lead to embryonic folate deficiency or 
affect the uterine environment. Isolated embryonic folate deficiency could also arise 
from defective maternal-to-fetal folate transport or insufficient uptake of folate by 
embryonic cells. Thus, it has been proposed by several groups that defective 
intracellular transport of folate, as a result of a genetic variation in genes encoding the 
folate receptors, could increase susceptibility to NTDs. Folic acid supplementation 
could be envisaged to promote intracellular uptake either by the defective receptor, due 
to an increase in folate availability, or the presence of a different folate species could 
perhaps promote uptake by an alternative receptor. To investigate this mechanism, the
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role of the folate receptors has been examined using transgenic mice and studies of 
genetic variants of the human folate receptors.
Targeted inactivation of RFC1 causes early embryonic death at E9.5 with very severe 
growth retardation. However, the development of RFC-/- embryos could be sustained 
until E18.5 with supplemental folic acid, but the authors did not find any evidence of a 
NTD phenotype in these supplemented embryos (Zhao et al., 2001). The impact of a 
known A80G polymorphic variant in the human RFC1 gene on NTD risk was evaluated 
in 174 Italian probands. The data supported the hypothesis that the RFC1 A80G 
variant may contribute to NTD susceptibility in the Italian population (De Marco et al., 
2003b). However this finding was not supported by a second study in a different 
population (Shaw et al., 2002) (Table 1.2.). A recent study reported that mothers with 
the homozygous mutant GG genotype, with a low red blood cell folate, were at 
increased risk for having a child with a NTD (Morin et al., 2003), suggesting an 
interaction between genotype and nutritional status.
Loss of function of the recently identified PCFT intestinal folate receptor has been 
associated with hereditary folate malabsorption. However, patients with this disease 
have no evidence of NTDs and symptoms appear months after birth, implying that this 
gene is not absolutely required for neural tube closure (Qiu et al., 2006). Rather, owing 
to its role in intestinal folate absorption, polymorphisms in this gene might contribute to 
maternal folate deficiency and thereby increase the chances of NTDs associated with 
dietary folate deficiency. Thus, if polymorphisms which affect function of PCFT are 
identified it would be of interest to investigate the frequency of NTDs in offspring of 
mothers who carry those polymorphisms.
Inactivation of Folbpl (murine homologue of FRa) causes early embryonic death 
although when embryos are sustained until later in development, following 
supplementation of dams with exogenous folate, embryos do develop NTDs (Piedrahita 
et al., 1999). In the same study, embryos were reported to be unaffected following the 
loss of Folbp2 (murine homologue of FRp). An antisense oligonucleotide against 
Folbpl mRNA was found to cause NTDs in a dose-dependent manner when injected 
into the amniotic sac of mouse embryos (Hansen et al., 2003). Thus, overall, cellular 
uptake of folate by Folbpl appears to be essential for murine neural tube closure. 
However, candidate gene analysis has failed to demonstrate evidence for an 
association between genetic variations in FRa and the incidence of NTDs (Table 1.2).
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Human
Gene
Reference Sample Conclusion
FRa (Trembath et al., 
1999)
172 US families No evidence for an association
FRP (Trembath et al., 
1999)
172 US families No evidence for an association
RFC1 (De Marco et al., 
2002)
203 cases, 98 
mothers and 67 
fathers (Italian)
Higher frequency of the RFC1 A80G  
and MTHFR A1298C polymorphisms 
in cases, mothers and fathers
RFC1 (Shaw et al., 
2002)
133 case infants and 
188 control infants 
(California)
Non-significant increase in risk 
associated with A80G in newborns 
whose mothers had not used 
vitamins.
RFC1 (De Marco et al., 
2003a)
174 cases, 43
!
mothers, 53 fathers 
and 156 controls 
(Italian)
Evidence for increased risk to cases 
and mothers (A80G), but not in 
combination with MTHFR
PCFT - No studies undertaken to date
Table 1.3. Genetic variants in genes coding for folate transporters and their association 
with NTDs.
A pilot study in humans has shown that serum from women with a pregnancy 
complicated by a NTD contains auto-antibodies that bind to folate receptors (FR) and 
may block the cellular uptake of folate (Rothenberg et al., 2004). It could be envisaged 
that the blockage of cellular folate uptake by the auto-antibody could be bypassed by 
folic acid because it is transported into cells by the reduced folate carrier (RFC1). 
Alternatively, folic acid which has a high affinity for the folate receptors (FR) may 
displace an autoantibody with a lower affinity for the folate receptors (FR). This study 
highlights a possible role for FR in NTD affected pregnancies, independent of a 
mutation in folate receptor genes.
1.5.3 Disorders in folate metabolism
Disorders in folate metabolism in either the fetus or the mother may contribute to NTD 
risk, such that supplemental folate could act to overcome this metabolic disturbance. 
Thus, following the recognition of folate as an important environmental contributor to 
the risk of NTD, numerous studies have attempted to identify polymorphic variants in 
genes related to folate metabolism that alter NTD risk. This led to the emergence of 
the first genetic risk factor for NTDs, at bp 677 in the folate enzyme 
methylenetetrahydrofolate reductase (MTHFR).
A thermolabile variant of MTHFR was first reported in a group of coronary artery 
disease patients, in which reduced residual enzyme activity was observed after heating 
lymphocyte extracts at 46 °C for 5 minutes (Kang et al., 1988). Following the isolation 
of the cDNA for MTHFR (Goyette et al., 1994), a C - > T  base substitution at bp 677 
was identified, which converted an alanine residue to a valine residue (Frosst et al.,
1995). Biochemical analysis showed that this was the previously described 
thermolabile variant and, furthermore, reduced specific activity was recorded at 37 °C. 
Later reports demonstrated that individuals with the 677TT genotype were predisposed 
to hyperhomocysteinemia, when associated with low folate status (Jacques et al.,
1996). Folate has been shown to stabilise the wild-type and mutant enzyme, by 
preventing the loss of flavin adenine dinucleotide. Thus with higher folate levels the 
mutant enzyme is able to function relatively normally, providing adequate amounts of 5- 
MeTHF to prevent hyperhomocysteinemia (Guenther et al., 1999;Malinow et al., 
1997;Yamada et al., 2001).
Two groups demonstrated that mothers of NTD infants have higher than normal 
homocysteine concentrations (Mills et al., 1995;Steegers-Theunissen et al., 1994). 
Since plasma homocysteine is a sensitive marker of folate status, researchers turned
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their attention to investigating whether folate metabolism was abnormal in these 
mothers. This ultimately led to the identification of MTHFR 677C -> T variant as the 
first genetic risk factor for NTD in patients and parents (Van der Put et al., 1995). 
Following the initial report, many studies worldwide reported similar findings, although 
in other cases its association with NTDs was not detected (Boyles et al., 2005). The 
MTHFR C677T variant is extremely common occurring in approximately 5-15% of the 
population (Botto and Yang, 2000), although this varies widely between different 
populations. It is believed that in areas where the frequency of homozygosity is low, 
the relationship between the C677T and the incidence of NTDs may not be apparent, 
thus explaining why some studies were inconclusive. To clarify the relationship 
between MTHFR and NTD risk, various meta-analyses have been performed taking 
into account all studies (Blom et al., 2006;Botto and Yang, 2000;Van der Put et al., 
1997a). The most up-to-date estimate calculated that mothers who were homozygous 
for the 677TT variant have a 60% increased risk of having an NTD-affected pregnancy, 
whereas homozygous offspring themselves have a 90% increased risk of being born 
with an NTD (Blom et al., 2006). Additionally, there is a 10% and 30% increased risk 
for mothers and offspring who are heterozygous (677CT) (Blom et al., 2006).
Despite the identification of the MTHFR C677T variant, the search to find other genetic 
variants involved in folate metabolism has been relatively unsuccessful (Boyles et al., 
2005;Rozen, 2006). A second common variant in MTHFR, A1298C, by itself does not 
appear to affect NTD risk (Botto and Yang, 2000;Van der Put et al., 1998). However, 
compound heterozygosity for 1298C and 677T has been suggested to increase risk, 
although the results are conflicting (Richter et al., 2001;Trembath et al., 1999;Van der 
Put et al., 1998).
Mouse models in which enzymes involved in folate metabolism are disrupted may be 
very useful in studying the relationship between abnormal folate metabolism and risk of 
NTD. Examples of folate metabolising enzymes that have been knocked out in mice by 
gene targeting include CBS, MTHFR and MS (Figure 1.5 and 1.6), all of which are 
associated with hyperhomocysteinenia. Mice with a disruption of CBS, the first enzyme 
in the transsulfation pathway for homocysteine metabolism, do not develop NTDs 
(Watanabe et al., 1995). The significance of this model for the study of NTDs may be 
limited as it appears that this enzyme, which is found primarily in the adult liver, is not 
expressed in embryonic tissues at neurulation stages (VanAerts et al., 1995). 
However, an effect via maternal metabolism may be plausible.
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In order to further investigate the possible association between MTHFR deficiency and 
increased risk for NTD, a MTHFR null mutant mouse was generated by gene targeting 
(Chen et al., 2001a). Heterozygous mutant mice appeared normal, whilst homozygous 
mice were smaller and developmental^ retarded with a cerebellar pathology. Pre-natal 
survival of homozygous mice was reduced and surviving pups died within the first two 
weeks of their lives. The homozygous mutant animals that died before weaning had 
the appearance of a kinked tail, but there was no evidence of exencephaly or spina 
bifida.
Methionine Synthase (MS) would be an interesting candidate to influence NTD risk 
since it requires vitamin B12 as a co-factor and lies at the intersection between the 
folate and methylation cycle. A knockout model of MS was generated to gain further 
insight into the physiological roles of MS and the effects of impaired MS activity 
(Swanson et al., 2001). Heterozgous MS knockout mice were found to be 
indistinguishable from wild-type littermates despite having slightly elevated 
homocysteine and methionine, whilst homozygous MS knockout mice die soon after 
implantation, demonstrating the importance of this enzyme for early embryonic 
development (Swanson et al., 2001). Since MS null mice die prior to neurulation, the 
role of MS in neurulation has yet to be clarified in mouse embryos. A large study of 
plasma vitamin B12 levels collected at the first antenatal clinic conclusively showed that 
women affected by NTD pregnancies had lower plasma B12, in addition to lower plasma 
folate and RCF, compared to controls (Kirke et al., 1993). Moreover, candidate gene 
analysis of the MS A2756G polymorphism has been associated with reduced risk for 
NTDs (Christensen et al., 1999), although this finding has not been supported by other 
groups (Boyles et al., 2005).
Overall, knockouts of MTHFR, CBS and MS have not provided immediately obvious 
animal models of NTDs. However, it is possible that heterozygotes may prove useful 
since it is possible that heterozygotes would be more susceptible to dietary deficiencies 
than wild-types and thus, would enable interactions between genetic and nutritional 
status to be studied. In addition, it is possible that crosses between heterozygous mice 
deficient in different enzymes involved in folate metabolism may uncover genetic 
interactions which increase NTD risk. Further work is required to study the roles of the 
other enzymes in the folate and methylation cycle. However, other techniques may 
need to be employed since many folate enzymes are essential for embryonic 
development such that genetic knockouts of folate enzymes may result in homozygotes 
which do not survive to neurulation stages.
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1.5.4 Disorders in one-carbon metabolism
Recent findings have prompted the “methylation hypothesis” which proposes that folic 
acid prevents NTDs by stimulating cellular methylation reactions (Blom et al., 2006). 
The strongest genetic variant identified to date which increases risk of an NTD-affected 
pregnancy is the MTHFR C677T polymorphism (Van der Put et al., 1995). The 
MTHFR enzyme directs one-carbon units, away from DNA synthesis, towards the 
methylation cycle. Thus, an association between the MTHFR C677T polymorphism 
and NTDs supports a role for the methylation cycle in the etiology of NTDs. Moreover, 
MTHFR polymorphisms which affect the efficiency of this enzyme have been 
associated with DNA hypomethylation (Castro et al., 2004;Friso et al., 2002b). 
However, MTHFR null mice do not develop NTDs (Chen et al., 2001a) therefore 
compensatory mechanisms may operate to overcome this disruption in one-carbon 
metabolism.
Cancer research has clearly demonstrated that variation in dietary levels of methyl- 
donors and folate can alter DNA methylation and subsequently, gene transcription 
(Poirier, 2002). For example, alterations in hepatic p53 gene methylation patterns were 
observed during tumour progression with folate/methyl deficiency in the rat (Pogribny et 
al., 1997). Increases in levels of plasma homocysteine, such as those associated with 
nutritional deficiencies or genetic polymorphisms in the folate pathway, have also been 
associated with parallel increases in plasma SAH and lymphocyte DNA 
hypomethylation (Yi et al., 2000). Similarly, diet induced folate-depletion in post­
menopausal women was found to increase homocysteine levels and decrease 
lymphocyte DNA methylation (Jacob et al., 1998). A study in pregnant women and 
newborns has also linked vitamin deficiency with low SAM/SAH ratios (Guerra- 
Shinohara et al., 2004).
A direct link between dietary folate, DNA methylation and gene transcription has been 
demonstrated in animal models. For example, epigenetic regulation of transcription 
was demonstrated in the viable yellow agouti (Avy/a) mouse model using a methyl-rich 
diet which caused increased DNA methylation. This methylation silenced transcription 
of a retro-viral transposon within the agouti gene and normalised expression of the 
agouti gene, resulting in a change of coat colour from yellow to brown (Waterland and 
Jirtle, 2003;Wolff et al., 1998). Thus, it is evident that folate nutrition may play a key 
role in the regulation of the methylation cycle and DNA methylation. However, it 
remains to be definitively established how the diet, particularly the folate content, might 
affect methylation in NTD models.
42
Microarray analysis following folic acid supplementation to rescue NTDs in Folbp-/- 
embryos demonstrated an increase in the expression of the PCMT1 gene (which 
encodes the protein repair enzyme L-isoaspartate O-methyltransferase, PIMT), thus 
implicating a possible role for protein methylation in the prevention of NTD 
(Spiegelstein et al., 2004). Additionally, a known functional polymorphism of the 
PCMT1 protein (lle120Val) in the SAM binding motif has been found to be associated 
with a reduced risk for spina bifida when patients are of the Val120Val genotype (Zhu 
et al., 2006).
Other pathways involved in one-carbon metabolism, besides the folate and methylation 
cycles, may also play a role in the pathogenesis of NTDs. These include the pathways 
for polyamine synthesis and the catabolism of choline and betaine. Decarboxylated 
SAM, formed from the methylation cycle metabolite SAM, is required for the synthesis 
of the polyamines, spermidine and spermine. Polyamines are positively charged 
molecules which interact with DNA, RNA and phospholipids, and play essential roles in 
the growth and function of normal cells (Wallace et al., 2003). Their role during 
neurulation has yet to be investigated but the recent development of polyamine 
inhibitors may prove useful agents in the future. Choline can be metabolised to 
betaine, which serves as an alternative methyl donor for the remethylation of 
homocysteine to methionine by the enzyme BHMT (Figure 1.6). Dietary intake of 
choline and betaine has been associated with reduced risk of NTDs (Shaw et al., 
2004), whilst perturbation of choline metabolism in mouse embryo culture causes 
NTDs (Fisher et al., 2001;Fisher et al., 2002). However, to date, there is no evidence 
implicating abnormalities in the BHMT gene as NTD risk factors (Boyles et al., 2005).
1.5.5 NTD causing teratogens and folates
Embryonic exposure to environmental agents and conditions plays a key role in the 
aetiology of NTDs (see section 1.2.2). Described below are three examples whereby 
folate has been shown to prevent NTDs induced by teratogenic or environmental 
agents.
1.5.5.1 Valproic Acid
Maternal use of the anti-convulsant drug, valproic acid (VPA), is associated with a 1- 
2% risk of spina bifida in infants, compared with a risk of 0.06% in the general 
population (Robert and Guidbaud, 1982). In contrast, VPA treatment in mice induces
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mainly exencephaly, whilst spina bifida is rarely reported (Ehlers et al., 1992;Nau et al., 
1991). The reason why VPA induces exencephaly in mice and spina bifida in humans 
is not understood but it may be that there are some common events in cranial and 
spinal closure which are susceptible to VPA. Published reports of the effects of folic 
acid on the frequency and severity of VPA-induced NTDs have described differing 
results claiming both ameliorative and augmentative effects, whilst some studies report 
no effects at all (Hansen et al., 1995;Hansen and Grafton, 1991 ;Nau et al., 
1991;Padmanabhan, 1997;Padmanabhan and Shafiullah, 2003;Seller, 1994b;Trotz et 
al., 1987). These differences may have arisen due to species and strain variations, 
and differences in dose and timing of folic acid treatment.
Epileptic patients with malformed infants have a particularly low plasma folate 
concentration (Dansky and Finnell, 1991;Ogawa et al., 1991). The link between VPA 
therapy and alterations in folate metabolism comes from the fact that anti-epileptic 
agents, including VPA, were shown to interfere with folate metabolism in the embryo 
(Hansen and Billings, 1985;Netzloff et al., 1979). Folate levels are known to be 
lowered during pregnancy and anti-epileptic drugs including VPA, intensify this effect 
(Handel et al., 1984;Lewis et al., 1998). VPA may also reduce folic acid and B12 levels 
in pregnant mice (Padmanabhan, 1997). One study, investigating maternal metabolic 
effects after treating pregnant mice with VPA reported methioinine deficiency. This 
was associated with elevated homocysteine in plasma, whilst hepatic concentrations of 
SAM and SAH were both increased (Hishida and Nau, 1998). Thus, VPA-induced 
NTDs may be associated with impaired folate or methylation cycle metabolism which 
can be ameliorated by supplemental folate metabolites.
1.5.5.2 Fumonisins
Fumonisins are a family of toxic and carcinogenic mycotoxins produced by a common 
fungal contaminant of maize (Gelderblom et al., 1988). Fumonisins cause 
accumulation of bioactive sphingolipid intermediates as well as the depletion of 
complex sphingolipids, through inhibition of ceramide synthase. Disruption of 
sphingolipids can affect cell membrane lipid microdomains which are required for the 
function of membrane proteins. High incidences of NTDs occur in some regions of the 
world where substantial consumption of fumonisins has been documented or 
suggested, suggesting that fumonisin intake is a risk factor for human NTDs.
In mouse embryos, exposure to a prevalent fumonisin isoform, FB^ affects overall 
growth and causes cranial NTDs both in vivo and in embryos maintained in culture
44
(Marasas et al., 2004;Sadler et al., 2002). Significantly, administration of supplemental 
folate or complex sphingolipids protected embryos from the teratogenic effects of FE .^ 
A potential link between fumonisins, folates and NTD risk originates from studies by 
Stevens and Tang who demonstrated that receptor-mediated folate uptake was halved 
in cells pretreated with fumonisin (Stevens and Tang, 1997). The folate transporter 
(Folbpl/FRa) is a glycosylphophatidylinositol-anchored protein associated with lipid 
microdomains. Since fumonisins act via the inhibition of ceramide synthase, it has 
been proposed that this teratogen interferes with the function of the folate receptor, and 
thereby affects growth and neural tube closure. Thus, fumonisin may cause embryonic 
folate deficiency due to impaired function of the placental folate receptor.
1.5.5.3 Hyperthermia-induced NTDs
Both in humans and laboratory animals, brief maternal exposure to high temperatures 
(>2.5 °C above normal) early in pregnancy has been associated with the occurrence of 
NTDs (Edwards et al., 1995). Experimental exposure to hyperthermia in mouse 
embryos causes exencephaly, the frequency of which can be modified by other 
exogenous agents such as alcohol (Shiota, 1988;Shiota et al., 1988). Supplemental 
folic acid is capable of preventing hyperthermia-induced NTDs (Shin and Shiota, 1999), 
thus, demonstrating that FA can protect against environmentally induced NTDs. It is 
not clear how FA can prevent heat-induced NTDs but it has been proposed that FA 
may ameliorate the transient arrest of cell proliferation, which has been reported 
following brief maternal hyperthermia (Shin and Shiota, 1999).
1.6 Summary
In summary, there has been a vast array of studies investigating the role of folate in the 
prevention of NTDs and several mechanisms have been described. Overall, studies of 
folate-preventable NTDs implicate a role for multiple interacting genes and 
environmental influences. Further work is needed to study the role of gene-gene and 
gene-environment interactions that alter NTD risk. Nonetheless, despite worldwide 
recommendations on folate supplementation and folate fortification in the USA, women 
are still having NTD-affected pregnancies. This fact demonstrates the need for 
adequate education about the benefit of folic acid and highlights the need for 
approaches for prevention of folate-resistant NTD.
45
1.7 Aims of this study
The main aims behind this study are to gain a greater understanding of the protective 
effect exerted by folic acid against neural tube defects, to study how low folate status 
increases NTD risk and to investigate other agents capable of preventing NTDs, which 
can be used in conjunction with folic acid. The study attempts to answer the following 
questions;
1) What is the abundance of methylation cycle intermediates in neurulation- 
stage embryos?
To explore the role of embryonic one-carbon metabolism in the pathogenesis of NTDs, 
a novel method was developed using Liquid Chromatography Tandem Mass 
Spectrometry (LC-MS/MS) to quantify the concentration of two one-carbon metabolites, 
S-Adenosylmethionine (SAM) and S-Adenosylhomocysteine (SAH) in neurulation- 
stage mouse embryos.
2) Are NTDs associated with perturbations of the methylation cycle?
The method developed to quantify SAM and SAH provided the means to analyse 
mouse embryos in which NTDs occurred following perturbation of the methylation cycle 
or DNA methylation. The method was further adapted to quantify SAM and SAH in 
cells derived from two populations of NTD patients, to test whether the methylation 
cycle was disturbed.
3) Does dietary folate deficiency influence the incidence of NTDs in a folate- 
preventable mouse model?
A folate-deficient diet was used to test whether dietary folate deficiency increases the 
incidence of NTDs in a folate-preventable (splotch) mutant mouse strain. Using this 
system, I explored the interaction between an environmental and a genetic factor in the 
etiology of folate-preventable NTDs.
4) Does dietary folate deficiency influence the incidence of NTDs in a mouse 
model which does not respond to folic acid supplementation?
A folate-deficient diet was used to test the effect of dietary folate deficiency on the 
incidence of NTDs in the curly tail mutant mouse strain, in which spinal NTDs are not 
preventable by folic acid. Folate deficiency caused an increased rate of exencephaly 
both in curly tail and a genetically matched wild-type strain. Maternal and embryonic 
one-carbon metabolism was then studied in these mice.
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CHAPTER 2
General Methods
2.1 Materials
Unless stated, all compounds were purchased from Sigma-Aldrich. Solvents and water 
used for LC-MS/MS were of HPLC grade (Fisher Scientific). For the L.casei 
micobiological assay and the protein determination assay, samples were analysed in 
sterile microwell (96 well) plates (Nunc). The folic acid L  casei media provided by 
Prof. John Scott was purchased from Difco in large batches to ensure consistency for 
clinical assays. Prof. John Scott also kindly donated the prepared Lactobaccillius casei 
(L.casei) bacteria inoculums. Samples were analysed by LC-MS/MS using vials with 
200 pi inserts sealed with standard PTFE caps (Chromocol). Sterile phosphate 
buffered saline (PBS) solutions, prepared by adding 1 PBS tablet (Oxoid) to 100 ml of 
dH20, were sterilised by autoclaving at 115 °C for 10 min.
2.2 Mouse Colonies
Non-mutant CD1 mice (Charles River Laboratories Inc.) and wild-type mice on a 
partially congenic curly tail background (+/+ct) were maintained as random bred 
colonies. Curly tail mice (ct/ct) were maintained as a homozygous, random-bred stock 
to ensure that all mice/embryos were homozygous for the unknown ct mutation. 
Splotch (Sp2H) mice were maintained as a closed colony by matings of Sp2H/+  males 
with wild-type females. Heterozygous offspring, which are identified by the presence of 
a belly spot, were used for generation of experimental litters. Female Sp2H/+ were 
mated with Sp2H/+ males to produce embryos of +/+, Sp2H/+ and Sp2H/Sp2H genotype 
(section 2.5). All mice were housed in plastic-bottomed cages with shavings and were 
exposed to a 12 hour light/dark cycle in a temperature-controlled room.
2.3 Dietary Studies
A normal diet (ND; Harlan, Ref. No. 2018), the recommended diet intended for 
laboratory animals (Harlan), contained adequate quantities of all nutrients (Table 2.1). 
For the dietary studies in chapters 5 and 6, mice received synthetic diets which, apart 
from the folic acid, succinylsulfathiazole and myo-inositol content, contained identical 
levels of all other nutrients (Table 2.1). Mice had free access to the assigned diets for 
a minimum of three weeks prior to mating. Injections (I.P. injections) of folic acid, 
thymidine, and myo-inositol, dissolved in PBS, into the peritoneal cavity were given at 
E7.5, E8.5, E9.5 and E10.5 (for further details see section 5.2 and 6.2).
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Vitamins
Vitamin A iu/g 15.40
Retinol mg/kg 4.65
Vitamin D3 iu/g 1.54
Cholecalciferol pg/kg 38.39
Vitamin E mg/kg 101.00
Vitamin K3 mg/kg 51.00
Vitamin Bi mg/kg 16.50
Vitamin B2 mg/kg 14.90
Available Niacin mg/kg 41.20
Vitamin B6 mg/kg 18.50
Pantothenic Acid mg/kg 33.00
Vitamin B-i2 mg/kg 0.08
Available Biotin mg/kg 0.30
Folate mg/kg 3.34
Vitamin C mg/kg 0.00
Choline mg/kg 1120.00
B Carotene mg/kg 2.47
Inositol mg/kg 1455.00
Minerals
Calcium i  %
i
1.01
Phosphorus % 0.65
Sodium !  %
i
0.23
Potassium % 0.68
Chloride ! % 0.40
Magnesium
!  % 0.20
Zinc ! mg/kg 77.00
Manganese I mg/kg 118.00
Copper I mg/kg 15.21
Iodine (added) | mg/kg 11.55
Iron j  mg/kg 226.00
Selenium mg/kg
j
0.20
Cobalt mg/kg
I
0.63
Chromium | mg/kg 0.53
Amino Acids
Aspartic Acid % 1.42
Glutamic Acid | % 3.70
Alanine % 1.08
Glycine % 0.79
Threonine % 0.67
Proline % 1.55
Serine ■ % 0.97
Leucine % 1.94
Isoleucine % 0.85
Valine % 0.95
Phenylalanine % 0.99
Tyrosine % 0.61
Phe + Tyr % 1.60
Methionine % 0.35
Cysteine % 0.33
M et + Cyst % 0.69
Lysine : % 0.92
Histidine % 0.47
Arginine % 1.06
Tryptophan % 0.20
Available Lysine % 0.83
Fatty Acids
C 12:0  Laurie g/kg 0.26
C 14:0  Myristic g/kg 0.06
C 16:0  Palmitic g/kg 7.64
C 18:0  Stearic g/kg 1.50
C20:O Arachidic g/kg 0.10
C 22:0  Behenic g/kg 0.03
C16:1cj7 Palmitoleic g/kg 0.07
C18:1 w9 Oleic g/kg 12.59
C20:1uj9 Gadoleic g/kg 0.17
C22:1w9 Erucic g/kg 0.01
C18:2co6 Linoleic g/kg 31.35
C18:3co3 Linolenic g/kg 2.76
Proximate Analysis
Crude Protein % 18.90
Crude Oil % 6.00
Crude Fiber % 3.80
Ash % 5.90
NFE % 55.40
Carbohydrate % 57.33
Starch % 41.24
Sugar % 4.93
Digestible Energy Kcal/g 3.4
Metabolizable Energy Kcal/g 3.4
Table 2.1. Nutritional content of mouse diets. Italics indicate nutrients that were removed to 
give rise to the various research diets (FD, FID, BFD, DFD). Succinylsulfathiazole (10 g/Kg) was 
added to the FD, FID and BFD diets to eliminate folate produced by the gut bacteria.
2.4 Maternal whole blood and plasma collection
After a minimum of three weeks on the designated diet, blood was collected from the 
dams immediately after anaesthesia with halothane. A 1 ml syringe with a 21 gauge 
needle was inserted directly into the contracting heart and the blood slowly withdrawn. 
The blood was then transferred to a lithium-heparin coated tube (Microtainer™, BD) to 
stop the blood from clotting. For whole blood folate analysis, 50 pi of blood was diluted 
into a fresh eppendorf with 50 pi of 1 % ascorbic acid to prevent oxidation of folates 
during storage, and stored at -80 °C until required (maternal folate analysis; section 
2.9.1). For homocysteine analysis, the whole blood sample was centrifuged at 12,000g 
for 15 min to collect plasma. Plasma was stored briefly at -20 °C prior to shipment 
overnight on dry ice.
The measurement of total homocysteine in the collected plasma samples was 
undertaken by Ms. R. Dempsey at the Vitamin Research Laboratory (Trinity College, 
Dublin, Ireland) using the Abbott IMx instrument set-up for the FPIA (Fluorescent 
Polarisation Immunoassay) method.
2.5 Embryo collection and dissection
Experimental litters were generated by timed matings in which females were paired 
with males overnight and checked for a copulation plug the following morning, this 
being designated embryonic day 0.5 (E0.5). To study neurulation-stage embryos, 
litters were collected at embryonic day (E) 9.5, 10.5 and 11.5.
On the required embryonic day, each female mouse was killed by cervical dislocation 
and the uterus was explanted into Dulbecco’s Modified Eagle’s medium (DMEM) 
containing 10% fetal calf serum. The total number of implantations (classified as viable 
embryos/fetuses) or resorptions, was recorded. For embryos not undergoing whole 
embryo culture, embryos were explanted from the maternal decidua and separated 
from the visceral yolk sac and Reichert’s membrane.
2.6 Embryo Culture
At E8.5, mice were killed by cervical dislocation and the uterus was explanted into 
Dulbecco’s Modified Eagle’s medium (DMEM) containing 10% fetal calf serum. 
Embryos, contained within the visceral yolk sac, were explanted from the maternal 
deciduas and cultured in immediately centrifuged, heat inactivated rat serum at 37 °C
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(section 2.7). At E8.5, serum was equilibrated with 5% 0 2, 5% C 02, 90% N2, and then 
at E9.5, with 20% 0 2, 5% C 02, and 75% N2. Embryos from within litters were randomly 
selected for different treatment groups to minimise any effect of litter to litter variation.
Stock solutions of 400 mM methionine (ICN Biomedicals Inc.), 200 mM ethionine, 375 
mM cycloleucine and 410 mM azacytidine in phosphate-buffered saline (PBS) were 
prepared and added as 0.2 - 4.0 % additions to the culture medium (2 - 40 pl/ml) giving 
final concentrations of 5 mM methionine, 5 mM ethionine, 15 mM cycloleucine and, 0.8 
and 2 mM azacytidine. PBS alone was added to control groups at the same volume as 
reagent being tested. At the end of the culture period, the yolk sac circulation was 
observed as an indication of viability and quantified on a scale of 0 (no circulation) to 3 
(vigourous circulation throughout the entire yolk sac). For further details on embryo 
culture refer to (Copp et al., 1999).
2.7 Preparation of rat serum for culture of mouse embryos
Wistar rats were anaesthetised using diethyl ether and then dissected to reveal the
dorsal aorta. A 21 gauge needle attached to a 20 ml syringe was inserted into the
dorsal aorta and blood was extracted. The diaphragm was punctured to ensure the rat 
could not survive post-operation. The extracted blood was immediately centrifuged for 
5 minutes at 4000 rpm. The blood which had by then separated into plasma and red 
blood cells was left at room temperature to allow clotting. The resulting fibrin clot was 
then squeezed to allow a maximal amount of serum to be collected. Serum was 
removed and centrifuged again for 5 minutes at 4000 rpm to remove any residual blood 
cells. Serum was then heat inactivated at 56°C for 30 minutes, and allowed to cool to 
room temperature before aliquoting into bijoux tubes for storage at -20°C.
2.8 Processing of Embryos
After dissection or whole embryo culture, the embryos were inspected for the presence 
of cranial defects, consistent with the appearance of exposed and open neural folds or 
cranial tissue or, openings in the cranial neural tube. The number of somites was 
counted as a measure of developmental progression. The crown-rump length and 
posterior neuropore length were recorded using an eyepiece graticule, to give an 
indication of embryonic growth and progression of spinal neural tube closure, 
respectively. The position of each embryo with respect to the uterine horn and 
neighbouring embryos was also noted in some experiments. For biochemical assays, 
embryos were briefly washed with PBS and immediately frozen on dry-ice prior to 
storage at -80 °C. The yolk sacs were retained for genotyping by PCR.
51
2.9 Genotyping of embryos by Polymerase Chain Reaction (PCR)
2.9.1 Extraction of DNA from yolk sac samples
Yolk sacs, previously dissected from the embryos, were digested with 50 pi of 10 pg/ml 
proteinase K (Invitrogen) at 50 °C overnight. The solution was subsequently incubated 
at 100 °C for 10 minutes to denature the proteinase K followed by centrifugation at 
14,000 rpm for 5 min to pellet the cell debris. A 2 pi sample of the supernatant was 
used for the PCR reaction.
2.9.2 PCR Protocol
A reaction mixture was prepared containing 1X NH4-PCR buffer (Bioline), 1.5 mM 
MgCI2 (Bioline), 0.25 mM of each deoxynucleoside triphosphate (dNTP) (Bioline), and 
0.8 mM of both reverse and forward primers (Table 2.2). The reaction mixture was 
kept on ice and immediately prior to use 1 unit of Taq polymerase (Bioline) per reaction 
was added followed by distilled deionised water (ddH20) to give a final volume of 23 pi 
for each reaction. The resulting solution was mixed and 23 pi was added to 2 pi of yolk 
sac DNA solution. Controls were run with each PCR reaction; the negative control did 
not contain any DNA to ensure the reaction mixture was not contaminated and the 
positive control used previously genotyped DNA to check the components of the 
reaction mixture (Table 2.2). The amplification reaction was carried out on a PTC-200 
DNA Engine (MJ Research) and involved an initial denaturation step followed by 
amplification cycles of denaturation, annealing and extension (Table 2.2). Each 
amplification cycle was repeated a number of times (Table 2.2) before a final extension 
step was carried out (Table 2.2).
The primers used to genotype Sp2H mice were designed to span the 32 bp deletion in 
the paired box region of the Pax3 gene, as described by Epstein and colleagues 
(Epstein et al., 1991), resulting in different sized bands for wild type and mutant alleles 
(Table 2.2, Figure 2.1 and 2.2). The sex of the embryo was determined by PCR using 
sex-specific primers to amplify the Smcx and Smcy genes (Agulnik et al., 1999). In 
each case, the PCR products were resolved by horizontal agarose gel electrophoresis 
(section 2.9.3).
2.9.3 Agarose gel electrophoresis
A 2% (w/v) agarose in 1X TAE (0.04 M Tris-acetate, 0.001 M EDTA) gel was made by 
melting the mixture in a microwave with occasional stirring. The gel was then left to
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cool, approximately 0.5 mg/ml ethidium bromide was added and the mixture was 
poured into a casting tray with combs and allowed to set at room temperature. Once 
the gel was solid, it was placed in a horizon gel tank (Gibco BRL) containing 1X TAE 
buffer and 10 pi of the PCR products containing 1X loading dye (0.25% bromophenol 
blue, 0.25% Xylene cyanol FF, 15% Ficoll in water) were loaded into the wells. A 
molecular weight marker (Hyperladder V, Bioline) was run in a lane alongside the 
samples on each gel to allow the identification of the size of the products. After 
electrophoresis at 120 volts for 1 hour the PCR products were visualised under UV light 
and photographed using an alpha imager system (Alpha Innotech).
Genotvpinq Sd2h embryos
Forward Primer Sequence 5’ CCTCG GTAAG CTTCG CCCTCTG 3’
Reverse Primer Sequence 5’ CAGCGCAGGAGCAGAACCACCTTC 3’
PCR product size Wild type allele 122bp 
Mutant allele 90bp
| Initial Denaturation Step 94 °C for 4 min
Amplification Cycle Denaturation at 94 °C for 1 min 
Annealing at 58 °C for 1 min 
Extension at 72 °C for 1 min
Number of cycle 30
Final Extension Step 72 °C for 10 min !
Genotvpinq embryonic sex
Forward Primer Sequence 5’ CCTATGAAATCCTTTGCTGCACA 3 ’
Reverse Primer Sequence 5' AAG AT AAGCTT AC AT AAT C AC AT 3 ’
PCR product size
]
Male allele 370bp 
Female allele 350bp
Initial Denaturation Step 95 °C for 5min
Amplification Cycle Denaturation 92 °C for 1 min 
Annealing 60 °C for 1 min 
Extension 72 °C for 2 min
Number of cycles 72 °C for 10 min
Final Extension Step 30
Table 2.2. The primer sequences, product sizes and PCR conditions for determining Sp2H 
genotype and sex.
primer
band
Figue 2.1. Visualisation of Sp2H PCR products after agarose gel electrophoresis. Lane 1 
contains 5 pi (960 ng DNA) of hyperladder. The negative and positive controls are shown in 
lane 2 and 3, respectively. The positive control, using heterozygote DNA, illustrates both the 
wild type allele (the upper band at 122bp) and the mutant allele (the lower band at 90bp). The 
remaining lanes show the genotyping of wild type (lane 6 and 7), heterozygous (lane 4) and 
homozygous mutant (lane 5) embryos.
Figue 2.2. Visualisation of Smcx/Smcy PCR products after agarose gel electrophoresis.
Lane 1 contains 5 pi (960 ng DNA) of hyperladder. Positive controls for male and female 
embryos are shown in lanes 2 and 3, respectively. The male positive control (Lane 2), using 
male DNA, contains both the Smcx and Smcy gene products. The female positive control (Lane 
3) using female DNA, contains just the Smcx gene product. The remaining lane (Lane 4) shows 
the genotyping of a male embryo.
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2.10 Determination of Folate using the L. Casei Microbiological
Assay
2.10.1 Preparation of maternal whole blood samples to determine total 
folate content
Blood samples were defrosted at room temperature. To deconjugate the 
polyglutamylfolates to assayable monoglutamylfolates, 6 pi of whole blood was diluted 
10:1 with freshly made 1% ascorbic acid and incubated at 37 °C for 1 hr. Directly 
following deconjugation, 25 pi of the sample was diluted 50:1 with 0.5 % sodium 
ascorbate. The sample was then assayed immediately or stored at -20 °C until 
required.
To set-up a sample plate for the whole-blood folate assay, 50 pi of the prepared blood 
sample was added to each well in one row of a 96-well microplate. Therefore, each 
sample was analysed in eight replicates enabling up to twelve samples to be analysed 
per microplate. To each sample well, 50 pi of 0.5 % sodium ascorbate was added 
using a multichannel pipette.
2.10.2 Preparation of conjugase extract
Since it was not known whether neurulation-stage embryos express the conjugase 
enzyme, exogenous conjugase extract was added to the embryo homogenates to 
convert polyglutamylfolates to monoglutamylfolates. The conjugase extract was 
prepared from rat serum using the method described by McKillop et al. (McKillop et al.,
2002).
Rat serum was collected and stored as described (section 2.7) but was not heat 
deactivated. To partially purify the rat serum, 5 ml was dialysed for 24 hrs at 2-4 °C in 
500 ml Hepes/Ches buffer, pH 7.85 (50 mM Hepes, 50 mM Ches, 20 g/L Ascorbic acid, 
10 mM 2-mercaptoethanol) using Slide-A-Lyser dialysis cassettes (10,000 molecular 
weight cut-off; Pierce). The crude rat serum conjugase was then filtered through a 0.2 
pm syringe filter (Millipore) and divided into 100 pi portions and stored at -80 °C. The 
conjugase extract was tested for folate content and no measurable folate was detected.
2.10.3 Preparation of embryo samples to determine folate content
Neurulation-stage mouse embryos (E9.5-E10.5) were sonicated on ice in 100 pi of 
distilled water, for 10 s at 12 amplitude microns, to produce a homogenate. A 10 pi
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aliquot was stored at -20 °C to determine the protein content in the embryo sample 
(section 2.10). The homogenate was then diluted 2:1 with 0.5 % sodium ascorbate to 
stabilise the folates during handling and storage.
To determine monoglutamylfolate content, a 10 pi aliquot was taken from the 
homogenised embryo sample and diluted 200:1 with 1990 pi of 0.5 % sodium 
ascorbate to provide sufficient sample for analysis on two different days. The prepared 
sample was analysed immediately and the remaining sample was stored at -20 °C for 
analysis on a different day (within a week).
To determine total folate content, a 10 pi aliquot from a homogenised embryo sample 
was diluted 10:1 with 10 pi of conjugase extract (prepared as described in section 
2.10.2) and 80 pi of 1 % ascorbic acid. The solution was incubated at 37 °C for 60 min 
to deconjugate polyglutamylfolates to assayable monoglutamyfolates. Following this, 
the solution was diluted 20:1 with 1900 pi of 0.5% sodium ascorbate to provide 
sufficient sample for analysis on two different days. The prepared sample was 
analysed immediately and the remaining sample was stored at -20 °C for analysis on a 
different day (within a week).
To set-up a sample microwell plate for the assay, 100 pi aliquots of the prepared 
embryo sample was plated into each well of one lane. The position of each sample on 
the microplate was recorded along with the sample type (monoglutamylfolate or total 
folate).
2.10.4 Quality Control
A minimum of two quality controls (QC) were included in each assay run. QCs were 
prepared by diluting the entire homogenised solution from either one (200 pi) or two 
(400 pi) embryos with 40 ml of 0.5 % sodium ascorbate to provide a high and a low 
value QC. 1 ml aliquots of each QC were stored at -80 °C until required. On the day 
of analysis an aliquot was freshly defrosted and 100 pi was plated into each well of one 
row on the sample plate. Following completion of the assay, the folate content was 
measured from the standard curve and the results recorded.
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2.10.5 L. Casei Microbiological Assay
2.10.5.1 Preparation of Folate Media
The folate media was made up fresh immediately prior to analysis as follows. To 100 
ml of distilled water was added 7 g of folic acid casei media (stored at 4 °C) and 3 mg 
of chloramphenicol and mixed gently. The media was warmed for 40 s in a microwave 
before the addition of 30 pi Tween-80. The media was further heated for approximately 
1 min until it boiled and then left to cool at room temperature. Once cooled, 75 mg of 
ascorbic acid was added.
Immediately prior to plating, a vial of cryopreserved L.casei innoculum was removed 
from the -80 °C freezer and allowed to thaw. The innoculum was thoroughly mixed by 
inverting ten times and 200 pi was added to 100 ml of media. The media was placed 
on a magnetic stirrer and mixed for 10 min before plating.
The above protocol provided 100 ml of media which was enough for 5 plates (4 sample 
plates and 1 standard plate). For more then five plates, the amount of each reagent 
was doubled to provide a total of 200 ml of media.
2.10.5.2 Preparation of Folate Working Standard
Solution A (20 pg/ml) was prepared by dissolving 20 mg of folic acid with a few drops of 
0.1 M sodium hydroxide and this solution plus the washings were added to 1 L of 
distilled water. Solution A was diluted 200:1 with 0.5 % sodium ascorbate to give 
Solution B (100 ng/ml). Solution B was dispensed into 750 pi aliquots and stored at - 
80 °C.
The final working standard, called Solution C, was prepared fresh on the day of the 
assay. An aliquot of Solution B was diluted 200:1 in 50 ml of 0.5 % sodium ascorbate 
to give a working standard concentration of 500 pg/ml. A series of dilutions were 
prepared from Solution C to create the standard curve for the assay.
2.10.5.3 Performing the Assay
The sample plates and solutions were prepared as described above. The “standards 
plate” was then made up by diluting the folate working standard Solution C, with 0.5% 
sodium ascorbate to give a series of concentrations (Figure 2.3). Just before use, the 
L. casei bacterial innoculum was added to the folate media as described (section
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2.9.4.2.1) and 200 |jl of the inoculated media was added to each well on all plates 
using a multichannel pipette ensuring the tips did not touch the sample in the wells. 
Plates were sealed, with the time noted on the plate seal (Perkin-Elmer), and incubated 
at 37 °C for 42 hr. Following incubation, the OD595nm for each plate was read using a 
MRX Revelation microplate reader (Dynex Technologies) and the readings were 
printed out for data analysis.
1 2 3  4 5  6 7 8  9 10 11 12
Solution C (pi)
A
B
C
D
E
F
G
H
0.5%  Sodium Ascorbate
Final Concentration 
(pg folic acid / well)
40 50
Figure 2.3. Diagram of the “Standards Plate”. The standards plate was prepared to give 
serial dilutions of solution C (500 pg/ml) in 0.5% sodium ascorbate such that each dilution was 
replicated in eight wells of one column.
2.10.5.4 Data Analysis
Based on readings from the standards plate, a calibration curve was plotted for each 
assay (Figure 2.4) using the polynomial cubic regression function (Sigma Plot Version 
7, SPSS Inc.). To determine folate content in an analytical sample, firstly the average 
absorbance reading was calculated for the corresponding eight wells. The standard 
deviation was also noted and if shown to be greater than 0.05 the sample was re­
analysed. Using the standard plot equation, the folate content /100 pi (folate content / 
well) was calculated from the mean absorbance reading. To determine the folate 
content in the analytical sample (embryo homogenate or whole blood sample), the 
folate content / 100 pi was multiplied by the final dilution factor. For embryo samples, 
the folate per embryo was also normalised to protein content to give the folate 
concentration in the embryo. Monoglutamylfolate concentrations were quantified in 
embryo homogenates, in addition to total folate (monoglutamylfolate + 
polyglutamylfolate). Polyglutamylfolate concentrations were calculated by subtracting 
the monoglutamylfolate concentration from the total folate. Each sample was assayed
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on two different days and the results were compared. If the coefficient of variation 
between the results from the two different days was greater than 5 % then the sample 
was analysed again.
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Figure 2.4. Standard curve based on the growth response of L. casei to folic acid. Points 
represent the means +/- standard deviation of eight replicates in the case of the folic-acid 
containing standards and sixteen replicates for the zero standard.
2.11 Determination of Embryonic Protein Content
From embryo homogenates, 10 pi aliquots were used for the determination of 
embryonic protein content using the bicinchoninic acid (BCA) protein assay reagent 
(Pierce) following the manufacturer’s instructions for the microplate procedure. Various 
dilutions (25:1, 50:1, 100:1, 200:1) of the homogenates were prepared to achieve a 
sample within the standard curve range. A series of standard protein solutions were 
made, ranging between 0-100 pg/ml, from an initial 2 mg/ml standard protein solution 
(bovine serum albumin). For the microplate procedure, replicate 25 pi aliquots of each 
standard or unknown sample were added to each microplate well. The BCA working 
reagent, a 50:1 mixture of reagents A and B (Pierce), was made fresh for each assay. 
BCA working reagent (200 pi) was added to each standard/sample well and incubated 
for 30 minutes at 37 °C. The OD562nm for each well was read using a MRX Revelation
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microplate reader, a standard curve was plotted and protein concentration of the 
samples calculated, using pre-installed software (Revelation Software Version 4.2.1).
2.12 Liquid Chromatography Tandem Mass Spectrometry 
(LC-MS/MS)
2.12.1 LC-MS/MS Method
Prior to analysis by mass spectrometry, metabolites were separated on a column using 
a 2795XE high performance liquid chromatography (HPLC) unit with solvent divert 
valve (Waters, Manchester, UK). The HPLC was coupled to a MicroMass Quattro 
micro™ triple quadrupole tandem mass spectrometer (Waters) operating in the desired 
ion mode using the following settings (unless stated otherwise): source temperature 
150°C, desolvation temperature 350°C, cone gas flow rate 50 L/hr, desolvation gas 
flow rate 650 L/hr, inter channel delay 0.030 sec, inter scan time 0.030 sec, dwell 0.100 
sec and span 0.2 Da. The mass spectrometer was equipped with an electrospray 
ionisation (ESI) source. In each case, the Selected Reaction Monitoring (SRM) mode 
was used for quantification and data were acquired and processed using MassLynx 
software (version 4.0, Waters). Precursor and product ion spectra were obtained at a 
resolution of 15.0 (LM1, HM1, LM2 and HM2), whilst all other analyses were obtained 
at a resolution of 13.5 (LM1, HM1, LM2 and HM2).
2.12.2 Calibration curve method for quantification
To generate a calibration curve, the “peak area of the calibrator / peak area of the 
internal standard” was plotted against increasing concentrations of calibrator spiked 
into the biological matrix (Figure 3.8 and 7.11). This calibration curve was then used to 
deduce the endogenous metabolite level in the biological matrix by determining the 
intercept on the x-axis when y = 0. The endogenous metabolite level was subtracted 
from each of the calibrators to create a curve that passed through zero on the x-axis. 
These working calibration curves were then used to quantify the levels of metabolites in 
samples. Linear regression analysis (un-weighted) was performed using Sigma Plot 
Version 7.0 (SPSS Inc., Chicago, Illinois).
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2.13 Cell culture
2.13.1 Basic cell culture procedures for fetal fibroblasts
Sterile conditions were used throughout the cell culture procedures to minimise the 
possibility of contamination. Procedures were carried out in a class II microbiological 
safety cabinet (Envair) and before entering the safety cabinet, all materials were 
sprayed with 70% industrial methylated spirits (IMS). Solutions were warmed to 37 °C 
before use. DMEM (Dulbecco’s Modified Eagle’s Medium) containing 1.5 g/l sodium 
bicarbonate, 10% fetal calf serum, 2% chicken serum, 100 Units penicillin and 100 
pg/ml streptomycin was used as culture medium throughout this study and is referred 
to as “medium”. Medium was made up in 500 ml bottles when needed, sterilised by 
vacuum driven filtration through a 0.22 pm filter stericup (Millipore) and used or 
discarded within a two week period. Cells were cultured in a Galaxy R C 02 incubator 
(Scientific Laboratory Supplies Ltd.), with 5% C02at 37 °C.
2.13.2 Sample collection and processing of fetal fibroblasts
Samples of amniotic fluid, skin, cord or cartilage were collected with ethical permission 
by fetal pathologists at University College Hospital, from fetuses aged 12-21 weeks. 
Samples were allocated to one of two groups, NTD-affected or control (normal fetuses 
or fetuses affected with malformations other than NTD). The samples were sent to 
Great Ormond Street Hospital (GOSH) cytogenetics laboratory where fibroblastic cell 
lines were established.
Human cell lines established by the GOSH Cytogentics Laboratoy were frozen down in 
medium containing 10% dimethyl sulfoxide (DMSO) and stored in liquid nitrogen until 
required. Cells were defrosted and immediately placed in 5 ml medium to dilute the 
DMSO, which could cause cellular damage. The cells were pelleted by centrifugation 
at 1,000 rpm for 5 minutes. The supernatant was discarded and the cells resuspended 
in 3 ml of medium then seeded into a 3 cm plate and incubated with 5% C 02 at 37 °C.
Cells were grown to confluence with changes of medium when necessary. To change 
the medium, spent medium was removed by aspiration and the cells were washed with 
3 ml PBS then 3 ml of fresh medium was added. The growth and health of cultures 
was checked daily using an inverted microscope (Zeiss).
Once the cells were confluent, they were removed from the culture plates by 
trypsinisation. A stock solution of 10X trypsin-EDTA was diluted to 1X in PBS and 1 
ml was added to the cells for 2-3 minutes at 37 °C until they had rounded up and begun
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to detach from the bottom of the flask. The digestion was stopped by centrifuging 
(1000 rpm, 5 min) and resuspending the cells in 1 ml of medium and subsequently 
transferring them into a larger 6 cm plate containing 9 ml of medium. Cells were grown 
again to confluence, passaged by trypsinisation and then each sample was seeded 
onto 2 plates.
2.13.3 Collecting fetal fibroblast cell pellets
At this stage each sample had been seeded onto two 6 cm plates. Cells were grown to 
confluence and subsequently, cells on both plates were detached by trypsinisation. 
The cells from one plate were pelleted by centrifugation for 5 minutes at 1,000 rpm. 
The supernatant was discarded and the cell pellet was stored at - 80 °C prior to 
analysis. The cells from the second plate were seeded onto two further 6 cm plates. 
The plated cells were grown again to confluence and the process repeated to obtain a 
sufficient cell pellet sample for LC-MS/MS analysis. A homogenised cell pellet (see
section 3.3.6) with a protein concentration greater than 1 mg/ml was found to provide
sufficient sample for analysis.
2.13.4 Cycloleucine treatment of 3T3 mouse fibroblasts
Frozen aliquots of mouse 3T3 fibroblasts were grown as described in section 4.2.4.2 
until they covered approximately three quarters of the surface area of a 6 cm plate. 
Spent media was replaced with fresh media containing 0, 15, 30 or 60mM cycloleucine 
and cells were incubated with 5% C 02 at 37 °C for a further 24 h. Cell pellets from all 
plates were subsequently collected by trypsinisation as described in section 4.2.4.3.
2.13.5 EBV transformed lymphoblast cell lines
Cell pellets from EBV (Epstein-Barr Virus) transformed lymphoblast cells were 
prepared by Dr. P. Gustavsson (Karolinska Institute, Sweden). Briefly, peripheral blood 
was taken from Swedish children with open spina bifida and lymphocytes were 
separated using Ficoll. EBV was used to transform the cells to generate a population 
of immortal B lymphocytes. Control cell lines were obtained from normal Swedish 
blood donors. Cells were grown as a suspension in RPMI (RPMI-1640, Roswell Park 
Memorial Institute) media supplemented with 10 % fetal calf serum, 100 u penicillin and 
100 pg/ml streptomycin. Media was changed twice a week and after four weeks of 
growth, cells were harvested the morning following the last media change. To harvest 
the cells, excess media was removed and the remaining media was centrifuged at 
1,000 rpm for 5 minutes to collect the suspended cells. The cell pellet was washed 
with cold PBS and stored at -80 °C prior to analysis of SAM and SAH by LC-MS/MS. 
All cell pellets were analysed as described in chapter 3.
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CHAPTER 3
Quantitative analysis of s-adenosvlmethionine and 
s-adenosvlhomocvsteine in neurulation-stage mouse 
embryos by liquid chromatography tandem mass
spectrometry.
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3.1 Introduction
3.1.1 The Methylation Cycle
The role of folates is to carry one-carbon units, not only for the metabolism of both 
pyrimidines and purines for DNA synthesis, but also for the methylation of a wide variety of 
substrates. The methylation cycle involves the transfer of a methyl group from 5- 
methyltetrahydrofolate to homocysteine by methionine synthase (MS; Figure 3.1). The 
adenosyl moiety of ATP is then transferred to methionine to form S-Adenosylmethionine 
(SAM; Figure 3.2) (Lombardini and Talalay, 1971). SAM is the universal methyl donor for 
methyltransferase-catalysed reactions (Loenen, 2006). Methylation of biomolecules 
including DNA, RNA, lipids and proteins, is essential for a range of cellular processes 
including epigenetic control of gene expression (Friso and Choi, 2002) and regulation of 
protein function (Bergo et al., 2000;Vafai and Stock, 2002).
Cytosine-CH Cytosine
SAH SAM
Methylation
CycleSAHH MAT
MethionineHomocysteine
5-methyltetrahydrofolate TetrahydrofolateFolate
Cycle
MTHFR
5,10-methylenetetrahydrofolate
Figure 3.1. The M ethylation C ycle. MTHFR; 5,10-Methylenetetrahydrofolate Reductase, MAT; 
Methionine Adenosyl-transferase, SAHH; SAH Hydrolase, MT; Methyltransferase, MS: Methionine 
Synthase. Enzyme inhibition by SAM (//) or SAH (II).
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S-adenosylhomocysteine (SAH), formed following the donation of the methyl group from 
SAM (Figure 3.2), acts as a product inhibitor of methyltransferases (De Cabo et al., 1995) 
such that the ratio of SAM to SAH is crucial for regulation of methylation. SAH must be 
efficiently recycled, via the production of homocysteine and methionine, for methylation 
potential to be maintained (Finkelstein, 1998a;Scott, 1999). Thus, the relative abundance 
of SAM to SAH is not only important for methylation, but can also influence flux through 
the folate cycle, which is interlinked to the methylation cycle, since SAM is able to inhibit 
5,10-methylene tetrahydrofolate reductase (MTHFR; EC1.7.99.5) (Kutzbach and Stokstad, 
1971).
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Figure 3.2. S-Adenosylmethionine (SAM) and S-Adenosylhomocysteine (SAH).
3.1.2 Methylation of bio-molecules
DNA methylation involves the addition of a methyl group (donated by SAM) to the 5’ 
carbon position of cytosine, predominantly within a series of cytosine guanine 
dinucleotides (CpG) in the DNA sequence. Clusters of CpGs found in gene promoter 
regions, termed “CpG islands”, play a key role in epigenetics; modifications of DNA that 
alter gene transcription without altering the nucleotide sequence (Oommen et al., 2005).
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Methylation of CpG islands at the site of transcriptional initiation, an epigenetic 
modification, is generally capable of silencing gene transcription either by directly impeding 
the binding of transcription factors, or indirectly, through the binding of methyl-binding 
proteins which restrict the access of transcription factors to the gene promoter or alter the 
chromatin structure to a repressive state (reviewed in Newell-Price et al., 2000;Van den 
Veyver, 2002). DNA methylation is required to silence one allele of imprinted genes 
(Barlow, 1995) or to silence genes on the inactive X chromosome (Hemberger, 2002). 
Scattered transposable DNA elements which make up 30% of the genome must also be 
silenced by DNA methylation as their transcription can disrupt functional genes or induce 
chromosome rearrangements (Yoder et al., 1997). However, there have been reports of 
certain proteins exhibiting increased transcription following promoter methylation (Murrell 
et al., 2001; Hantusch et al., 2007). Furthermore, methylation of CpG islands downstream 
of transcription initiation does not block elongation in mammalian cells, rather methylation 
in the transcribed region is often correlated with gene expression (Jones et al., 1999) and 
hypermethylation of CpG islands has been detected in actively transcribed regions of 
cancer cells (Liang et al., 1998).
Protein methylation, catalysed by protein methyltransferase enzymes, involves the addition 
of the methyl-group provided by SAM to arginine or lysine amino acid residues in the 
protein sequence. Protein methylation may be involved in the ageing/repair of proteins 
and signal transduction (Grillo and Colombatto, 2005), whilst histone protein methylation is 
implicated in chromatin remodelling and transcriptional regulation (Martin and Zhang,
2005). Phospholipid methylation provides an alternative pathway, catalysed by 
phosphatidylethanolamine A/-methyltransferase (PEMT), for the synthesis of 
phosphatidylcholine, a structural component of cell membranes (Hartz and Schalinske,
2006).
3.1.3 Investigating the link between methylation and neural tube closure
The ability to accurately measure SAM and SAH in neurulation-stage mouse embryos will 
provide a means to assess how the methylation capacity of an embryo is affected by 
genetic and environmental disturbances. Comparisons of SAM and SAH levels between 
NTD affected embryos and normal embryos, may provide clarification of the role of these 
two metabolites in the pathogenesis of NTDs. Indeed, the prevention of NTDs by folic acid 
could be associated with increased flux through the methylation cycle (Blom et al., 2006)
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and a change in the levels of SAM and SAH. Provision of SAM for DNA methylation does 
appear essential for neural tube closure, since NTDs are observed in mouse embryos that 
are homozygous null for DNA methyltransferase 3b (Okano et al., 1999). Thus, the 
potential importance of the methylation cycle during embryonic development necessitates 
the establishment of methodology for an accurate and sensitive assay of SAM and SAH in 
an embryonic experimental system such as mouse embryos.
3.1.4 Current methods to quantify SAM and SAH
An outline of the methods currently available to measure SAM and SAH is displayed in 
Table 3.1. Previously, UV detection following HPLC or capillary electrophoresis has been 
used for the detection of SAM and SAH in tissue samples as well as urine, red blood cells 
and lymphocytes (She et al., 1994b); (Luippold et al., 1999). Increased sensitivity can be 
achieved through derivatisation of SAH and SAM followed by fluorescent detection 
(Capdevila and Wagner, 1998). However, these methods were deemed unsuitable for the 
analysis of embryonic levels of SAM and SAH due to the requirement for relatively large 
amounts of tissue sample and limited sensitivity with laborious sample preparation and low 
recovery.
Recently, liquid chromatography coupled to mass spectrometry (LC-MS) has been utilised 
for determination of SAM and SAH owing to the high sensitivity of detection and the ability 
to use stable-isotope-labelled internal standards for precise quantification (Gellekink et al., 
2005;Stabler and Allen, 2004;Struys et al., 2000). The previously reported LC-MS method 
allows assay of tissues (rat liver and lung) as well as fluids (whole blood, plasma, serum 
and urine) (Stabler and Allen, 2004). In comparison, tandem mass spectrometry (LC- 
MS/MS) provides enhanced selectivity, less time-consuming sample preparation and has 
been utilised for plasma and cerebrospinal fluid samples (Gellekink et al., 2005;Struys et 
al., 2000). The LC-MS/MS method developed by Struys et al. has been used to determine 
the abundance of SAM and SAH in chick embryos following the application of inhibitors of 
S-adenosylhomocysteine hydrolase and of methionine adenosyltransferase (Afman et al.,
2006). In each case a delay of anterior neuropore closure was observed associated with a 
decreased SAM/SAH ratio, indicating reduced transmethylation. Here, I developed a 
modified LC-MS/MS method to allow precise and simultaneous quantification of SAM and 
SAH in low abundance tissue samples, in this case neurulation-stage mouse embryos (at 
embryonic day 9.5 and 10.5). The method has also been applied to cell pellets collected 
from NTD and control patient cell lines, an alternative low abundance tissue sample.
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Paper Method Tissue LOD Linearity Sample size Sample Preparation Run
Time
CV Recovery Tissue values
She, Q. et 
al. (1994)
HPLC with 
UV detection
Rat Liver 25 pmol 50-2000 pmol 50 mg Deproteinate (H C I0 4), 
centrifuge & filter
2 0  min Intra-assay 
2% SAM  
3% SAH
1 0 0 % 28-95 nmol/g SAM  
33-109 nmol/g SAH
Capdevila, 
A. &
Wagner, C. 
(1998)
HPLC with 
fluorescent 
detection
Human
Plasma
1 0  pmol 1 0 - 1 0 0  pmol 0.5 ml Deproteinate (TCA), 
centrifuge, remove 
TCA using solvent.
33 min Not stated 65% 0.026-0.110 pM SAM  
0.022-0.029 pM SAH
Luippold, G. 
et al. (1999)
HPLC with 
UV detection
Rat
Kidney & 
Urine
5 pmol 0.5-100 pM 2 ml of urine 
or tissue 
extract
Deproteinate (HCIO 4 ) 
centrifuge, adjust pH, 
SPE
30 min Not stated 90% Rat kidney 
46.2 nmol/g SAM  
0.67 nmol/g SAH
Struys, E. A. 
et al. (2 0 0 0 )
LC-MS Plasma & 
SF
0.005 pM 0.01-0 .02 pM 500ul Deproteinate (HCIO 4 ) 
centrifuge, SPE
3 min Intra-assay 
5.5%  SAM* 
5.5% SAH* 
Interassay 
5.9%  SAM* 
5.7%  SAH*
93% Plasma
0.049-0.091 pM SAM  
0.019-0.040 pM SAH  
CSF
0.137-0.385 pM SAM  
0.009-0.014 pM SAH
Uthus, E. 0 .  
(2003)
Capillary
Electrophor­
esis
Rat Liver
& Kidney,
Mouse
Liver,
Whole
Blood
0 . 0 1  pmol 
(unable to 
detect 
SAH in 
whole 
blood)
1-250 pM Not stated Deproteinate (HCIO 4 ) 
centrifuge, filter.
16 min Intra-assay 
1.8% SAM  
4.5%  SAH 
Inter-assay 
3.6%  SAM  
6.1%  SAH
Not stated Whole blood 
2.2 -3 .5pM SAM
Stabler and 
Allen, 2004
LC-M S/M S Human 
Serum  
and Urine, 
Rat Liver 
and Lung
5 pmol Quantified by 
comparing 
ratio of peak 
areas using 
internal 
standards
0.5 ml 
plasma, 
serum, CSF, 
100-300 mg 
wet weight 
tissue
Deproteinate (HCIO 4 ) 
SPE
49 min Intra-assay
5%
Inter-assay
17%
95% Serum
0.071-0.168 pM SAM  
0.008-0.026 pM SAH
Gellekink,H. 
et al. (2006)
LC-M S/M S Plasma 2.0 nmol/L 5-400 nmol/L 20 pi SPE columns 
containing 
phenylboronic acid
5 min Intra-assay 
4.2%  SAM  
6.7%  SAH  
Inter-assay 
3.9%  SAM  
8.3%  SAH
95% Plasma
Mean 94.5 nmol/L 
SAM, 12.3nmol/L 
SAH
Table 3.1. A comparison of published methods to quantify SAM and SAH.
3.2 Materials and Method
3.2.1 Materials
SAM and SAH were purchased from Sigma-Aldrich (Dorset, UK). The internal standard, 
[2H3]-SAM, was purchased from CDN Isotopes (Pointe-Claire, Quebec, Canada). Ultra­
grade (HPLC) Ammonium acetate, formic acid and heptafluorobutyric acid were purchased 
from Sigma-Aldrich (Dorset, UK).
3.2.2 Samples
Non-mutant CD1 mouse embryos were collected at embryonic day (E) 9.5 and 10.5 as 
described (section 2.5 and 2.8). Cell pellets, from NTD and control human cell lines, were 
also collected for analysis (described in chapter 3).
3.2.3 Preparation of Samples
3.2.3.1. Preparation of neurulation-stage embryos
Embryos at E9.5 or E10.5 were suspended in 200 pi of ice-cold aqueous mobile phase 
(100% B, see below) containing 1 pM [2H3]-SAM, and sonicated immediately at 12 micron 
amplitude for 10 seconds on ice, to produce a homogeneous solution. A 10 pi aliquot was 
retained for determination of protein concentration using the bicinchoninic acid (BCA) 
protein assay reagent (section 2.11). Various methods were tested for sample preparation 
prior to analysis by LC-MS/MS (Table 3.2).
Following testing, heat treatment was chosen as the optimal sample preparation method. 
This involved heating the sample at 80°C for 5 minutes to precipitate endogenous proteins, 
cooling immediately on ice for 2 minutes and centrifuging for 15 minutes at 12,000 g to 
remove any particulate. Prepared samples were subsequently analysed immediately by 
LC-MS/MS.
3.2.3.2. Preparation of cell pellets
Cell pellets were re-suspended on ice in 200 pi of cold PBS and the protein concentration 
was assayed using the BCA protein assay in a 10 pi aliquot (section 2.11). Suspensions 
were pooled to provide approximately 1 mg of protein and subsequently centrifuged for 5 
min at 12,000 g. The cell pellet was then re-suspended in 200 pi of ice-cold aqueous
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mobile phase (100% B, see below) containing 1 pM [2H3]-SAM and sonicated immediately 
at 12 micron amplitude for 10 seconds on ice, to produce a homogeneous solution. The 
solution was heated at 80°C for 5 minutes to precipitate endogenous proteins, cooled 
immediately on ice for 2 min and centrifuged for 15 min at 12,000 g to remove any 
particulate. Samples were analysed immediately by LC-MS/MS.
Method Sample Volume, pi 
(No. of embryos per 
sample)
Description
Acetonitrile 200 (1) Add 200 pi acetonitrile, mix thoroughly for 2 min and 
centrifuge for 15 min.
Acetone 200 (1) Add 200 pi acetone, mix thoroughly for 2 min and 
centrifuge for 15 min.
Perchloric Acid 200(1) Add 200 pi perchloric acid (100 ml/L), mix thoroughly for 
2 min and centrifuge for 15 min.
Ethanol 200 (1) Add 200 pi ethanol, mix thoroughly for 2 min and 
centrifuge for 15 min.
Spin Column 
Filtration
400 (2) Filtered using the Centricon YM-10 Centrifugal Filter 
Device (Millipore) according to the manufacturer’s 
instructions.
Heat 200 (1) Heat at 80 °C for 5 min, cool on ice for 2 min and 
centrifuge for 15 min.
Table 3.2. Sample preparation methods used for the analysis of endogenous SAM and SAH 
in a pooled sample of homogenised E10.5 embryos. In each case samples were centrifuged at 
12,000 g for 15 min prior to analysis to collect precipitated proteins.
3.2.4 Calibration and quantification
In order to quantify endogenous levels of SAM and SAH in whole embryos, the “calibration 
curve method” was implemented (section 2.12.1) using combined SAM and SAH
70
calibrators made up in a matrix of pooled mouse embryos. For neurulation stage (E9.5 -  
E10.5) embryos, calibrators containing 0.5, 1, 2.5, 5, 10, 25 pM of SAM and 0.01, 0.02, 
0.05, 0.1, 0.2, 0.5 pM of SAH were utilised. All calibrators contained 1 pM of the internal 
standard, [2H3]-SAM. The “calibration curve method” was also used to quantify
endogenous levels of SAM and SAH in cell pellets. For cell pellets containing 1 mg/ml 
protein, calibrators containing 0, 0.25, 0.5, 1, 2 and 5 pM of SAM and 0, 0.01, 0.02, 0.05, 
0.1 and 0.2 pM of SAH were utilised. All calibrators contained 1 pM of the internal 
standard, [2H3]-SAM.
3.2.5 LC-MS/MS Method
SAM, SAH and [2H3]-SAM were separated on a pentafluorophenylpropyl (PFPP)-bonded 
silica column (Discovery HS F5; 50 x 2.1 mm (i.d.); 5 pm bead size; Supelco, Sigma- 
Aldrich). Solvents for HPLC were: A, 100% methanol; B, 4 mM ammonium acetate, 0.1% 
formic acid, 0.1% heptafluorobutyric acid (pH 2.5). The F5 column was equilibrated with 
40% A: 60% B. The sample injection volume was 40 pi. The HPLC protocol consisted of 
40% A: 60% B for 2 minutes, followed by a gradient of 40-100% A over a 2 minute period. 
The column was then washed with 100% A for 4 minutes before re-equilibration for 7 
minutes. The flow rate was 0.5 ml/min and the first 72 seconds after sample injection was 
diverted to waste, to minimise accumulation of endogenous compounds on the ionisation 
source which will reduce the performance of the instrument over time. The mass 
spectrometer was operated in positive-ion mode using the following settings: capillary 3.86 
kV, cone voltage 20 V, collision energy 26V. A C8 reverse phase column (Discovery 
Hypurity C8; 10 x 2.1 mm (i.d.); 5 pm bead size) was also tested for its ability to retain 
SAM and SAH. Various isocratic and gradient HPLC protocols were tested using the 
same HPLC solvents and parameters.
3.2.6 Statistical Analysis
Analyte concentrations were compared by One Way ANOVA. Ratios of SAM:SAH (overall 
and within each sex) were compared by t-test. Statistical tests were computed using 
SigmaStat Version 2.03 (SPSS Inc.).
71
3.3. Results
3.3.1. Mass Spectra
The expected [M+H]+ protonated molecules (precursor ions) were m/z 402.2, 399.2 and
385.2 for 2H3-SAM, SAM and SAH, respectively (Figure 3.3). Observed experimental 
results matched the theoretical masses. Product ion spectra for each of the three 
molecules yielded a fragment of m/z 136.1 (Figure 3.3), believed to correspond to the 
adenine backbone (Struys et al., 2000). Thus, the final SRM transitions were as follows: 
SAM, 399.2 -> 136.1; 2H3-SAM, 402.2 ->136.1; SAH 385.2 ->136.1.
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Figure 3.3. Product ion spectra of protonated molecules used for quantification. Precursor 
ions were at m/z 402.2 for [2H3]-SAM (A), 399.2 for SAM (B) and 385.2 for SAH (C). In each case 
the MS/MS conditions were optimised to favour the transition to a major product ion at m/z 136.1, 
thought to correspond to the adenine backbone (Struys et al., 2000).
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3.3.2. Sample Preparation
Embryo tissue samples typically contained approximately 100 or 400 pg protein for E9.5 
and E10.5 embryos respectively. Several procedures were evaluated for preparation of 
samples for LC-MS/MS following homogenisation. These included acetone precipitation, 
acetonitrile precipitation, ethanol precipitation, heat precipitation, acidification with 
perchloric acid and filtration on spin-columns (Figure 3.4). All are common methods used 
to precipitate proteins from solution for the analysis of metabolites. Removal of 
extraneous matrix components from the sample helps eliminate matrix-induced ion 
suppression and prevents sample components from blocking the HPLC column. The 
applicability of a particular sample preparation method depends on efficiency of protein 
precipitation, recovery losses (loss of material during analysis), compatibility with desired 
column, convenience of use and type of sample matrix. Solid phase extraction was not 
suitable, due to low sample volume (200 pi) inherent in the analysis of individual mouse 
embryos (or other low abundance tissue samples).
Preparation of embryonic samples using the spin columns required twice as much sample 
due to handling constraints. Thus, in order to achieve the required volume either the 
embryo sample needed to be diluted which caused a loss of sensitivity or, embryo 
samples needed to be pooled for analysis. A comparison of peak area to the other 
methods used demonstrates that filtration on spin-columns did recover sufficient SAM from 
the pooled sample consisting of two homogenised embryos (Figure 3.4E). However, since 
this method was being established purposely to measure SAM and SAH in whole 
embryos, without pooling, this method was not suitable. Precipitation with acetonitrile 
resulted in poor sample recovery as shown by the smaller peak area in comparison to the 
other peaks (Figure 3.4A). Overall, the recovery of SAM was greatest when samples were 
heat or acetone treated to precipitate endogenous proteins (Figure 3.4).
The peak shape of the chromatography was dramatically affected by the sample 
preparation. Optimum peak shape was achieved with acetone precipitation. A 
subsequent increase in the flow rate from 0.25 ml/min to 0.5 ml/min was found to reduce 
peak tailing when samples were prepared by heat treatment. In addition, regular 
replacement of guard cartridges was required. Heat treatment was chosen as the method 
of choice as it was convenient, cheap and unlikely to pose any problems with column 
incompatibility since it did not involve the use of any solvents.
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Figure 3.4. Comparison of sample preparation methods for the analysis of SAM. LC-MS/MS 
chromatograms for SAM obtained in SRM mode using the Discovery HS F5 column (50 x 2.1 mm 
(i.d.); 5 pm bead size): sample preparation affected both retention time and peak shape. 
Representative chromatograms are shown for endogenous SAM in a pooled sample of 
homogenised E10.5 mouse embryos (>35 somites). Samples were prepared using various 
methods to precipitate proteins (Table 3.2); acetonitrile (A), acetone (B), Perchloric acid (C), 
Ethanol (D), Spin column filtration (E) and Heat (F). Flow rate = 0.25 ml/min.
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Recent reports indicate that, unless acidified, SAM in plasma may be unstable during 
storage at -2 0  °C (Gellekink et al., 2005;Stabler and Allen, 2004). For this reason, tissue 
samples were homogenised in acidified mobile phase (solution B). Additionally, embryos 
were stored for only short periods at -  80 °C.
To evaluate potential loss of SAM due to heat treatment, control standard samples were 
divided and analysed with or without the heat step. Using this brief heat treatment and 
immediate cooling there was no change in signal intensity for SAM, SAH or [2H3]-SAM 
compared to non-heat treated samples, indicating that heating for a short period did not 
cause degradation (Figure 3.5). Peak shape is much improved following heat treatment 
which suggests that the increased signal intensity following sample preparation is due to 
the removal of contaminants that cause ion suppression, as opposed to increased 
recovery.
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Figure 3.5. The effect of heat treatment on the signal intensity of SAM-D3, SAM and SAH.
Representative chromatograms are shown for 1 pmol/L aqueous standards which were analysed 
prior to, and following heat treatment at 80 °C for 5 min. Retention times are indicated above peaks.
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3.3.3. Chromatography
The retention of SAM and SAH in aqueous solution on a C8 column using reverse phase 
was 1.02 and 1.85 min, respectively (Figure 3.6). On a column of this dimension (100 x 
2.1mm; 5 pm), this suggests that these analytes are not being retained using reverse 
phase. Gellekink et al. (2005) also reported retention times less than 2 min using a C18 
column (100 x 2.1 mm; 5 pm) (Gellekink et al., 2005).
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Figure 3.6. LC-MS/MS chromatograms obtained in SRM mode using reverse phase 
chromatography. Column used: Discovery Hypurity C8 column (100 x 2.1 mm (i.d.); 5 pm bead 
size). Representative chromatograms are shown for 10 pmol/L aqueous standards. Retention 
times are indicated above peaks. Mobile phase consisted of 5% A (Methanol):95% B (4 mM 
ammonium acetate, 0.1% formic acid, 0.1% heptafluorobutyric acid (pH2.5)).
On a pentafluorophenylpropyl-bonded silica (PFPP) column (Figure 3.7), basic analytes 
exhibit retention that increases with the organic content, with some analytes failing to elute 
from the column even in 100% organic mobile phase (Needham et al., 2000). This type of 
retention profile, referred to as a U-shaped retention (Figure 3.7), has been shown to be 
due largely to ion exchange mechanisms. Retention at high organic percentage is
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beneficial for LC-MS/MS experiments since it can lead to an increase in sensitivity through 
facilitated desolvation and can enhance peak shape. Also, PFPP columns often induce 
retention otherwise not obtained in reverse phase. Retention aids the elimination of 
endogenous interferences plus, the use of a solvent-divert valve enables early eluting 
contaminants to be diverted to waste preventing accumulation on the ion source.
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Figure 3.7. The molecular structure (A) and U-shaped retention profile (B) of the 
pentafluorophenylpropyl-bonded silica, PFPP column.
The retention of SAM and SAH in aqueous solution on a PFPP column using a mobile 
phase of high organic content was 3.22 and 1.92 min, respectively (Figure 3.8). Thus, the 
PFPP column was chosen over standard reverse-phase columns due prolonged retention 
avoiding co-elution with early eluting endogenous compounds and retention in high 
organic percentage. 0.1% heptafluorobutyric acid was also added to the mobile phase in 
each case as it results in greater retention due to ion pairing interactions (Struys et al., 
2000).
Representative chromatograms of SAM and SAH in both aqueous solution and in an 
analytical sample prepared by heat treatment, comprising an E10.5 mouse embryo, are
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shown (Figure 3.8). In all cases there was a change in the retention time of SAM, SAH 
and 2H3-SAM, resulting in earlier elution of the three compounds in embryo samples under 
analysis compared to aqueous standards. Similarly, the spiking of calibrators into pooled 
embryo matrix resulted in the same change of retention compared to analysis of standards 
in aqueous solution. The reason for the change in retention time of all three compounds 
when analysed in an embryo matrix compared to aqueous solution is not clear. I 
hypothesise that this is due an interaction with unidentified compounds present in the 
embryo matrix that result in slight changes in the retention time of SAM/SAH on the HPLC 
column.
3.3.4. Linearity, Limits of Detection and Precision
The internal standard, [2H3]-SAM, was used for quantification of both SAM and SAH. 
Calibration curves, made up in a matrix of pooled homogenised embryos, were linear 
throughout a concentration range of 0.5-25 pM and 0.01-0.5 pM for SAM and SAH, 
respectively (Figure 3.9). Therefore, it seems that the minor structural difference of [2H3]- 
SAM from SAH, which lacks a methyl group, had minimal effect on both the linearity and 
precision of quantification. Moreover, as the coefficients of variation (CV%) for SAH were 
comparable to SAM and within acceptable limits (Table 3.5), it was deemed unnecessary 
to synthesise an additional SAH internal standard.
The range of concentrations used in the calibration curves was found to be suitable for the 
analysis of individual mouse embryos at E9.5 and E10.5, encompassing the period when 
neural tube closure is completed in the cranial and spinal regions. The coefficient of linear 
correlation (r2) was 0.997 and 0.998 for SAM and SAH, respectively. The limits of detection 
(determined at a signal-to-noise ratio of 5:1) for SAM and SAH were 10 nmol/L and 2.5 
nmol/L, respectively, corresponding to 0.4 pmoles and 0.1 pmoles in the 40 pi injection. 
The lower and upper limits of quantification for SAM and SAH using this method were 
0.02-25 pM and 0.01-10 pM, respectively. Analysis of SAM would be expected to be more 
sensitive than SAH due to the more polar nature of the molecule. However this is not the 
case since mass spectromteric analysis of SAH is in fact more sensitive than SAM. The 
reason for this is unknown.
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Figure 3.8. LC-MS/MS chromatograms obtained in SRM mode using the Discovery HS F5 
column (50 x 2.1 mm (i.d.); 5 |jm bead size). Representative chromatograms are shown for, (A) 1 
(jmol/L aqueous standards and, (B) endogenous SAM and SAH in an E10.5 mouse embryo, 
containing measured concentrations of 0.766 pmol/L SAM and 0.121 pmol/L SAH. Retention times 
are indicated above peaks.
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Figure 3.9. Calibration curves of peak-area ratios plotted against concentration of SAM (A)
and SAH (B) concentration. Calibrators were made up in a pooled sample of homogenised 
embryos with 1.0 pmol/L of [2H3]-SAM (internal standard) added to each sample. SAM data points 
correspond to 0.5, 1, 2.5, 5, 10, 25 pM of SAM and the SAH data points correspond to 0.01, 0.02, 
0.05, 0.1, 0.2, 0.5 pM. Each sample was run in triplicate (n=3).
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To determine the precision for analysis of tissue samples, experiments were performed by 
pooling homogenised whole embryo samples either from E9.5 embryos at the 24-26 
somite stage or from late stage E10.5 embryos at the 37 somite stage. All samples 
contained 1 pM of the internal standard, [2H3]-SAM. Overall, intra-assay coefficients of 
variation (CVs) ranged from 4.09-4.13% for SAM and 4.64-5.68% for SAH and inter-assay 
CVs ranged from 6.34-7.74% for SAM and 11.56-11.93% for SAH in tissue samples (Table 
3.3).
Sample Precision
SAM SAH
Mean 
concentration 
(pM ±SD)
o < Mean 
concentration 
(pM ±SD)
CV
(%)
E9.5 mouse 
embryo
Intra-assay
(n=12)
2.52 ±0.10 4.13 0.044 ± 0.002 4.64
E10.5 mouse 
embryo
Intra-assay 
(n=12) .
11.72 ±0.48 4.09 0.21 ±0.01 5.68
E9.5 mouse 
embryo
Inter-assay
(n=8)
2.55 ± 0.20 7.74 0.040 ± 0.005 11.93
E10.5 mouse 
embryo
Inter-assay
(n=8)
12.18 ±0.77 6.34 0.20 ±0 .02 11.56
Table 3.3. Inter- and Intra-assay precision of the LC-MS/MS method for aqueous and 
embryonic samples. The precision was determined by repeated assay of standard aqueous 
solutions and embryo samples, which consisted of pools of homogenised embryos collected at E9.5 
and E10.5. CV, coefficient of variation.
Accuracy was evaluated by spiking whole embryo homogenates with increasing 
concentrations of SAM or SAH, and quantifying the total SAM or SAH (Table 3.4). The 
measured concentration was expressed as a percentage of the predicted ‘nominal’ 
concentration, which was the sum of the added concentration and endogenous level 
(determined in the 0 pM added sample). In the majority of cases the measured value was 
greater than 90% of the predicted nominal value (Table 3.4). Recovery was assessed by 
comparing the response of samples that were spiked before extraction (pre-extraction) to 
samples that were spiked after extraction (post-extraction) (Matuszewski et al., 2003). 
Mean recoveries for SAM and SAH from E9.5 and E10.5 pooled mouse embryo matrices 
were 97 % and 92 %, respectively (Table 3.4).
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Sample Spiked
conc.
added
(pm
Measured 
conc. (pM)
Accuracy
(%
Nominal
Conc.)
Measured 
conc. (pM)
Accuracy
(%
Nominal
Conc.)
Recovery
(%)
SAM
Added
(MM)
Spiked
pre-extraction
Spi
post-exi
ked
traction
E9.5
mouse
embryo
0 0.08 ± 0.02
0.5 0.57 ± 0.03 98 0.57 ± 0.02 98 100
1.0 1.06 ±0 .02 98 1.09 ±0.06 101 97
2.0 2.08 ± 
0.004
100 2.12 ±0.09 102 98
E10.5
mouse
embryo
0 0.79 ±0.01
0.5 1.21 ±0.01 94 1.19 ± 0.17 92 101
1.0 1.82 ±0 .04 102 2.03 ±0.28 113 90
2.0 2.64 ± 0.04 95 2.83 ±0.27 101 94
SAH
Added
(MM)
Spiked
pre-extraction
Spi
post-ex
ked
traction
E9.5
mouse
embryo
0 0.11 ±0.009
0.05 0.13 ±0.002 81 0.14 ±0.003 88 97
0.1 0.19 ±0.001 86 0.21 ± 0.009 100 87
0.2 0.33 ± 0.027 106 0.35 ±0.03 113 92
E10.5
mouse
embryo
0 0.20 ± 0.03
0.05 0.23 ±0.001 92 0.24 ± 0.006 96 90
0.1 0.30 ±0 .07 100 0.34 ±0 .03 113 91
0.2 0.38 ± 0.04 95 0.42 ± 0.05 105 95
Table 3.4. Accuracy and recovery data for the LC-MS/MS quantification of SAM and SAH in 
mouse embryos. Embryo samples consisted of pools of homogenised embryos collected at E9.5 
and E10.5. Accuracy (% nominal concentration) was determined by comparing the measured 
concentration of SAM or SAH against the nominal concentration (the predicted value equating to 
the baseline concentration + spiked concentration). Thus, %Nominal concentration = [Measured 
Conc.]/[Baseline conc. + Spiked conc.] x 100. Recovery was determined by comparing the assay 
results for embryo samples spiked pre- and post- extraction (n = 3 for each condition). % Recovery 
= ([Response of Pre-Extracted Spiked Sample] / [Response of Post-Extracted Spiked Sample]) x 
100 [as ref. (Luippold et al., 1999)]. Concentration values are given as mean ± standard deviation.
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Repeated injections into the mass spectrometer can lead to a build-up of residues on the 
source, which can affect sample ionisation and subsequently, sensitivity. This loss in 
sensitivity is increased if the sample preparation is inadequate or if the organic content of 
the mobile phase is low. The performance of the instrument over a long period of time 
was evaluated using repeated injections of the same sample. The loss in sensitivity was 
monitored by calculating the peak area response for the internal standard following the 
analysis of consecutive embryo samples (Figure 3.10). Thus, repeated injections of sixty 
samples led to a 25% drop in sensitivity over sixty injections which corresponded to 15 
hours of analysis. This loss in sensitivity is generally not a problem, when analysing 
strong signals, as all compounds should be affected equally. However, since levels of 
SAM and SAH in embryo samples are limiting, being aware of the limitations of repeated 
injections is advisable. To overcome reduced sensitivity, long sample lists were avoided 
and regular cleaning of the source was undertaken.
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Figure 3.10. Analysis of signal intensity following repeated injections of embryonic samples.
The peak area of the 1 pM internal standard, SAM-D3 was monitored for sixty consecutive injections 
of embryonic samples, r2 = 0.684.
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3.3.5. Mouse embryo samples
A series of non-mutant CD-1 mouse embryos were collected and analysed to establish 
reference intervals of SAM and SAH. Levels were normalised to protein concentration and 
correlated with developmental stage (Table 3.5).
Embryonic
stage
No. samples SAM
nmol/mg protein
SAH
nmol/mg protein
SAM:SAH
Ratio
E9.5 Total (n=24) 1.98 ±0.71 0.031 ±0.011 67.8 ± 23.2
Male (n=13) 2.23 ± 0.64 0.034 ±0.012 71.6 ±24.3
Female (n=11) 1.69 ±0.71 0.027 ± 0.009 63.4 ± 22.2
E10.5 Total (n=26) 2.78 ± 0.67** 0.057 ± 0.029** 53.0 ±13.9**
Male (n=15) 2.75 ± 0.65 0.051 ± 0.021 46.8 ± 13.3
Female (n=11) 2.83 ± 0.65 0.065 ± 0.023 57.6 ± 12.8
Table 3.5. SAM and SAH abundance in mouse embryos determined by LC-MS/MS. SAM and
SAH were quantified in individual CD1 embryos at E9.5 (Mean number of somites 25.7 (standard 
deviation 1.4)) and E10.5 (Mean number of somites 33.6 (standard deviation 2.4)). Values are given 
as mean ± standard deviation. ** p < 0.02 when compared to E9.5 (unpaired student t-test).
In embryos at E9.5 and E10.5, mean concentrations of SAM were 1.98 and 2.78 nmol/mg 
protein respectively, while mean concentrations of SAH were 0.031 and 0.057 nmol/mg 
protein (Table 3.5). Thus, SAM levels are typically 50-70 fold higher than SAH levels in 
mouse embryos at these stages of development. At a particular stage, comparison of male 
and female embryos did not indicate any sex difference in SAH or SAM levels (Table 3.5). 
Moreover, within litters there was no apparent effect of position of the embryo within the 
uterus as levels were comparable for conceptuses close to the cervix compared with those 
close to the ovary. Conversely, significant changes occur in the concentration of both 
SAM and SAH as development proceeds (Table 3.5). Thus, at E10.5 the concentration of 
both SAM and SAH had increased compared to a day earlier in development. As the 
abundance of SAH increased to a greater extent than SAM, the SAM:SAH ratio decreased 
significantly at E10.5 compared to E9.5.
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3.3.6 Analysis of cell pellets collected from human cell lines
During the study, a series of lymphoblast and fibroblast cell lines collected from NTD 
patients became available from which cell pellets were collected as described (Chapter 4). 
The cell pellet was prepared subsequently for LC-MS/MS analysis using the same 
approach as that used to analyse neurulation-stage embryos. A representative 
chromatogram of endogenous SAM and SAH in a cell line sample is shown (Figure 3.12). 
The retention times of SAM and SAH were comparable to those observed in embryo 
samples. Calibration curves, made up in a matrix of pooled homogenised cell pellets, 
were linear throughout a concentration range of 0.25-5 pM and 0.01-0.20 pM for SAM and 
SAH, respectively (Figure 3.13). This range of concentrations was found to be suitable for 
the analysis of cell pellets (approx. 1 mg protein) collected from cell lines of fibroblast and 
lymphocyte origin. As with the analysis of embryo samples, the internal standard, [2H3]- 
SAM, was used for quantification of both SAM and SAH. The coefficient of linear 
correlation (r2) was 0.995 and 0.999 for SAM and SAH, respectively.
SAM-D3
Peak Area 5.66e3
Peak Area 1.26e3
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Figure 3.12. LC-MS/MS chromatograms for [2H3]-SAM, SAM and SAH obtained in SRM mode 
using the Discovery HS F5 column (50 x 2.1 mm (i.d.); 5 pm bead size). Representative 
chromatograms are shown for endogenous SAM and SAH in a cell pellet spiked with 1 pM [2H3]- 
SAM-D3. The measured concentrations were 0.323 pmol/L SAM and 0.041 pmol/L SAH. Retention 
times indicated above peaks.
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Figure 3.13. Calibration curves of peak-area ratios plotted against SAM (A) and SAH (B) 
concentration for cell line samples. Calibrators were made up in a pooled sample of cell pellets 
with 1.0 pmol/L of [2H3]-SAM (internal standard) added to each. SAM data points correspond to 0, 
0.25, 0.5, 1, 2, 5 pM of SAM and the SAH data points correspond to 0, 0.01, 0.02, 0.05, 0.1, 0.2 pM. 
Each sample was run in triplicate (n=3).
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3.4 Conclusion and Discussion
3.4.1 Method Development
SAM and SAH are key metabolites in one-carbon metabolism as their ratio determines the 
methylation potential in a tissue (Carmel and Jacobsen, 2001;Scott, 1999). Since sub- 
optimal methylation capacity is associated with various diseases (James et al., 
2002;Mattson, 2003;Seshadri et al., 2002), as well as developmental abnormalities, it was 
necessary to develop new methodology for quantification of SAM and SAH in limiting 
amounts of sample. For this reason, LC-MS/MS methodology was used for the 
simultaneous quantification of SAM and SAH in tissue samples. The sample preparation 
method allowed analysis of tissue quantities (less than 1 mg) considerably lower than used 
in methods that utilise solid phase extraction (typically 100-300 mg wet weight (Needham 
et al., 2000)).
Previously, UV detection following HPLC or capillary electrophoresis has been used for 
detection of SAM and SAH (Luippold et al., 1999;She et al., 1994a;Uthus, 2003). 
Increased sensitivity can be achieved by the use of coulometric electrochemical detection 
(Melnyk et al., 2000) or through derivatisation of SAH and SAM followed by fluorescent 
detection, although this is time-consuming and requires additional sample preparation 
steps (Capdevila and Wagner, 1998;Weir et al., 1992). Here, a method has been 
developed that exploits the selectivity and sensitivity of tandem mass spectrometry, 
yielding a method with limits of detection of 10 nmol/L and 2.5 nmol/L for SAM and SAH, 
respectively, with very little sample preparation necessary.
Sample preparation is minimised compared to previous MS-based methods, which require 
solid phase extraction (Gellekink et al., 2005;Struys et al., 2000). Instead, the method 
developed in this study involved homogenisation of samples in an acidified mobile phase 
and heat precipitation of proteins. This resulted in increased throughput, reduced sample 
loss (with a resulting increase in sensitivity) and without degradation of SAM. A single 
internal standard was used for both assays, since although [2H3]-SAM is technically a type 
II internal standard when used in the quantitation of SAH, the inter- and intra-coefficients of 
variation observed were within acceptable limits of analytical biochemistry. Presumably, 
this is due to the superior ability of the HS F5 column to retain small, polar metabolites 
over conventional reverse phase columns, resulting in fewer co-eluting and interfering 
compounds that can lead to ionic suppression.
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In mouse embryos the concentration of SAM detected (2-2.8 nmol/mg protein) was 
approximately 20-40 times higher than values reported for adult liver and kidney in rats 
(Luippold et al., 1999;She et al., 1994a). However, the values for adult tissue were 
expressed per wet weight of tissue, which is not practical with small tissue samples such 
as embryos. I estimate that SAM levels in embryonic and adult tissue are approximately 
comparable, based on comparison of protein content and wet weight for a limited number 
of embryos. SAH concentrations reported in adult rats vary widely between tissues 
(Luippold et al., 1999;She et al., 1994a), and are similar or an order of magnitude lower 
than in mouse embryos, although direct comparison is again complicated by normalisation 
to wet weight rather than protein. However, the concentrations of SAM and SAH detected 
in neurulation-stage mouse embryos are similar to the levels (also normalised to protein 
content) measured in a recent study of pooled chick embryos (Afman et al., 2006) A 
significant increase in the concentration of both SAM and SAH is detected in the period 
from E9.5 to E10.5, despite the fact that there is a concomitant increase in the protein 
content of the embryo. At the same developmental period there is a decrease in the 
SAM:SAH ratio, since the magnitude of the increase in SAH concentration is greater than 
that for SAM, possibly due to increased demand for SAM in transmethylation reactions or 
as a precursor in polyamine synthesis.
In summary, the use of LC-MS/MS enables sensitive, precise and accurate quantification 
of the picomole quantities of SAM and SAH in neurulation-stage mouse embryos. 
Although, the method was particularly designed for the analysis of individual mouse 
embryos, it could potentially be applied to any tissue where limited amount of sample is 
available depending on the matrix and the levels of SAM and SAH in the tissue to be 
analysed. Indeed, I went on to apply the method to the quantification of SAM and SAH in 
cell pellets in which the levels were found to be similar to those in embryonic tissue 
samples. The suitability of this method for cell pellets is demonstrated by the identical 
retention times observed on the HS F5 column compared to embryonic samples and the 
linearity of calibration.
3.4.2 Changes in methyltransferase activity with gestation
It remains to be established how variations in the abundance of SAM and SAH through 
gestation affect the activity of methyltransferases (MT) and the subsequent biological 
significance. The values for the kinetic constants (Km value for SAM and K, value for SAH) 
are known for several mammalian MT (Carmel and Jacobsen, 2001). The range of Ki
values demonstrates that some MT will be much more sensitive to the inhibitory action of 
SAH. The catalytic activity of each MT is also dependent on the concentration of SAM 
since SAH acts as a competitive inhibitor. Using the K, and Km stated by Clarke and 
Banfield, it was possible to calculate relative enzyme activities of each MT at E9.5 and 
E10.5 (Table 3.6), using the Michalis Menton equation for competitive inhibition (Carmel 
and Jacobsen, 2001).
Fraction of maximal velocity = [SAM] / (Km + Km [SAH]/ K, + [SAM])
[SAM] = concentration of SAM, [SAH] = concentration of SAH,
K, = inhibition constant for SAH, Km = Michaelis constant for SAM.
The percentage activity of each MT at E10.5 relative to E9.5 provides an illustration of how 
the activity of each MT may change with gestational age (Table 3.6). Thus, enzymes with 
low K, values relative to Km values are more markedly inhibited by a lower SAM/SAH ratio.
The results of this data analysis demonstrate that the activity of some MTs may be 
relatively unaffected by the change in the abundance of SAM and SAH with gestational 
age. Examples include three of the MTs involved in RNA processing, tRNA (cytosine-5-)- 
methyltransferase, tRNA (adenine-/\/ 1-)-methyltransferase and rRNA (2’-ribose-0-)- 
methyltransferase, for which the predicted change in activity is less than 10%. By 
contrast, several other MTs appear to be particularly sensitive to changes in SAM and 
SAH abundance. At E10.5, the activity of phosphatidylethanolamine methyltransferase, 
which is involved in phosphatidylcholine synthesis (Hartz and Schalinske, 2006), is 
predicted to increase by 34%. Similarly, the activity of several N-methyltransferases is 
increased by over 30%, including glycine methyltransferase which is required for the 
synthesis of sarcosine and is also involved in the regulation of the methyl- group 
metabolism (Wagner et al., 1985).
It must be appreciated that the Ki and Km values for these MTs were established in adult 
tissues of various types. Indeed some of these enzymes may not be present in 
neurulation stage embryos or the embryonic isoforms of these enzymes may be 
functionally different. The activity of the methyltransferases may also be subject to 
additional regulatory influences. Clearly investigations of MT expression and activity in 
embryonic tissues is required to establish definitively how the activity of each MT is 
affected by gestational changes and furthermore, to understand changes as a result of a 
genetic or environmental disturbance.
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Fraction of maximal 
methyltransferase 
activity
Methvltransferase Km for K, for E9.5 E10.5 % activity at E10.5
DNA
DNA (cytosine 5-)
SAM
1.4
SAH
1.4 0.580 0.656
relative to E9.5
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RNA
tRNA (cytosine 5-) 0.5 0.9 0.793 0.839 106
tRNA (guanine-N 1-) 3 0.11 0.340 0.379 112
tRNA (guanine-N 2-) 2 23 0.497 0.581 117
tRNA (adenine-N 1-) 0.3 0.85 0.864 0.897 104
rRNA (2-ribose-O-) 0.24 0.17 0.875 0.897 103
Lipids
Phosphatidylethanolamine 18.2 3.8 0.097 0.131 134
Protein
Carboxyl
Protein-L-isoaspartate 2 0.08 0.416 0.448 108
Protein S-isoprenylcysteine 2.1 9.2 0.484 0.568 117
Lysine
Calmodulin-lysine N- 2 15.2 0.497 0.581 117
Histone-lysine N- 12.5 5.9 0.136 0.181 133
Arginine
[Myelin basic proteinj-arginine 4.4 1.8 0.307 0.380 124
Protein arginine I 8 2.3 0.196 0.253 129
Small Molecules 
N~methyltransferase
Guanidinoacetate 49 16 0.039 0.054 138
Histamine 1.7 11.8 0.537 0.619 115
Glycine 100 35 0.019 0.027 139
Phenylethanolamine 10 1.4 0.162 0.211 130
3-Carboline-2 81 14.8 0.024 0.033 139
Indolethylamine 54.3 8.65 0.035 0.048 138
O-Methyltransferase
Hydroxyindole 14 2.1 0.122 0.162 132
Catechol 3.1 1 0.383 0.459 120
S-Methyltransferase
Thiopurine 3 5.8 0.396 0.479 121
Thioether 1 40 0.664 0.735 111
Table 3.6. Sensitivity of methyltransferases to changes in SAM and SAH concentration with 
gestation. Theoretical activities for methyltransferases were calculated based on known Ki and Km 
values (Carmel and Jacobsen, 2001) and the measured concentrations of SAM and SAH in E9.5 
and E10.5 mouse embryos. Fraction of maximal methyltransferase activity was calculated using 
the Michaelis Menton equation for competitive inhibition and the concentrations of SAM and SAH at 
E9.5 and E10.5 stated in Table 3.7.
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CHAPTER 4
Impact of methylation cycle perturbation on cranial 
neural tube closure and the abundance of 
s-adenosvlmethionine and s-adenosvlhomocvsteine
91
4.1 Introduction
4.1.1 The Methylation Cycle and NTDs
Several lines of evidence suggest that the methylation cycle (Figure 4.1), plays a key 
role in determining susceptibility to NTDs. Risk factors for human NTDs include 
elevated maternal plasma levels of homocysteine and reduced levels of vitamin Bi2, 
the co-factor for methionine synthase (Figure 4.1) (Kirke et al., 1993;Steegers- 
Theunissen et al., 1994). Additionally, a thermolabile polymorphic variant (C677T) of 
the enzyme MTHFR, which exhibits reduced catalytic activity, causes elevated levels of 
homocysteine in NTD patients and their mothers (Eskes, 1998). Although 
homocysteine has been shown to induce NTDs in chick embryos (Rosenquist et al.,
1996), similar studies in mammalian embryos have shown that while homocysteine is 
toxic it does not cause NTDs (Bennett et al., 2005;Greene et al., 2003;VanAerts et al., 
1994). Hence, elevated homocysteine may not be the primary factor leading to NTDs 
in human pregnancy; it may simply be a marker for methylation cycle integrity or 
another metabolic abnormality.
As homocysteine is the precursor for methionine, high homocysteine levels could be 
linked with limited production of methionine. Indeed, rat embryos cultured in serum 
containing low levels of methionine develop cranial NTDs unless methionine is added 
(Coelho et al., 1989). In humans, low dietary methionine intake is reported to be 
associated with increased risk of NTDs hence it has been proposed that a high intake 
of methionine may be protective against NTDs (Shoob et al., 2001). This hypothesis is 
supported by a study whereby in vivo administration of methionine to pregnant dams 
reduces the incidence of spinal NTDs in the Axial defects mutant mouse (Essien, 
1992). In contrast, research from our group unexpectedly showed that adding 
methionine to embryo cultures specifically causes cranial NTDs, in both wild-type 
(Dunlevy et al., 2006a) and splotch embryos (Fleming and Copp, 1998). Thus, it 
appears that both deficient and excess methionine can cause increases in the 
incidence of NTDs, suggesting that optimum methionine levels are critical for the 
closure of the neural tube. Indeed, it has been suggested that methionine may 
promote DNA methylation yet iocus-specific hypermethylation of DNA could be 
deleterious (Waterland, 2006).
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Figure 4.1. Pertubation of the methylation cycle by exogenous agents. Purple boxes 
highlight exogenous agents used in this study. MTHFR; 5,10-Methylenetetrahydrofolate 
Reductase, MAT; Methionine Adenosyl-transferase, SAHH; SAH Hydrolase, MT; 
Methyltransferase, MS: Methionine Synthase.
Previous work from our group has also shown that inhibition of methylation cycle 
reactions, using ethionine and cycloleucine (see figure 4.1), causes cranial NTDs in 
wild-type mice (Dunlevy et al., 2006b). Ethionine, a methionine analog, is converted to 
s-adenosylethionine, which is not utilised by methyltransferases and in turn acts as a 
competitive inhibitor of methionine adenosyltransferase (MAT; E.C.2.5.1.6)(Cox and 
Irving, 1977), whereas cycloleucine acts as a direct non-competitive inhibitor of MAT. 
A similar study in chick recorded a delay in closure of the neural folds following 
exposure to cycloleucine and inhibitors of SAH hydrolase (Afman et al., 2006). Of 
note, the conversion of ethionine to s-adenosylethionine by MAT causes depletion of 
ATP, whereas cycloleucine does not affect ATP levels.
Cranial closure defects following exposure of embryos to methionine and inhibitors of 
the methylation cycle indicates an essential requirement for the methylation cycle in 
cranial neurulation. Disruption of the methylation cycle could potentially affect various 
biochemical processes including DNA and protein methylation. A disturbance of global
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DNA methylation could affect the transcriptional control of one or more important genes 
involved in the closure of the cranial neural tune. Alternatively, since protein 
methylation can influence protein function, aberrant protein methylation could also play 
a major role in the failure of neural tube closure. Cytoskeletal proteins such as P-actin 
and tubulin are known to become methylated during neurulation (Moephuli et al.,
1997). Moreover, studies in which the cytoskeleton was experimentally disrupted have 
shown conclusively that integrity of the cytoskeleton is essential for cranial neural tube 
closure (Matsuda and Keino, 1994;Smedley and Stanisstreet, 1986;Ybot-Gonzalez and 
Copp, 1999). Therefore, it may be possible that altered function of cytoskeletal proteins 
through lack of methylation could detrimentally influence closure. In this study, the 
method described in chapter 3 has been utilised to quantify the abundance of SAM and 
SAH in embryos cultured in the presence of methionine and methylation cycle inhibitors 
as previously described (Dunlevy et al., 2006a;Dunlevy et al., 2006b) to provide a 
greater understanding of how these inhibitors affect the flux through the methylation 
cycle.
It has been previously reported that M/7/r-deficient mice have a disrupted balance 
between SAM and SAH due to either a decrease in SAM or an increase in SAH levels, 
or both, with the effect being dependent on the number of disrupted Mthfr alleles (Chen 
et al., 2001b). The authors went on to demonstrate, using the cytosine-extension 
assay, that the effect on SAM and SAH levels resulted in a detectable decrease in DNA 
methylation in the brain and ovaries from both heterozygous and homozygous Mthfr- 
deficient adult mice (Chen et al., 2001b). A second study similarly demonstrated that 
elevations in plasma homocysteine and SAH levels are associated with a parallel 
increase in lymphocyte DNA hypomethylation (Yi et al., 2000) To attempt to detect 
aberrant changes in DNA methylation following exposure to methionine and 
methylation inhibitors, a method using LC-MS/MS to assess global DNA methylation 
(Friso et al., 2002) has been adapted for this study at a minimal cost.
4.1.2 DNA Methylation and NTDs
In the mouse, inhibition of DNA methylation following genetic deletion of the DNA 
methyltransferase Dnmt3b causes exencephaly (Okano et al., 1999). In zebrafish, 
inhibition of DNA methylation using the inhibitors 5-azacytidine and 5-aza-2- 
deoxycytidine causes defects in the notochord, somite and muscle development 
suggesting a requirement for DNA methylation in axial development (Martin et al., 
1999). An extensive search of past literature, also reveals that 5-azacytidine, used 
previously in mouse studies, has been shown to cause exencephaly in mouse embryos
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following administration in utero (Matsuda, 1990;Takeuchi and Takeuchi, 1985). 
Similarly, in this study I demonstrate that exposure of CD1 mouse embryos to 5- 
azacytidine in culture specifically causes a high incidence of exencephaly.
Suppression of DNA methylation could lead to abnormal expression of genes critical for 
successful closure of the neural tube. An alternative explanation is that inhibition of 
DNA methylation may cause a build up of SAM due to a lack of substrates for the 
methyl-group. This could affect the regulation of the methylation cycle, causing a 
subsequent build up of methionine and homocysteine, which in turn may affect the 
inter-linked folate cycle. To determine if inhibition of DNA methylation suppresses the 
methylation cycle, the abundance of SAM and SAH has been quantified in the embryos 
cultured in the presence of 5-azacytidine. If 5-azacytidine treatment is found to cause 
exencephaly without disturbing the methylation cycle this would provide substantial 
evidence for the proposed methylation hypothesis, which suggests that folic acid 
prevents NTDs by stimulating cellular methylation reactions (Blom et al., 2006).
4.1.3 Biomarkers of Human NTDs
There is now a plethora of evidence implicating the methylation cycle in the 
susceptibility to NTDs, however this association remains to be definitively elucidated. 
Two main possibilities exist to explain the elevated homocysteine found in NTD 
patients and their mothers (Kirke et al., 1993); (i) an altered diet (for example low 
folate) or, (ii) a genetic defect which affects one-carbon metabolism. In order to assess 
whether genetically-determined abnormalities in the methylation cycle are associated 
with increased risk of NTDs in humans, a collection of human cell lines grown under 
identical conditions have been analysed for the abundance of SAM and SAH.
Firstly, to investigate potential abnormalities in the methylation cycle in the embryo 
itself, SAM and SAH levels have been quantified in cell pellets of primary fibroblastic 
cell lines derived from fetuses affected by NTD (Dunlevy et al., 2007). The integrity of 
the folate cycle in these cell lines has been previously examined using the deoxyuridine 
(dU) suppression test which measures the ability of deoxyuridine monophosphate 
(dUMP) to suppress thymidine incorporation into DNA. Briefly, deoxythymidine 
monophosphate, the precursor of pyrimidines, can be generated from either dUMP (de 
novo pathway catalysed by thymidylate synthase) or by phosphorylation of thymidine 
(the salvage pathway catalysed by thymidylate kinase). Exogenous dUMP stimulates 
the de novo pathway and thereby suppresses incorporation of thymidine into genomic 
DNA, provided that the key intermediate 5,10-methylene tetrahydrofolate is available
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as part of normal folate metabolism. Cell lines are scored depending on their ability to 
stimulate the de novo pathway and suppress thymidine incorporation.
The deoxyuridine (dU) suppression test demonstrated that a subset of these fetal cell 
lines from NTD cases exhibited abnormalities in folate-cycling believed to result from 
as yet unrecognised genetic variants (Dunlevy et al., unpublished). Analysis of SAM 
and SAH would determine whether the abnormal dU suppression result for NTD cell 
lines is due to a defect in the methylation cycle. The dU suppression test was unable 
to detect inhibition of the methylation cycle by cycloleucine treatment, yet quantitative 
analysis of SAM and SAH using LC-MS/MS (Burren et al., 2006) may be more 
informative. Alternatively, if the dU suppression test result was normal, a change in the 
abundance of SAM or SAH would indicate a methylation defect which did not affect the 
folate cycle, yet could potentially be a contributor to NTD development and/or be 
rescued by supplemental folate.
Secondly, SAM and SAH have been quantified in a group of immortalised B 
lymphocyte cell lines collected from Swedish children with open spina bifida. The 
analysis of a second group of cell lines enables comparison to be made between cell 
types and, between fetal and adult cells. Changes in the abundance of SAM and SAH 
in these cell lines would indicate underlying genetic defects which affect the flux 
through the methylation cycle.
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4.2. Materials and Methods
4.2.1. Mouse embryo culture
Embryos were cultured for 18 and 28 hours as described in Chapter 2. At the end of 
the culture period the embryos were analysed for neural tube defects (described in 
section 2.8) and other gross morphological defects. The viability (yolk sac circulation 
and heart beat), growth (crown-rump length) and developmental progression (somite 
number) of each embryo was recorded (described in section 2.8). Embryos were then 
rinsed in PBS and stored at -80 °C, prior to analysis of SAM and SAH, or global DNA 
methylation.
4.2.2 S-Adenosylmethionine and S-Adenosylhomocysteine Assay
Samples consisting of a pool of 2-4 embryos from a specific treatment group were 
sonicated in 120 pi of aqueous mobile phase (4 mM ammonium acetate, 0.1 % formic 
acid, 0.1 % heptafluorobutyric acid, pH 2.5) containing 1 pM SAM-D3 and heat-treated 
to precipitate proteins. Each sample was then analysed in duplicate by liquid 
chromatography tandem mass spectrometry, as described previously (Burren et al., 
2006). Prior to heat treatment, a 10 pi aliquot was removed to determine protein 
concentration using the protein assay described in section 2.11.
4.2.3 Method to assess global DNA Methylation
DNA from whole embryos was prepared (see 4.2.3.3) and analysed using an adapted 
version of the liquid chromatography tandem mass spectrometry method described by 
Friso et al. (Friso et al., 2002).
4.2.3.1 Apparatus
All analyses were performed on a triple quadrupole tandem mass spectrometer 
coupled to a HPLC (described in section 2.12.1). A C18 guard cartridge (4mm x 3mm, 
5 pm) fitted to a Security Guard holder (Phenomenex, UK) was used and the 
instrument was operating in positive ion mode.
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4.2.3.2 Reagents
2’-deoxycytidine and 5-methyl-2’-deoxycytidine were purchased, along with all other 
reagents unless stated, from Sigma-Aldrich (Dorset, UK). All solvents and water used 
were of HPLC grade (Fisher Scientific UK Ltd., Loughborough, UK). The mobile phase 
consisted of 7 mM ammonium acetate (pH 6.7) with 5% methanol.
4.2.3.3 DNA Extraction and Hydrolysis
To extract the DNA, whole embryos were suspended in 180 pi of PBS and immediately 
sonicated on ice at 12 pm amplitude for 10 s. Homogenised samples were then 
incubated overnight at 56 °C with 20 pi of 10 mg/ml proteinase K. Thereafter, 1 pi of 10 
mg/ml RNase A was added and incubated for 15 min at 37 °C. The sample mixture 
was then heated to 100 °C for 5 min and subsequently cooled to room temperature. A 
200 pi volume of phenol:chloroform (v/v 50:50) was added to the solution, mixed 
thoroughly and centrifuged at 12,000 g for 5 min. The aqueous layer was decanted 
into a clean eppendorf tube, mixed with 200 pi of chloroform and centrifuged again. 
The aqueous layer was then added to an eppendorf containing 600 pi of 1.3 % 
potassium acetate dissolved in 95 % ethanol. The mixture was left to incubate at -20 
°C for 2 hr or overnight, subsequently centrifuged at 12,000g for 10 min at 4 °C and the 
resulting supernatant was poured off. The DNA pellet was washed with 70 % ethanol 
and resuspended in 20 pi of dH20. The optical density at 260 nm was measured (UV 
Mini 1240 Spectrophotometer, Shimadzu) using quartz cuvettes to determine the 
concentration of DNA.
To hydrolyse the DNA into single bases, 1 pg of DNA was denatured by heating at 100 
°C for 3 min and subsequently chilled in ice slush. One-tenth volume of 0.1 M 
ammonium acetate (pH 5.3) and 2 units of nuclease P1 (Roche Molecular 
Biochemicals, Manneheim, Germany) were added. The mixture was then incubated at 
45 °C for 2 h. To the solution was subsequently added 1/10 volume of 1 M ammonium 
bicarbonate and 0.002 units of venom phosphodiesterase I The incubation was 
continued for an additional 2 h at 37 °C. Thereafter, the mixture was incubated for 1 h 
at 37 °C with 0.5 units alkaline phosphatase. Hydrolysed samples were stored at -20 
°C overnight prior to analysis by LC-MS/MS.
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4.2.3.4 LC-MS/MS Procedure
A 20 pi portion of the hydrolysed DNA solution was injected onto the analytical column
thermostated at 21 °C. The separation of 2’-deoxycytidine and 5-methyl-2’-
deoxycytidine was obtained by isocratic elution. The mobile phase flow rate was 0.3 
ml/min and the run time was 2 min. The following settings were used: capillary 3.86 
kV, cone voltage 20 V and collision energy 26 V.
4.2.4 Cell Culture
For details of the methods used to culture the cell lines see Chapter 2 (section 2.13) 
and for the analysis of SAM and SAH in cell pellets refer to Chapter 3 (section 3.3.6).
4.2.5 Statistical Analysis
Statistical analyses were performed using SigmaPlot Version 7, SigmaStat Version 3.5 
and SPSS Version 13. To determine the effect of the culture treatments on embryonic 
growth and development, mean yolk sac circulation, number of somites and crown- 
rump length were compared to the PBS-treated controls either by group-wise 
comparisons (methionine, ethionine and cycloleucine) using One-Way ANOVA or by 
pair-wise comparisons (Azacytidine) using the un-paired student t-test. Incidence of 
cranial NTDs following exposure to culture treatments was compared to the PBS- 
treated control either by group-wise comparison using the Chi-square test or by pair­
wise comparison using the Fishers Exact test. The effect of culture treatments on the 
abundance of SAM and SAH, the ratio of SAM/SAH and the peak area ratio of methyl- 
cytosine/cytosine was compared to PBS-treated controls by pair-wise comparison 
using the un-paired student t-test. All p-values less than 0.05 were considered 
significant.
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4.3 Results
4.3.1 The effect of methylation cycle perturbation on the incidence of 
cranial NTDs and the abundance of SAM and SAH in non-mutant, 
CD1 embryos.
The effect of methionine, ethionine and cycloleucine on the development of 
neurulation-stage embryos was previously investigated in non-mutant CD1 embryos 
cultured for 24 hours from E8.5 (4-6 somites) to E9.5 (Dunlevy et al., 2006a;Dunlevy et 
al., 2006b). Embryo culture experiments were repeated using the same method and 
the new data are presented herein.
Exposure to 5 mM methionine, 5 mM ethionine or 15 mM cycloleucine for 28 hours did 
not adversely affect embryo survival, developmental progression (number of somites), 
growth (crown to rump length) or viability (yolk sac circulation) of the embryos (Table 
4.1). Nevertheless, at these concentrations a significant number of embryos exhibited 
open cranial neural tubes compared to PBS-treated control embryos (Table 4.2). 
These embryos were classed as exencephalic if they had reached the developmental 
stage (16 somites or more) when cranial neural tube closure is normally completed in 
CD1 embryos (Table 4.2 and Figure 4.2).
Culture 
T reatment
Time in 
culture 
(hrs)
No. live embryos 
(% of total 
cultured)
Yolk sac 
circulation
Number of 
somites
Crown-rump 
length (mm)
PBS 28 33 (67) 2.94 ± 0.04 19.7 ±0 .49 2.62 ± 0.08
Methionine 28 21 (66) 2.95 ± 0 .0 5 19.7 ±0 .6 4 2.58 ± 0.08
Ethionine 28 22 (55) 3.00 ± 0 .0 0 20.6 ±0.51 2.67 ± 0.06
Cycloleucine 28 31 (46) 3.00 ± 0.00 19.8 ±0.51 2.50 ± 0 .0 8
Table 4.1. Growth and development of mouse embryos following perturbation of the 
methylation cycle. Non-mutant CD1 embryos were cultured from E8.5 to E9.5 in the presence 
of PBS (control), 5 mM methionine, 5 mM ethionine or 15 mM cycloleucine for 28 hours. Values 
are given as mean ± standard error of the mean. Statistical analysis by ANOVA demonstrated 
no statistical differences (p >0.05) in embryo survival, yolk sac circulation, number of somites or 
crown-rump length between culture treatments.
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Culture 
T reatment
Time in 
culture (hrs)
No. live 
embryos
Open cranial 
neural tube
No. embryos 
> 16 somites
Cranial
NTDs
PBS 28 33 0 (0.0) 31 0 (0.0)
Methionine 28 21 11 (52.4) 17 7 (41.2)**
Ethionine 28 22 15 (68.2) 22 14 (63.6)**
Cycloleucine 28 31 26 (83.9) 30 25 (83.3)**
Table 4.2. Incidence of neural tube closure abnormalities in mouse embryos following 
perturbation of the methylation cycle. Non-mutant CD1 embryos were cultured from E8.5 to 
E9.5 in the presence of PBS (control), 5 mM methionine, 5 mM ethionine or 15mM cycloleucine. 
Cranial NTDs are defined as failure of cranial neural tube closure in embryos that have 
completed embryonic turning and have 16 or more somites. This is based on the observation 
that cranial neural tube closure, in vivo, is completed by the 16 somite stage in CD1 embryos in 
our laboratory. Data are presented as number of embryos with percentage in each treatment 
group in parentheses. ** p < 0.001 when compared to PBS treated control group (Fishers 
Exact).
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Figure 4.2. Incidence of cranial NTDs in mouse embryos following perturbation of the 
methylation cycle. Non-mutant CD1 embryos were cultured from E8.5 to E9.5 in the presence 
of PBS (control), 5 mM methionine, 5 mM ethionine or 15 mM cycloleucine for 28 hours and 
scored for the presence of exencephaly, defined as persistently open cranial neural folds in an 
embryo with 16 or more somites. ** p > 0.001 when compared to PBS-treated control group 
(Fishers Exact).
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To determine if male and female embryos are equally susceptible to exencephaly 
induced by methionine, ethionine or cycloleucine, the gender of each embryo was 
determined through genotyping the SMC locus by PCR (section 2.9, (Agulnik et al., 
1999)). Correlation of gender with phenotype revealed that in each treatment group it 
appears that the female embryos are more susceptible to cranial NTDs (Table 4.3). 
However, statistical analyses demonstrated that this trend does not reach significance 
except when treatment groups were pooled.
Culture 
T reatment
Total no. of 
male embryos
No. of male 
embryos with 
cranial NTDs
Total no. of
female
embryos
No. of female 
embryos with cranial 
NTDs
PBS 22 0 (0) | 9 0 (0 )
Methionine 16 5 (3 1 ) 6 3 (50)
Ethionine 17 11 (65) 11 9 (82)
Cycloleucine 11 8 (7 3 ) 20 17 (85)
Total 66 24 (36) 46 29 (63) **
Table 4.3. The effect of gender on the incidence of cranial NTDs following perturbation of 
the methylation cycle. Non-mutant CD1 embryos were cultured from E8.5 to E9.5 in the 
presence of PBS (control), 5 mM methionine, 5 mM ethionine or 15mM cycloleucine for 28 
hours. Data are presented as number of embryos with percentage in each treatment group in 
parentheses. ** p < 0.02 when pair-wise comparisons were made between genders for each 
culture treatment (Chi-square).
The effect of methionine, ethionine, and cycloleucine on the abundance of SAM and 
SAH in neurulation-stage embryos was measured using the method described in 
chapter 3 (Burren et al., 2006). Although the LC-MS/MS method was shown to be 
suitable for E9.5 CD1 embryos that developed in vivo, somite-matched CD1 embryos 
that have been cultured in vitro tended to be smaller such that the abundance of SAH 
in a single embryo was reduced. Therefore, pools of 2-4 embryos were analysed to 
ensure that the level of SAH was above the limit of detection (LOD = 2.5 nmol/L). 
Initially, embryos were cultured as described for 28 hr from E8.5 to E9.5 and analysed 
for the abundance of SAM and SAH (Table 4.4). Statistical analysis revealed that the 
changes in metabolite concentrations following exposure to methionine, ethionine or 
cycloleucine were insignificant, compared to the PBS-treated control embryos.
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Culture
treatment
No.
samples
SAM
(nmol/mg protein)
SAH
(nmol/mg protein)
Ratio SAM/SAH
PBS 6 2.99 ± 0.61 0.022 ± 0.005 144 ± 1 .0
Methionine 7 2.57± 0.47 0.019 ±0.003 133 ± 0 .5
Ethionine 4 1.57 ±0 .25 0.015 ±0.005 117 ± 1.7
Cycloleucine 5 2.67 ± 0.62 0.024 ± 0.006 119 ± 1.1
Table 4.4. The abundance of SAM and SAH following methylation cycle perturbation: 28 
hour culture period. Concentrations of SAM and SAH were determined by LC-MS/MS in 
mouse embryo samples (pools of 2-4 embryos) following culture from E8.5 to E9.5 for 28 hours 
in the presence of PBS, 5 mM Methionine, 5 mM Ethionine or 15 mM Cycloleucine. Values are 
given as mean ± standard error of the mean, p > 0.05 compared to PBS control treated 
embryos (un-paired student t-test).
This finding might suggest that the inhibitors do not affect the abundance of SAM  and 
SAH. Alternatively, the agents may have had an immediate effect but, owing to the  
long duration of the culture period, the metabolic effect may have worn off, for exam ple  
over time the embryo may have metabolised and broken down the inhibitors preventing 
further metabolic effects and the abundance of SAM and SAH may have returned to 
normal baseline levels. The tem perature of the embryo culture cham ber could also  
potentially promote degradation of the exogenous molecules. Thus, in order to detect 
any earlier effects of methylation cycle perturbation on the abundance of SAM  and 
SAH, non-mutant CD1 embryos were cultured for a shorter period (from late E 8.5  to 
early E9.5) for approximately 18 hours. Cultures were started later (immediately prior 
to, or during cranial neural tube closure) to m easure the metabolic effect at the tim e of 
neurulation (Figure 4.3).
18 hour culture period 
28 hour culture period
\ \ \ \ \ v \ \ \ \ > w w w w w w
m 00
N vvvvvvvvc
.5 E9.0 E9.5
Cranial neurulation
Figure 4.3. Time line depicting the two culture periods used to study perturbation of the 
methylation cycle.
103
Consistent with the 28 hr cultures, shorter cultures for 18 hr did not adversely affect the 
development, growth or viability of the cultured embryos (Table 4.5). However it was 
expected that since neural tube closure may have already begun at the start of the 
culture period the incidence rates of exencephaly may differ when compared to 28 hr 
cultures. In fact, the incidence of neural tube defects was reduced in the methionine, 
ethionine or cycloleucine treated embryos in 18 hour compared to 28 hour cultures 
(Table 4.6). These data suggest that older E8.5 embryos are less susceptible to NTDs 
following exposure to methionine, ethionine and cycloleucine and therefore, exposure 
at an earlier stage could have targeted a more sensitive period in neurulation.
Culture
Treatment
Time in 
culture (hrs)
No. live embryos 
(% of total cultured)
Yolk sac 
circulation
Number of 
somites
Crown-rump 
length (mm)
PBS 18 21 (87.5) 2.80 ±0.11 21.8 ± 0 .4 2 2.61 ± 0.08
Methionine 18 19 (90.1) 2.94 ±0 .0 5 21.7 ± 0.35 2.74 ± 0.05
Ethione 18 15 (88.2) 2.71 ±0 .19 19.5 ± 1.42 2.36 ± 0.17
Cycloleucine 18 20 (95.2) 2.64 ±0 .1 8 25.1 ± 1.69 2.09 ± 0.14
Table 4.5. Growth and development of mouse embryos following methylation cycle 
perturbation: 18 hour culture period. Non-mutant CD1 embryos were cultured from E8.5 to 
E9.5 in the presence of PBS (control), 5 mM methionine, 5 mM ethionine or 15 mM cycloleucine 
for 18 hours. Values given as mean ± standard error of the mean. Statistical analysis by 
ANOVA demonstrated no statistical differences (p >0.05) in yolk sac circulation, number of 
somites or crown-rump length between culture treatments.
Culture 
T reatment
Time in 
culture (hrs)
No. live 
embryos
Open cranial 
neural tube
No. embryos 
£ 16 somites
Cranial
NTDs
PBS 18 24 2 (8.3) 24 2 (8.3)
Methionine 18 21 3 (14.3) 21 3 (14.3)
Ethione 18 17 4 (23.5) 17 4 (23.5)
Cycloleucine 18 21 15 (71.4) 17 11 (64.7)
Table 4.6. Incidence of neural tube closure abnormalities in mouse embryos following 
methylation cycle perturbation: 18 hour culture period. Non-mutant CD1 embryos were 
cultured from E8.5 to E9.5 in the presence of PBS (control), 5 mM methionine, 5 mM ethionine 
or 15 mM cycloleucine for 18 hours. Cranial NTDs are defined as failure of cranial neural tube 
closure in embryos that have completed embryonic turning and have 16 or more somites. Data 
are presented as number of embryos with percentage in each treatment group in parentheses.
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Metabolite analysis showed that, in embryos exposed to methionine or cycloleucine for 
18 hours, there was a significant decrease in the ratio of SAM/SAH. This difference 
was mainly due to a significant increase in the abundance of SAH when compared to 
PBS control treated embryos (Table 4.7 and Figure 4.4). In ethionine-treated embryos, 
a significant decrease in SAM also contributed to the significant decrease in the ratio of 
SAM/SAH (Table 4.7 and Figure 4.4).
Culture treatment No.
samples
SAM
(nmol/mg protein)
SAH
(nmol/mg protein)
Ratio SAM/SAH
PBS 8 3.91 ± 0 .3 8 0.023 ± 0.003 178 ± 11.8
Methionine 5 4.40 ± 0.46 0.043 ± 0.006** 104 ± 4 .7 * *
Ethionine 5 2.67 ± 0.55* 0.034 ± 0 .009* 79 ± 3.2**
Cycloleucine 6 4.16 ± 0 .7 3 0.032 ± 0.003* 130 ± 12.1**
Table 4.7. The abundance of SAM and SAH following methylation cycle perturbation: 18 
hour culture period. Concentrations of SAM and SAH were determined by LC-MS/MS in 
mouse embryo samples (pools of 2-4 embryos) following culture from E8.5 to E9.5 for 18 hours 
in the presence of PBS, 5 mM Methionine, 5 mM Ethionine or 15 mM Cycloleucine. Values are 
given as mean ± standard error of the mean. * p < 0.05, ** p < 0.01 when compared to PBS- 
treated control embryos (un-paired student t-test).
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Figure 4.4. Embryonic concentrations of SAM (A), SAH (B) and ratio SAM/SAH (C) 
following perturbation of the methylation cycle: 18 hour culture period. Concentrations of 
SAM and SAH were determined by LC-MS/MS in mouse embryo samples (pools of 2-4 
embryos) following culture from E8.5 to E9.5 for 18 hours in the presence of PBS, 5 mM 
Methionine, 5 mM Ethionine or 15 mM Cycloleucine. Values are given as mean ± standard error 
of the mean. * p < 0.05, ** p < 0.01 when compared to PBS-treated control embryos (un-paired 
student t-test).
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4.3.2 Development of a method to quantify genomic DNA methylation in 
mouse embryos
The next step in this investigation was to determine whether the increase in SAH 
following exposure to excess methionine or the methylation inhibitors was sufficient to 
cause DNA hypomethylation. In order to assess changes in embryonic DNA 
methylation, the method of Friso and colleagues was adapted (Friso et al., 2002). Due 
to high cost implications, it was decided that the peak area ratio of methyl-cytosine to 
cytosine would be calculated, instead of using internal standards, to quantify genomic 
DNA methylation.
To tune the mass spectrometer for the specific detection of 2’-deoxycytidine and 5- 
methyl-2’-deoxycytidine, aqueous standards were directly infused into the mass 
spectrometer. Despite using a relatively “soft” ionisation method, the electrospray 
ionisation conditions caused a loss of the 2’-deoxyribose pentose moiety from both the 
2’-deoxycytidine and 5-methyl-2’-deoxycytidine resulting in the production of cytosine 
(wt = 111.10) and 5-methylcytosine (wt = 125.13), respectively. Thus in positive ion 
mode the [M+H]+ precursor ions were m/z 111.7 and 125.8 (Figure 4.5), consistent with 
the addition of a proton to the pyrimidine rings of both bases. Product ion spectra for 
cytosine and methyl-cytosine yielded fragments of m/z 95.0 and 109.1 (Figure 4.5), 
respectively, through the loss of a fragment of 16 Da thought to correspond to loss of 
oxygen or more likely, NH2. Thus, the final SRM transitions were as follows: 111.7 
95.0; 125.8 109.1.
Following the extraction of DNA from homogenised embryos, the DNA was hydrolysed 
as described (Friso et al., 2002). Figure 4.6 illustrates representative chromatograms 
of cytosine and methyl-cytosine in both an analytical sample, comprising neurulation- 
stage embryonic DNA, and an aqueous sample. It was decided to use a C18 guard 
column over a reverse-phase analytical column since it was felt that the extensive 
sample preparation involved in the extraction and hydrolysis of DNA would ensure the 
removal of most interfering molecules. The use of a guard column also limits outlay 
costs and considerably shortens run times.
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Figure 4.5. Product ion spectra of protonated molecules used for quantification.
Precursor ions were at m/z 111.7 for cytosine (A) and 125.8 for 5-methyl cytosine (B). In each 
case the MS/MS conditions were optimised to favour the transition to the major product ion at 
m/z 95.0 and 109.1, respectively, due to a loss of 16 Da.
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Figure 4.6. LC-MS/MS chromatograms obtained in SRM mode. Representative 
chromatograms are shown for (A) endogenous 2 ’-cytosine and 5-methyl-2’-cytosine in 
hydrolysed neurulation-stage mouse DNA and (B) an aqueous standard containing 0.01 pM 5- 
methyl-2’-cytosine and 1 pM 2 ’-cytosine. The ratio of methyl-cytosine / cytosine is (A) 0.09 and 
(B) 0.01.
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Analysis of E9.5 CD1 embryos was undertaken to determine reference intervals of 
methyl-cytosine and cytosine during neurulation. In all cases, extraction of DNA from a 
single whole embryo yielded more than the required 1 |jg of DNA. Hydrolysis of 1 |jg of 
DNA produced detectable peaks corresponding to methyl-cytosine and cytosine with 
signal-to-noise ratios in excess of 10:1 (Figure 4.6). Overall, the ratio of methyl- 
cytosine / cytosine was found to be between 0.06 and 0.10 in all E9.5 embryos 
analysed.
Once the method had been established, CD1 embryos cultured in the presence of 
methionine or the methylation cycle inhibitors were analysed to determine the ratio of 
methyl-cytosine to cytosine (Table 4.8). Statistical analysis revealed that neither 
methionine, ethionine nor cycloleucine treatment significantly affected the ratio of 
methyl-cytosine to cytosine compared to PBS control treated embryos (ANOVA; p = 
0.842). A higher concentration of methionine was also tested but was found to have no 
further effect. Thus, the results seemed to suggest that perturbation of the methylation 
cycle, resulting in a subsequent increase in SAH, does not cause a detectable change 
in DNA methylation.
Culture treatment 
(conc.)
No. samples Peak area ratio 5-methyl-2’-cytosine / 2’-cytosine
PBS 10 0.0832 ± 0.0099
Methionine (5 mM) 8 0.0859 ± 0.0084
Methionine (10 mM) 3 0.0937 ± 0.0084
Ethionine 6 0.0736 ± 0.0087
Cycloleucine 4 0.0792 ±0 .0158
Table 4.8. The peak area ratio of methyl-cytosine/cytosine in hydrolysed DNA extracted 
from whole E9.5 CD1 embryos cultured in the presence of methionine, ethionine or 
cycloleucine. Values given as mean ± standard error of the mean.
M/7/r-deficient mice represent an ideal positive control to determine whether the LC- 
MS/MS assay used in this study was sensitive and precise enough to detect changes 
in DNA methylation relating to methylation cycle perturbation (Chen et al., 2001a). In 
brain tissue from Mthfr-deficient mice, the DNA is hypomethylated due to a decrease 
the SAM/SAH ratio, resulting from an increase in SAH caused by the genetic 
disturbance in the folate cycle (Chen et al., 2001a). Thus, DNA was extracted from the 
brains of heterozygous and homozygous Mthfr-deficient mice (donated by Dr. Rima
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Rozen) and subjected to hydrolysis and analysis using the described LC-MS/MS 
method.
The ratio of methyl-cytosine/cytosine in adult mouse brain tissue was found to be 
similar to values found in neurulation-stage mouse embryos (Table 4.9). As expected, 
DNA extracted from brain tissue of heterozygous and homozygous M/7/r-deficient mice 
was found to be hypomethylated compared to wild-type mice, as shown by the reduced 
ratio of 5-methyl-2’-cytosine to 2’-cytosine. However statistical analysis by the student 
t-test reveals that this decrease is only statistically significant for the heterozygotes (p = 
0.040), presumably due to the larger standard error of the overall mean for 
homozygotes and the low sample number.
Mthfr genotype No. samples Ratio 5-methyl-2’-cytosine / 2’-cytosine
Sample 1 Sample 2 Mean
Wild-type 2 0.0965 0.0934 0.0950 ±0 .0 0 2 2
Heterozygous 2 0.0679 0.0740 0.0710 ± 0 .0 0 4 4 *
Homozygous 2 0.0615 0.0786 0.0700 ±0 .0 1 2 0
Table 4.9. The peak area ratio of methyl-cytosine/cytosine in DNA extracted from brain 
tissue of Aft/ifr-deficient mice. Values given as mean ± standard error of the mean. * p < 0.05  
compared to wild-type.
4.3.3 Investigating the effect of inhibition of DNA Methylation on the 
incidence of cranial NTD and the abundance of SAM and SAH, in 
non mutant CD1 embryos
A different experimental approach was subsequently undertaken to investigate whether 
abnormal DNA methylation could be involved in the pathogenesis of NTDs. The DNA 
methylation inhibitor, 5’-azacytidine, has previously been reported to induce 
exencephaly (Matsuda, 1990;Takeuchi and Takeuchi, 1985). 5’-Azacytidine is an 
analogue of cytidine which becomes incorporated into the DNA but cannot be 
methylated since the 5’ carbon has been replaced with a nitrogen. This inhibitor has 
been well-documented to cause DNA hypomethylation in numerous other systems 
(Jones et al., 1983).
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AZA conc. 
(mM)
Duration of 
culture (hrs)
n= Yolk sac 
circulation
Number of 
somites
Crown-rump 
length (mm)
0.0 28 5 3.00 ± 0 .0 20.2 ± 0.58 2.67 ± 0.09
0.8 28 2 3.00 ± 0 .0 21.5 ± 0 .5 0 2.83 ± 0 .1 7
2.0 28 5 2.20 ± 0.4 19.0 ± 1.05 2.32 ± 0.08
0.0 18 5 2.80 ± 0 .2 0 19.6 ± 0 .9 8 2.20 ± 0.17
2.0 18 14 3.00 ± 0 .0 0 19.7 ± 0 .8 7 2.25 ± 0.08
Table 4.10. Growth and development of mouse embryos following exposure to an 
inhibitor of DNA methylation. Non-mutant CD1 embryos were cultured from E8.5 to E9.5 in 
the presence of PBS (control) or 5’-azacytidine (AZA) for 18 hours. Values are given as mean ± 
standard error of the mean, p > 0.05 compared to PBS control treated embryos (unpaired 
student t-test).
AZA conc. 
(mM)
Duration of 
culture (hrs)
No. live 
embryos
Cranial neural 
tube open
No. embryos 
> 16 somites
Cranial
NTDs
0.0 28 5 0 (0.0) 5 0 (0.0)
0.8 28 2 1 (50.0) 2 1 (50.0)
2.0 28 5 5 (100.0) 5 4 (80.0)*
0.0 18 5 0 (0.0) 5 0 (0.0)
2.0 18 14 8 (57.1) 14 8 (57.1)*
Table 4.11. Incidence of neural tube closure abnormalities in mouse embryos following 
exposure to an inhibitor of DNA methylation. Non mutant CD1 embryos were cultured from 
E8.5 to E9.5 in the prescence of PBS (control) or 5 ’-azacytidine (AZA). Cranial NTDs are 
defined as failure of cranial neural tube closure in embryos that have completed embryonic 
turning and have 16 or more somites. Data are presented as number of embryos with 
percentage in each treatment group in parentheses. * p < 0.05 when compared to PBS control 
treated embryos (Fisher Exact test).
A series of non mutant CD1 embryos were cultured for 28 hours in the presence of 5- 
azacytidine at the doses stated in previous studies (Matsuda and Yasutomi, 1992). 
Exposure to azacytidine concentrations of 0.8 mM and 2 mM did not result in 
embryotoxicity as shown by absence of an effect on yolk sac circulation scores (Table 
4.10). Embryos showed normal developmental progression, as indicated by 
comparable somite numbers among azacytidine-treated embryos and embryos
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cultured with PBS (Table 4.10). There were no differences in the mean crown-rump 
length between the treatment groups suggesting that azacytidine treatment does not 
cause growth retardation at these concentrations (Table 4.10). At the higher 
concentration (2 mM) a significant number of embryos exhibited open cranial neural 
tubes compared to PBS-treated control embryos (Table 4.11). These embryos were 
classed as exencephalic if they had reached the developmental stage (16 somites or 
more) when cranial neural tube closure is normally completed in CD1 embryos.
The effect of azacytidine exposure on the levels of SAM and SAH was measured using 
the method described in chapter 3 (Burren et al., 2006) in embryo samples (pools of 2- 
4 embryos) following short 18 hr cultures. Cultures were started immediately prior to, 
or during cranial neural tube closure to measure the metabolic effect at the time of 
neurulation (as in section 4.3.1). Consistent with the 28 hr cultures, shorter cultures for 
18 hr did not adversely affect the development, growth or viability of the cultured 
embryos (Table 4.10). There was a 22.9% decrease in the incidence of NTDs in 
embryos treated for just 18 hours compared to 28 hours (Table 4.11). This suggests 
that older E8.5 embryos are less susceptible to NTD following azacytidine exposure, as 
in short cultures, embryos were not placed in culture until the 8-10 somite stage 
compared to 5-7 somite stage for 28 hour cultures.
In azacytidine-treated embryos there was no significant change in the abundance of 
SAM, SAH or the ratio of abundance of SAM to SAH, compared to PBS-treated control 
embryos (Table 4.12 and Figure 4.7). Failure to detect a change in SAM and SAH 
implies that 5’-azacytidine does not affect the methylation cycle and any effect on DNA 
methylation is downstream of the methylation cycle.
AZA conc. 
(Mg/ml)
No.
samples
SAM
(nmol/mg
protein)
SAH
(nmol/mg
protein)
Ratio
SAM/SAH
0.0 7 5.40 ± 0.78 0.035 ±0 .005 155 ± 8 .3
2.0 5 4.29 ± 0.74 0.026 ± 0.005 166 ± 8.5
Table 4.12. The abundance of SAM and SAH in mouse embryos following exposure to an 
inhibitor of DNA methylation. Concentrations of SAM and SAH were determined by LC- 
MS/MS in mouse embryos (pools of 2-4 embryos) following culture from E8.5 to E9.5 for 18 
hours in the presence of PBS (control) or 2 mM Azacytidine (AZA). Values are given as mean ± 
standard error of the mean. No significant differences were detected (un-paired student t-test).
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Figure 4.7. The abundance of SAM and SAH in mouse embryos following exposure to 
an inhibitor of DNA methylation. Concentrations of SAM and SAH were determined by LC- 
MS/MS in mouse embryos (pools of 2-4 embryos) following culture from E8.5 to E9.5 for 18 
hours in the presence of PBS (control) or 2 mM Azacytidine (AZA). Values are given as mean ± 
standard error of the mean. The p-value (t-test) is displayed in the top RHS of each graph.
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4.3.4 Biochemical analysis of the abundance of SAM and SAH and the 
SAM/SAH ratio in human cell lines.
In the course of the study, fibroblast cell lines derived from human NTD cases became 
available. To establish whether perturbation of the methylation cycle in cell culture 
could cause a detectable change in the intracellular abundance of SAM and SAH, 
cycloleucine was added at various concentrations to the culture medium of mouse 3T3 
fibroblasts. Following incubation at 37°C with 5 % C 02 for 24 hours, cells were 
trypsinised and pellets collected for analysis of SAM and SAH by LC-MS/MS (see 
section 4.2.4.4). At all concentrations used (15, 30 and 60 mM), cycloleucine caused a 
significant decrease in the concentration of SAM (p-value < 0.02), whilst there were no 
significant changes in the abundance of SAH (Table 4.13). The change in the 
abundance of SAM caused a decrease in the ratio of SAM/SAH although this trend was 
not statistically significant at any concentration. Thus, the metabolic response to 
methylation cycle perturbation in these fibroblasts is different from that seen in cultured 
whole embryos in which cycloleucine exposure does not affect SAM levels but causes 
a significant increase in SAH (see section 4.3.1 and figure 4.4).
Concentration 
of cycloleucine 
(mM)
Mouse 3T3 
Fibroblasts
SAM
(nmoles/mg
protein)
SAH
(nmoles/mg
protein)
Ratio
SAM/SAH
0 Sample 1 0.716 0.032 22.3
Sample 2 0.672 0.022 30.6
Mean (n=2) 0.694 ± 0.022 0.027 ± 0.005 26.4 ±4 .1
15 Sample 1 0.480 0.024 20.04
Sample 2 0.512 0.022 23.05
Mean (n=2) 0.496 ±0 .016* 0.023 ±0.001 21.5 ± 1.5
30 Sample 1 0.446 0.021 21.6
Sample 2 0.423 0.017 25.2
Mean (n=2) 0.434 ±0 .017* 0.019 ±0 .0 0 2 23.4 ± 1.8
60 Sample 1 0.427 0.027 16.0
Sample 2 0.401 0.030 13.6
Mean (n=2) 0.414 ± 0.035* 0.028 ±0.001 14.8 ± 1.2
Table 4.13. Concentration of SAM, SAH and the ratio of SAM/SAH in mouse 3T3 
fibroblasts exposed to cycloleucine for 24hr at various concentrations. Mean values are 
given as mean ± standard error of the mean. * p < 0.05 when compared to untreated control, 0 
mM (unpaired student t-test).
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To investigate whether disturbances in the abundance of SAM or SAH are commonly 
seen in human NTDs, the concentrations of SAM and SAH were quantified in individual 
fetal cell lines from NTD cases and a subset of controls (Figure 4.8). As cell lines were 
cultured under identical conditions, it was reasoned that any abnormality in the ratio of 
methylation cycle intermediates would be due to a genetic variation. The integrity of 
the folate cycle in these cell lines had been previously examined by Dr. L. P. E. 
Dunlevy using the d ll suppression test (Dunlevy et al., 2006c). Cell lines were scored 
depending on their ability to stimulate the de novo pathway and suppress 3H-thymidine 
incorporation. A low score, representing a low 3H-thymidine suppression value, was 
indicative of reduced efficacy of folate metabolism.
The mean d ll suppression test score was significantly lower in NTD cases than control 
cell lines. When all cell lines were considered together the lowest quartile of scores all 
corresponded to NTD cell lines, whereas none of the control cell lines had a 
suppression score within this lowest quartile (Dunlevy et al., 2006c). When the NTD 
cell lines were ranked in order of d ll suppression score, with the lowest corresponding 
to abnormal folate metabolism, there was no apparent correlation between the results 
of the d ll suppression test and the abundance of SAM or SAH (Figure 4.8). In fact 
overall, there was very little variation in metabolite levels between cell lines with most 
values being less than one standard deviation from the mean. The only result that did 
highlight a potential disturbance in the methylation cycle was the NTD sample with the 
tenth lowest d ll suppression score which had an unusually high SAM/SAH ratio due to 
both a high concentration of SAM and a low concentration of SAH. However, as the 
dU suppression score was in the ‘normal’ range shared by cases and controls it is 
unlikely that the altered SAM/SAH ratio affected performance of folate metabolism.
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Figure 4.8. A comparison between dll suppression result and abundance of SAM and 
SAH in fibroblastic fetal cell lines, (a) dU suppression rank, (b) abundance of SAM, (c) 
abundance of SAH and (d) ratio of abundance of SAM/SAH. Samples were ranked in order of 
dU suppression score (dU suppression rank), with the 6 NTD samples with the lowest scores (1- 
6), exhibiting apparent abnormalities in folate metabolism. Figure taken from Dunlevy et al., 
2006c (unpublished). Data presented in 4.15a provided by Louisa Dunlevy.
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Comparing the mean concentration of SAM and SAH in fetal fibroblast cell lines (Table 
4.14) reveals that the concentration of SAM (p-value = 0.645), SAH (p-value = 0.223) 
and the SAM/SAH ratio (p-value = 0.634) is not significantly different between NTD and 
control cell lines. Thus overall, it appears that fibroblasts taken from NTD affected 
fetuses do not have a reduced efficacy of the methylation cycle, compared to normal 
controls.
Patient
Type
n= SAM
(nmoles/mg protein)
SAH
(nmoles/mg protein)
Ratio SAM/SAH
NTD 16 0.254 ± 0.032 0.0387 ± 0  0040 8.7 ± 2 .6
Control 4 0.288 ± 0.069 0.0497 ± 0.0067 6.1 ± 1.7
Table 4.14. A comparison of the mean concentration of SAM and SAH, and the mean 
SAM/SAH ratio between NTD and control sample cell pellets from fetal fibroblast cell 
lines. Values are given as the mean ± the standard error of the mean. * p < 0.05, ** p < 0.02  
when compared to control samples (un-paired student t-test).
Patient Type NTD Control
n= 28 10
SAM
(nmoles/mg protein)
Mean ± SEM 0.145 ±0 .009 0.148 ± 0 .0 2 0
Range 0 .0 7 5 -0 .2 5 5 0 .0 5 4 -0 .2 4 0
SAH
(nmoles/mg protein)
Mean ± SEM 0.0121 ± 0.0010 0.0115 ± 0 .0 0 1 7
Range 0.0051 -0 .0 3 0 4 0 .0 0 5 5 -0 .0 2 2 1
Ratio SAM/SAH Mean ± SEM 13.0 ± 0 .8 2 13.3 ± 1.24
Range 5 .8 - 2 0 .9 7 .8 - 1 7 .6
Table 4.15. A comparison of the mean concentration of SAM and SAH, and the mean 
SAM/SAH ratio between NTD and control sample cell pellets from EBV transformed B 
lymphocyte cell lines collected from Swedish children. Values are given as the mean ± the 
standard error of the mean, p > 0.05 when compared to control samples (un-paired student t- 
test).
A second population of cell lines of a different cell type was then studied. In this case 
immortalised B-lymphocyte cell lines were analysed to provide reference levels of SAM 
and SAH in lymphocytes and potentially reveal differences between NTD affected and 
normal cell lines. These cell pellets were provided by Dr. P. Gustavvson and 
concentrations of SAM and SAH were quantified using the method described in chapter 
3. A comparison of the mean concentration of SAM and SAH, and the mean SAM/SAH 
ratio from the NTD and control patient EBV transformed cell lines reveals no
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statistically significant differences in metabolite concentrations between patient types 
(Table 4.15). Overall, this finding would suggest that collectively B lymphocytes from 
Swedish children with open spina bifida do not have a defect in the methylation cycle.
Concentrations of SAM, SAH and the SAM/SAH ratio in individual samples were 
analysed further to identify isolated cases with potential genetic disturbances in the 
methylation cycle (Figure 4.9). Three NTD samples (13, 24 and 27) and three control 
samples (2, 5 and 6) had SAM concentrations greater than one standard deviation from 
the mean, whilst five NTD samples (10, 11, 19, 20 and 21) and three control samples 
(3, 7 and 10) had SAM concentrations less than one standard deviation from the mean. 
Thus, it appears that the concentration of SAM is not atypical in NTD samples. Sample 
number 24 (highlighted in figure 4.9 by the vertical blue dotted line), an NTD cell line, 
had the highest concentration of SAM, yet the concentration of SAH was very close to 
the overall mean resulting in a high SAM/SAH ratio. This result is analogous to that 
seen in 3T3 mouse fibroblast cultures following exposure to the methylation cycle 
inhibitor, cycloleucine (Table 4.13).
Two NTD samples (13 and 27) and two control samples (6 and 9) had SAH 
concentrations greater than one standard deviation from the mean, whilst one NTD 
sample (11) and two control samples (3 and 10) had SAH concentrations less than one 
standard deviation from the mean (Figure 4.9). Thus, concentrations of SAH in NTD 
samples are not indifferent to SAH concentrations in control samples. Likewise, it 
appears that an increased abundance of SAH is not a common feature in these human 
NTD samples, as was seen in mouse embryos following perturbation of the methylation 
cycle (see section 4.3.1. and figure 4.4). Sample number 13 (highlighted in figure 4.9 
by the vertical red dotted line) had the highest concentration of SAH although the ratio 
of SAM/SAH was not particularly low since the concentration of SAM was above the 
overall mean.
Two NTD samples (22 and 24), but no control samples, had a SAM/SAH ratio greater 
than one standard deviation from the mean, whilst seven NTD samples (1, 2, 13, 17, 
19, 20 and 21) and two control samples (7 and 9) had a SAM/SAH ratio less than one 
standard deviation below the mean (Figure 4.9). Thus, a trend appears to be 
developing whereby the outlying SAM/SAH ratios are more likely to be attributable to 
NTD cases as opposed to control cases. Likewise, analysis of the range of SAM/SAH 
ratios for NTD and control samples demonstrates a greater range in NTD samples 
compared to control samples (Table 4.15).
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Figure 4.9. A comparison of the concentration of SAM and SAH in EBV transformed B 
lymphocyte cell lines from Swedish children with open spin bifida and normal Swedish 
controls. The (A) concentration of SAM, (B) concentration of SAH and (C) ratio of SAM/SAH  
are plotted. In each graph the overall mean value (dashed line) and 1 standard deviation 
(dotted line) of all samples are indicated. The vertical red and blue dotted lines indicate the 
samples with the highest concentration of SAM and SAH, respectively.
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4.3 Conclusion and Discussion
4.3.1 Integrity of the methylation cycle is critical for cranial neurulation
Induction of exencephaly by exposure of embryos to excess methionine and inhibitors 
of the methylation cycle indicates an essential requirement for the methylation cycle in 
cranial neurulation. Furthermore, exposure to inhibitors of DNA methylation pinpoints a 
requirement for DNA methylation. In many cases in which exencephaly is induced 
experimentally by exogenous agents it is associated with lethality prior to closure, or 
generalised retardation of embryonic growth or developmental progression (Copp et 
al., 1990). However, none of the teratogens used in this study caused embryonic 
lethality or, suppressed growth or development at doses required to induce a significant 
incidence of exencephaly, suggesting a specific effect on cranial neurulation 
processes.
Ethionine and cycloleucine are both inhibitors of MAT. Ethionine was found to cause a 
significant decrease in the abundance of SAM, the product of this enzyme, and an 
increase in the level of SAH. Previous studies utilising ethionine in adult mice have 
demonstrated a 10-fold increase in the ratio of s-adenosylethionine (SAE) to s- 
adenosylmethionine (SAM) associated with the production of methyl-deficient DNA in 
the liver (Cox and Irving, 1977). Cycloleucine, however, did not affect the abundance 
of SAM but did cause a significant increase in the level of SAH. The increased 
abundance of SAH following inhibition of MAT is presumably due to feedback 
regulation around the methylation cycle, whereby the reversible reaction between 
homocysteine and SAH, catalysed by SAH hydrolase, favours the production of SAH 
(Finkelstein, 1998). The net effect is that both ethionine and cycloleucine cause a 
decrease in the SAM/SAH ratio, which is indicative of poor cellular methylation 
potential (James et al., 2002). Investigations using methyl-deficient cystathionine-(3- 
synthase heterozygous mice have demonstrated that elevation of intracellular SAH 
concentration and, to a lesser extent, decreased SAM/SAH ratio are biomarkers of 
global DNA hypomethylation, whereas changes in intracellular concentrations of SAM 
are not associated with changes in DNA methylation (Caudill et al., 2001). Thus, 
although cycloleucine did not apparently affect SAM levels in cultured mouse embryos, 
the significant effects on SAH concentration and SAM/SAH ratio strongly suggest that 
methylation reactions are suppressed.
Miller and colleagues demonstrated in the adult rat liver, that ethionine treatment, 
through the production of s-adenosylethionine, is an activator of cystathionine p- 
synthase and effectively promotes the catabolism of homocysteine through
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cystathionine (Miller et al., 1994). However, only adult tissues such as the liver, 
pancreas, kidney and brain that express CBS would be responsive to CBS regulation 
(James et al., 2002). In fact at this stage of embryonic development cells do not 
express CBS and therefore may be more sensitive to accumulation of SAH (VanAerts 
et al., 1995).
Consistent with metabolite concentrations in mouse embryos, a study of SAM and SAH 
levels in chick reported a mean SAM concentration of 1.12 nmol/mg protein and a 
mean SAH concentration of 0.06 nmol/mg protein in neurulation-stage embryos. In 
accordance with the findings from this study, treatment with cycloleucine also resulted 
in a decrease in the SAM/SAH ratio (Afman et al., 2006). Thus, at the same embryonic 
stage, there is little variation between mouse and chick in the global abundance of 
SAM and SAH and the metabolic response to methylation cycle perturbation with 
cycloleucine is similar.
In contrast to mouse embryos, exposure of mouse 3T3 fibroblasts to cycloleucine in 
this study caused a decrease in the concentration of SAM with no detectable change in 
the abundance of SAH. Thus, there appears to be a difference in regulation with no 
feedback mechanism causing a build-up of SAH to inhibit methylation. Since 
fibroblasts lack the transsulfation pathway, two possible mechanisms exist to avert 
potential intracellular accumulation of free SAH. First, at high levels, SAH can be 
exported out of the cell into the culture medium. Second, the lack of SAH accumulation 
may be due to facile transport of homocysteine across the plasma membrane (James 
et al., 2002). This may be more likely because the concentration of plasma 
homocysteine far exceeds that of SAH.
Methionine treatment was predicted to increase flux through the methylation cycle 
(Coelho et al., 1989), and the finding that excess methionine actually induces a 
significant incidence of cranial NTDs without affecting embryonic viability, growth or 
development, was therefore unexpected (Dunlevy et al., 2006a). Analysis of SAM and 
SAH levels in this study revealed that methionine has a similar metabolic effect to 
cycloleucine, causing a highly significant increase in SAH. It is presumed that this is 
again due to feedback suppression of the conversion of homocysteine to methionine, in 
turn leading to an increase in SAH (Finkelstein, 1998). The overall decrease in the 
SAM/SAH ratio due to a large increase in SAH is predicted to inhibit methyltransferase 
reactions (Caudill et al., 2001).
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4.4.2 Is maintenance of DNA methylation critical for cranial neural tube 
closure?
A possible mechanism envisaged to cause NTDs through suppression of the 
methylation cycle is aberrant DNA methylation (McKay et al., 2004). In this study, a 
method was adapted to assess genomic DNA methylation in neurulation stage mouse 
embryos using high performance liquid chromatography tandem mass spectrometry. 
However, analysis of the ratio of methyl-cytosine to cytosine in non-mutant CD1 
embryos cultured in the presence of methionine and the methylation inhibitors, 
ethionine and cycloleucine, did not reveal any detectable differences in global DNA 
methylation.
Subtle changes in global DNA methylation may have been below the limits of detection, 
although it was demonstrated that the method was sufficiently sensitive to detect 
significant changes in DNA methylation in brain tissue from Mthfr-6eT\c\ent mice. An 
alternative explanation is that certain tissues would be more sensitive to the increase in 
SAH, such that DNA methylation may be maintained in some tissues at the expense of 
others. Indeed, changes in DNA methylation in CBS- and Mthfr-6ef\c\enX mice are 
tissue specific (Chen et al., 2001a;Choumenkovitch et al., 2002). Assessment of DNA 
methylation in whole embryos provides an overview of embryonic metabolism which, 
depending on the number of tissues affected and the extent of the change, may not 
detect tissue specific DNA methylation. Due to the small size of mouse embryos it 
would be exceedingly difficult to assess DNA methylation in individual tissues using 
current methodologies.
In this study exencephaly was observed in mouse embryos following exposure to 5- 
azacytidine, as previously reported (Matsuda, 1990;Takeuchi and Takeuchi, 1985). It 
could be predicted that inhibition of DNA methylation may affect the regulation of other 
important reactions connected to the methylation cycle including polyamine synthesis, 
protein synthesis and folate metabolism. However, this study observed no change in 
the abundance of SAM or SAH in mouse embryos cultured in the presence of 5- 
azacytidine using the same conditions that were used with the methionine and the 
methylation inhibitors. The absence of an effect of 5’-azacytidine on the SAM/SAH 
ratio, suggests that this inhibitor is acting downstream of the methylation cycle 
presumably through inhibition of DNA methylation. The idea that DNA methylation is 
essential for processes underlying neural tube closure is consistent with exencephaly 
observed in Dnmt3b-deficient embryos, where changes in DNA methylation are thought 
to affect gene regulation (Okano et al., 1999). It remains to be established whether 
particular tissues or cell types are more sensitive to changes in DNA methylation
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following exposure to 5-azacytidine and furthermore, whether these cell types are 
involved in cranial neural tube closure.
4.4.3 Investigating methylation cycle integrity in human NTDs
Overall, there is now considerable evidence using experimental models that 
suppression of the methylation cycle can contribute to increased risk of NTDs. Levels 
of SAM and SAH are ideal markers of intracellular methylation potential. SAH- 
mediated DNA hypomethylation and associated alterations in gene expression may be 
the key to understanding the pathogenesis of NTDs related to risk factors such as sub- 
optimal folate, high homocysteine and reduced vitamin B12 (Kirke et al., 1993;Kirke et 
al., 1996;Steegers-Theunissen et al., 1994). To extrapolate this study to human cases 
of NTDs, the abundance of SAM and SAH was quantified in cells from NTD affected 
patients to determine any potential abnormalities in the methylation cycle.
Analysis of the abundance of SAM and SAH in fetal fibroblast cell lines revealed no 
correlation with d ll suppression score. Thus, overall it appears that the abnormal dU 
suppression result obtained in the previous study (Dunlevy et al., 2006c) is unlikely to 
result from a defect in the methylation cycle. Metabolite analysis led to the detection of 
a NTD sample with increased abundance of SAM which could be a potential biomarker 
for a genetically-determined disturbance in the methylation cycle. A high SAM/SAH 
would suggest that methylation was unaffected (Dunlevy et al., 2006c) therefore this 
result is unlikely to be biologically significant. More samples need to be analysed to 
establish the relevance of this finding.
A comparison of mean values demonstrated that NTD fetal samples have similar 
concentrations of SAM and SAH compared to control fetal samples. There was also no 
differences detected in mean concentrations of SAM and SAH between NTD and 
control samples in the second set of cell lines analysed: the immortalised B 
lymphocytes collected from Swedish children with open spina bifida compared to 
normal Swedish controls. Comparisons between the two cell types revealed that fetal 
fibroblasts have a 2-4 fold higher concentration of SAM and a 3-6 fold higher 
concentration of SAH compared to B lymphocytes collected from children (compare 
Table 4.14 and 4.15). The SAM/SAH ratio is approximately 1.5-fold lower in the fetal 
fibroblast cells. Thus it is apparent that metabolite concentrations do vary between cell 
types and/or with human development. This supports the previous hypothesis that 
different tissues may be more sensitive to changes in methylation cycle perturbation.
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To date there seems to have been a general lack of studies investigating the 
relationship between the abundance of SAM and SAH in human NTD cases. In part, 
this may have been due to lack of availability of a sufficiently sensitive and robust 
assay method. A recent publication reported increased levels of SAH and decreased 
SAM in plasma collected from women with an NTD affected pregnancy (Zhao et al., 
2006). This study highlighted NTD samples with potential genetically-determined 
disturbances in the methylation cycle, however it is not clear how physiologically 
relevant these changes in SAM and SAH levels are, and whether they are indeed risk 
factors for human NTDs. A large-scale investigation of SAM and SAH levels in human 
NTD cases is required to determine whether altered levels are associated with NTDs.
125
CHAPTER 5
Investigating the relationship between maternal dietary 
folate intake, embryonic one carbon metabolism and 
the incidence of neural tube defects in the splotch NTD
mouse model-
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5.1 Introduction
5.1.1 Dietary folate deficiency in mouse models
Burgoon and colleagues undertook research using wild-type mice to evaluate changes 
in maternal folate, homocysteine and reproductive outcome caused by a diet deficient 
in folic acid (Burgoon et al., 2002). They reported biochemical characteristics similar to 
human folic acid deficiency, including decreased plasma and red blood cell folate, and 
increased plasma homocysteine. Reproductive outcome was poor with increased rate 
of fetal deaths, decreased fetal weight and delay in embryonic development of the 
heart and palate. Notably, folate deficiency did not cause NTDs in wild-type mice. An 
analogous investigation by Heid and co-workers reported that folate deficient dietary 
conditions resulted in a high rate of resorption with fewer and smaller embryos yet, 
similarly, folate deficiency did not cause NTDs in wild-type mice (Heid et al., 1992).
A different approach would be to use an NTD mutant mouse strain to enable any 
interaction between folate deficiency (environmental factor) and a mutation causing an 
NTD phenotype (genetic factor) to be assessed. In this chapter, this study uses the 
folate-preventable splotch (Sp2H) NTD mutant mouse model to demonstrate that a 
folate-deficient (FD) diet causes increased incidence of exencephaly in Sp2H 
homozygous and heterozygous embryos, which can be rescued in utero by folic acid 
supplementation, but not by thymidine. Additionally, a diet deficient in both folate and 
inositol is shown to cause exencephaly in all Sp2H homozygous embryos.
Many bacterial species, including several present in the large intestine, are capable of 
synthesising folate, which can be absorbed across the large intestine and incorporated 
into tissue (Asrar and O'Connor, 2005). Thus to ensure a folate-deficient diet 
effectively reduces maternal folate status, it is recommended that an antibiotic is 
included to kill the gut bacteria and prevent the absorption of bacterially synthesised 
folate (Burgoon et al., 2002). To highlight potential adverse outcomes of adding the 
antibiotic to the diet, two control diets have been used to assess the effects of bacterial 
folate deficiency versus dietary folate deficiency. The bacterial folate deficient (BFD) 
diet used contained sufficient dietary folic acid but had the antibiotic added to exclude 
bacterial folate supplies. Therefore, this diet was sufficient in dietary folate but deficient 
in bacterial folate. In contrast, the dietary folate deficient (DFD) diet did not contain the 
antibiotic and the dietary folic acid was removed. Therefore, this diet was sufficient in 
bacterial folate but deficient in dietary folate.
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5.1.2 The folate-preventable splotch NTD mouse model
The splotch (Sp) mutation was originally identified in a mouse colony as a spontaneous 
semi-dominant allele (Russell, 1947). Since then multiple alleles at the same locus on 
murine chromosome 1 have arisen, including the radiation-induced Sp2H allele 
(Beechey and Searle, 1986). The Sp2H allele encodes a 32 nucleotide deletion in the 
Pax3 gene resulting in a truncated protein lacking the C-terminal homeodomain, while 
the octapeptide motif and paired domain remain intact (Epstein et al., 1991). Most 
homeodomains recognise DNA sequences containing the TAAT motif, however the 
homeodomain found in the Pax-3 protein enables co-operative dimerisation on a 
distinct palindromic DNA sequence not bound by other homeodomains (Chi and 
Epstein, 2002). The Sp2H mutation is thought to result in a functionally null protein.
The role of Pax3 during neural tube closure remains to be definitively identified, 
however the pattern of expression suggests functional importance in this process. 
Pax3 is expressed prior to closure at the dorsal aspect of the prosencephalon, the point 
of Closure site II, with expression extending to the posterior neuropore (Goulding et al., 
1991). The migratory population of neural crest cells emerge from this Pax3 
expressing domain. Neural crest cells migrate throughout the developing embryo and 
differentiate into many cell types, contributing to multiple organs (Chi and Epstein, 
2002).
Heterozygous splotch mice have a characteristic white patch on their belly due to the 
failure of neural crest cell derived melanocytes to migrate (Auerbach, 1954). 
Homozygous splotch mice develop spina bifida and/or exencephaly, in addition to 
abnormalities of neural crest migration including congenital heart disease which results 
in embryonic death at E14 (Auerbach, 1954). Historically, 40% of Sp2H/Sp2H embryos 
develop cranial and spinal NTDs, 25% develop isolated spinal NTDs and the remaining 
35% develop normally (Fleming and Copp, 1998). Humans with Waardenburg 
syndrome (types I and III) with mutations in PAX3 have an increased prevalence of 
NTDs in homozygotes, although PAX3 mutations do not appear to be associated with 
familial NTDs in humans (Chatkupt et al., 1995;Read and Newton, 1997).
Folic acid and thymidine administration both in vivo and in vitro reduce the incidence of 
NTDs by 35-45% among homozygous Sp2H mouse embryos, whilst methionine has an 
exacerbating effect (Fleming and Copp, 1998). Using the deoxyuridine suppression 
test (for further details see section 4.3.4), a disturbance in folate metabolism has also 
been identified in homozygous Sp2H embryos developing in vitro (Fleming and Copp, 
1998). The excessive incorporation of [H3]-thymidine indicated a metabolic deficiency
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in the supply of folate for the biosynthesis of pyrimidine. Unlike homozygous Sp2H 
embryos, studies using the Sp mouse colony found that folic acid does not rescue 
either spontaneous or arsenic-induced NTDs in Sp homozygotes (Gefrides et al., 
2002). In addition, the analysis of mice with both Sp and Mthfr mutations demonstrated 
that there were no differences in the incidence or severity of NTDs in embryos from 
double-mutant mating pairs compared to those from single Sp mutants (Li et al., 2006), 
suggesting there is no interaction between the Sp mutation and folate metabolism.
5.1.3 Biomarkers of folate metabolism
In addition to studying the incidence of NTDs following dietary intervention, this study 
has also focused on the biochemical effects of the diets on folate and one-carbon 
metabolism in Sp2H/+ dams and their embryos. In order to study embryonic folate 
metabolism and to determine maternal folate levels, a suitably sensitive and accurate 
method was required to measure folate. Of the procedures currently in use, the 
method of choice is the L.casei microbiological assay (Shane et al., 1980). This 
method is based on the folate-dependent growth of the bacterium Lactobacillus casei, 
which can be measured spectro-photometrically. An advantage of the L.casei 
microbiological method is that it is sensitive to all monoglutamylfolate species, and 
therefore provides a means to assess the monoglutamylfolate content within a 
biological sample. In addition to this, specific sample preparation enables the 
determination of polyglutamylfolate levels following enzymatic hydrolysis of the 
glutamate chain to produce the assayable monoglutamate folate species (Pfeiffer and 
Gregory, 1996). This well-established assay has been used to measure folate content 
in plasma, serum, whole blood and various tissue samples (Horne, 1997;Molloy and 
Scott, 1997). However, the present study was the first time it had been applied to 
measure folate in whole embryo samples. Therefore, for the purposes of this study, 
the method was suitably adapted to quantify both the abundance of monoglutamyl- and 
polyglutamylfolate in neurulation-stage whole embryos.
Whole blood and embryonic concentrations of folate are used to give direct measures 
of folate status in the dam and the embryo following exposure to folate deficiency. A 
functional biomarker of folate status is a parameter that reflects the integrity of a 
biochemical system that is dependent on folate (Mason, 2003). Plasma homocysteine 
and embryonic SAM and SAH have been selected for this study as functional 
biomarkers. An elevation in homocysteine is a sensitive indicator of folate depletion 
because the re-methylation of homocysteine to methionine is a folate-dependent 
process (Burgoon et al., 2002). The concentrations of SAM and SAH are determined
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largely by adequate methionine and homocysteine availability, therefore they constitute 
a functional reflection of one-carbon nutrient status. Additionally, the measurement of 
SAM and SAH is a functional indicator of methylation capacity (Mason, 2003).
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5.2 Materials and Methods
5.2.1 Mouse diets
Female Sp2H/+ mice were placed on five different diets, outlined in Table 5.1, to test the 
embryonic effects of folate deficiency. The folate-deficient diet (FD) was a rodent diet 
(Harlan) adapted to contain no folic acid and to include 1 % succinyl sulfathiazole 
(SST). Succinyl sulfathiazole is an antibiotic that reduces the gut flora responsible for 
the synthesis of a significant amount of folate.
Four additional diets were used in the study (all produced by Harlan). The first was a 
normal breeding rodent diet (ND), containing no SST and 2.7 mg FA/kg diet. The 
second was a control diet used to study solely the effects of bacterial folate deficiency 
but with normal dietary folate supply. Thus, a group of mice was fed a diet containing 
1% SST and 2.7 mg FA/kg diet (bacterial folate deficient, BFD). A third control diet 
was used to study solely the effects of dietary folate deficiency. Therefore, although 
these mice had no supply of dietary folate, they were able to absorb folate produced by 
their gut flora. Thus, a group of control mice was placed on a diet containing no SST 
and no folic acid (dietary folate deficient, DFD). A fourth diet was used to investigate 
the effect of both folate and inositol deficiency. Thus, a group of mice was fed a diet 
that contained no folic acid, 1% SST and no inositol (folate and inositol deficient, FID).
All mice were fed their respective diet for a minimum of 3 consecutive weeks, while 
being housed in standard breeding cages in a room with a 14-hr light/10-hr dark cycle. 
After three weeks on their respective diets, females were mated with male Sp2H/+ mice 
overnight and checked the following morning for the presence of a copulation plug. 
Plug day was termed embryonic day 0.5 (E0.5). Mice remained on the different diets 
until they were killed at E10.5-E11.5. At that time, numbers of implantations and 
resorption sites were determined and fetuses were examined for neural tube defects 
and gross malformations. All viable fetuses at E10.5 and E11.5 were rinsed with PBS 
and stored at -80 °C prior to analysis of embryonic folate or SAM/SAH levels.
To attempt to rescue cranial NTDs, pregnant mice on the folate deficient diet received 
an interperitoneal (i.p.) injection of 10 mg folic acid / kg body weight (FD+FA) or 1 mg 
thymidine / kg body weight (FD+THY) at embryonic days E7.5, 8.5, 9.5 and 10.5. Mice 
fed the folate and inositol diet (FID) were supplemented with 10 mg FA / kg body 
weight at embryonic days E7.5, E8.5, E9.5 and E10.5 to determine the effects of 
inositol deficiency on the rescue of cranial NTDs by folic acid.
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Diet FA
(mg/kg)
Inositol
(g/kg)
SST
(g/kg)
Supplements 
(per kg body 
weight)
Description
ND 2.7 1.9 X None Normal Diet
FD X 1.9 10 None Folate-deficient Diet
BFD 2.7 1.9 10 None Bacterial Folate-deficient Diet
DFD X 1.9 X None Dietary Folate-deficient Diet
FID X X 10 None Folate- and Inositol-deficient Diet
FD+FA X 1.9 10 10 mg folic acid Folate-deficient Diet + FA
FD+THY X 1.9 10 1 mg thymidine Folate-deficient Diet + THY
FID+FA X X 10 10 mg folic acid Folate- and inositol-deficient Diet + FA
Table 5.1. Details of the experimental diets fed to female Sp2H/+ mice. Supplements were 
administered by i.p. injection at embryonic day E7.5, 8.5, 9.5 and 10.5.
5.2.2 Metabolite Analysis
Maternal blood was collected and plasma prepared as described in section 2.4. 
Maternal whole blood and embryonic folate concentrations were measured by the 
Lactobacillus casei microbiological assay using the method described in section 2.10. 
Total plasma homocysteine levels (free + protein-bound) were determined as 
described in section 2.4. Plasma homocysteine and whole blood folate were not 
measured in the same samples due to limited volume of blood. Embryonic SAM and 
SAH were analysed in individual whole embryos as detailed in chapter 3.
5.2.3 Statistical Analysis
Statistical analyses were performed using SigmaPlot Version 7, SigmaStat Version 3.5 
and SPSS Version 13. Maternal whole blood folate and plasma homocysteine 
concentrations were compared with respect to the normal diet (ND) using the un-paired 
student t-test. To determine the effect of the different diets on reproductive success, 
the mean values for number of implants per litter and number of resorptions per litter 
were compared between groups by ANOVA followed by pair-wise analysis using the 
Holm-Sidak statistical test. The incidence of NTDs following dietary intervention and 
supplementation was compared using the chi-square statistical test followed by the 
Fishers Exact test for pair-wise comparisons. To determine the effect of dietary 
intervention on developmental progression, the mean number of somites developed by 
embryos from the ND and the FD diets were compared using the un-paired student t-
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test. Mean values for total folate content, total folate concentration, SAM, SAH and 
SAM/SAH ratio were compared between dietary groups by ANOVA followed by pair­
wise analysis using the Holm-Sidak statistical test. All p-values less than 0.05 were 
considered significant.
Multiple linear regression was applied to all scatter-plot graphs in section 5.3.8 and 
5.3.9. The p-value was calculated using the equation y = c + mx + 0z + yzx, where y = 
folate, x = somite and z = diet group (folate deficient diet = 0, normal diet = 1). The p- 
value represents the significance of the constant y, and therefore the significance of the 
difference between the gradients of the two graph lines. All p-values less than 0.05 
were considered significant.
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5.3 Results
5.3.1 Effect of folate deficiency on maternal folate and homocysteine.
After consumption of the folate-deficient diet for a minimum of three consecutive 
weeks, Sp2H/+ dams had a whole blood folate concentration only 35% of that in Sp2H/+ 
dams fed the normal diet (Table 5.2). This decrease in maternal folate caused by the 
folate-deficient diet was statistically significant (p < 0.001). Folic acid supplementation 
(E7-E10) of dams fed the folate-deficient diet caused a significant increase (p < 0.001) 
in maternal folate (E11) compared to dams fed the folate-deficient diet only. Thus, 
supplemental folic acid administered by intra-peritoneal injection successfully increases 
maternal folate status.
Diet Whole Blood Folate (pg/ml) Plasma Homocysteine (pmol/L)
n= Mean ± SEM n= Mean ± SEM
ND 17 0.43 ±0.021** 4 1.46 ± 0.64
FD 14 0.15 ±0.010** 6 9.23 ± 2.49**
BFD 10 0.23 ± 0.023**** 5 2.66 ± 0.23
DFD 11 0.17 ± 0.012** 5 6.37 ± 0.24’*
FID 8 0.23 ± 0.012****
FD+FA 4 0.28 ± 0.030**’*
Table 5.2. Maternal whole blood folate and plasma homocysteine concentration 
following dietary intervention. FD, Folate-deficient Diet; ND, Normal Diet; BFD, Bacterial 
Folate-deficient Diet; DFD, Dietary Folate-deficient Diet; FID, Folate- and Inositol- deficient Diet; 
FD+FA, Folate-deficient Diet + FA. ** p-value < 0.02 when compared to FD dietary group, u p ­
value < 0.02 when compared to ND dietary group (un-paired student t-test).
Similar to the folate-deficient diet, Sp2H/+ dams fed the dietary folate-deficient diet 
(DFD) had a whole blood folate concentration only 40% of that in dams fed the normal 
diet. In contrast, the whole blood folate concentrations in dams fed the bacterial folate 
deficient diet (BFD) had only declined to 0.23 pg/ml, a level 53% of that in dams fed the 
normal diet. Thus, the dietary folate deficient diet had a greater effect on maternal 
folate than the bacterial folate deficient diet (Table 5.2). Statistical analyses 
demonstrated that the maternal blood folate level was significantly lower in dams fed 
the dietary folate-deficient diet compared to dams feds the bacterial folate-deficient diet 
(p < 0.05). In dams fed the folate and inositol deficient diet (FID), the whole blood 
folate concentration was 0.23 pg/ml, a level 53% of that in dams fed the normal diet.
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Thus, inositol deficiency had no further detrimental effect on maternal folate levels 
compared to the three folate depleted diets (BFD, DFD and FD) (Tables 5.2).
Plasma homocysteine concentrations also varied among the different diet groups, with 
the lowest levels in dams fed the normal diet and highest levels in dams fed the folate- 
deficient diet (Table 5.2). The dams fed the dietary folate deficient diet had 
intermediate homocysteine levels, whilst the bacterial folate deficient diet did not 
significantly increase maternal homocysteine compared to the normal diet. Overall, 
maternal biochemical analyses showed that the folate-deficient diet used in this study 
lowered maternal folate status and increased levels of homocysteine. Bacterial folate 
deficiency was sufficient to affect maternal blood folate levels but not homocysteine 
levels. By comparison, dietary folate deficiency affected both blood folate and 
homocysteine but was not as effective as combined bacterial and dietary deficiency.
It is possible that Sp2H/+ dams have a defect in folate metabolism or are unable to 
uptake sufficient folate from the diet. To investigate this hypothesis maternal folate 
levels in Sp2H/+ dams were compared to CD1 dams, a non-mutant control strain 
assumed to have no folate-related defect. There was no difference in the whole blood 
folate concentration under normal and folate-deficient dietary conditions between the 
two strains (Figure 5.1) suggesting that Sp2H/+ dams do not have an abnormality in the 
uptake of folate from the diet.
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Figure 5.1. A comparison of maternal whole blood folate levels between Sp2H/+  and CD1 
dams. Values are given as mean ± standard error of the mean. ND: Normal Diet, FD: Folate 
Deficient diet, p > 0.05 when compared between strains for each dietary group (un-paired 
student t-test).
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5.3.3 Effect of folate deficiency on the incidence of NTDs in splotch 
embryos
The incidence of NTDs among E10.5 -  E11.5 splotch litters following maternal dietary 
intervention was noted and correlated with genotype (Table 5.4). The folate-deficient 
diet caused a 14% increase in exencephaly in Sp2H homozygous embryos compared to 
normal dietary conditions, whilst Sp2H heterozygous embryos in our colony have never 
previously been reported to develop isolated cranial NTDs but under folate-deficient 
conditions 25% of Sp2H embryos developed exencephaly. Pair-wise statistical 
analyses using the chi-square test demonstrated that the increased incidence of cranial 
NTDs in Sp2H heterozygous embryos was significant (p < 0.001) whilst the increased 
incidence of cranial NTDs in Sp2H homozygous embryos was not significant (p = 
0.339). Loss of bacterial folate (BFD) unexpectedly reduced the incidence of 
exencephaly in Sp2H homozygous embryos compared to normal dietary conditions (p = 
0.037), but did cause exencephaly in one Sp2H heterozygous embryos. In contrast, loss 
of dietary folate (DFD) did not affect the incidence of exencephaly in either Sp2H 
homozygous or heterozygous embryos compared to the normal diet group.
Combined folate and inositol deficiency (FID) caused 100% exencephaly in Sp2H 
homozygous embryos. However, pair-wise statistical analyses using the Fishers Exact 
test demonstrated that the increased incidence of NTDs was not significant (p = 0.075) 
compared to Sp2H homozygous embryos from the normal diet group, presumably due 
to insufficient sample size. Notably, combined folate and inositol deficiency (FID) did 
not cause exencephaly in Sp2H heterozygous or wild-type embryos.
Diet No. of 
viable 
embryos
+/+ Sp2H/+ Sp2H/S p m "  ■
n= EX n= EX n= EX
ND 122 27 0 (0 ) 61 0 (0 ) 34 20 (59)
FD 123 28 0 (0 ) 53 13 (25) 30 22 (73)
BFD 59 18 0 (0 ) 24 1 (4) 17 4 (2 4 )
DFD 45 14 0 (0 ) 14 0 (0 ) 17 10 (59)
FID 21 3 0 (0 ) 11 0 (0 ) 7 7 (100)
Table 5.4. Incidence of neural tube closure abnormalities in E10.5-E11.5 splotch  embryos 
following dietary intervention. Data are presented as number of embryos with percentage in 
each treatment group in parentheses. EX; exencephaly. FD, Folate-deficient Diet; ND, Normal 
Diet; BFD, Bacterial Folate-deficient Diet; DFD, Dietary Folate-deficient Diet; FID, Folate- and 
Inositol-deficient Diet.
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For the purposes of this study embryos were collected to study the relationship 
between folate deficiency, embryonic one-carbon metabolism and the incidence of 
neural tube defects. Additional embryos were collected and analysed by Dr. N. D. E. 
Greene (Table 5.5). The data collected by Dr. Greene shows that the folate-deficient 
diet caused a 27% increase in the incidence of exencephaly among Sp2H homozygous 
embryos compared to the normal diet.
Diet No. of 
viable 
embryos
+/+ Sp*H/+ Sp™ / Sp™
n= cNTD n= cNTD n= cNTD
ND 103 35 1 (3) 45 0 (0 ) 23 14 (61)
FD 139 25 0 (0 ) 77 1 (1) 37 29 (88)
BFD 8 3 0 (0 ) 2 0 (0 ) 3 1 (33)
DFD 4 0 0 (0 ) 2 0 (0 ) 2 0 (0 )
Table 5.5. Incidence of neural tube closure abnormalities in splotch  embryos following 
dietary intervention: data collected by Dr. N. D. E. Greene. Data are presented as number 
of embryos with percentage in each treatment group in parentheses. cNTD; cranial neural tube 
defect (exencephaly). FD, Folate-deficient Diet; ND, Normal Diet; BFD, Bacterial Folate- 
deficient Diet; DFD, Dietary Folate-deficient Diet.
As embryos were collected by myself and Dr. Greene from the same mouse colony 
and during the same period it was deemed appropriate to combine the data from 
Tables 5.4 and 5.5 in order to increase the sample size, and therefore, the power of 
each statistical test. Analysis of the combined data (Table 5.6) using the chi-square 
test showed significant differences between the incidence of exencephaly in Sp2H 
homozygous embryos among the various dietary groups (p < 0.001).
Pair-wise comparisons demonstrated that the incidence of cranial NTDs among Sp2H 
homozygous embryos in the folate-deficient diet group was significantly greater than 
the incidence among embryos in the normal diet (p = 0.033) and the bacterial folate- 
deficient diet (p < 0.001) but not the dietary folate-deficient diet (p = 0.083) groups. 
There were no significant differences in incidence between Sp2H homozygous embryos 
from the normal diet and the dietary folate-deficient diet groups (p = 0.603), although 
the incidence of exencephaly among Sp2H homozygous embryos from the bacterial 
folate-deficient diet group had significantly decreased compared to the normal diet 
group (p = 0.010). As demonstrated previously, the incidence of cranial NTDs in Sp2H 
heterozygous embryos from the folate-deficient diet group was significantly greater (p =
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0.004) than the normal diet group. Notably, folate deficiency did not induce NTDs 
among wild-type embryos. Overall, these results show removal of both bacterial and 
dietary sources of folate causes an increased incidence of cranial NTDs, whereas 
removal of only bacterial or dietary folate does not increase NTD frequency. In 
addition, embryos must carry at least one mutant Pax3 allele.
Diet No. of 
viable 
embryos
+/+ Sp2 7+ Sp2V S p 2H
n= cNTD n= cNTD n= cNTD
ND 225 62 1 (2) 106 0 (0 ) 57 34 (60)
FD 262 53 0 (0 ) 130 13 (10) 67 51 (76)
BFD 67 21 0 (0 ) 26 1 (4) 20 5 (2 5 )
DFD 49 14 0(0 ) 16 0 (0 ) 19 10 (53)
FID 76 16 0 (0 ) 38 0 (0 ) 22 21 (95)
Table 5.6. Incidence of neural tube closure abnormalities in splotch  embryos following 
dietary intervention: combined data from Table 6.4 and 6.5. Data are presented as number 
of embryos with percentage in each treatment group in parentheses. cNTD; cranial neural tube 
defect (exencephaly). FD, Folate-deficient Diet; ND, Normal Diet; BFD, Bacterial Folate- 
deficient Diet; DFD, Dietary Folate-deficient Diet; FID, Folate- and Inositol-deficient Diet.
The increased incidence of NTDs in Sp2H homozygous embryos in the folate- and 
inositol-deficient diet group (FID) compared to the normal diet group was highly 
significant (Fisher Exact; p < 0.001). Additionally, the incidence of NTDs in Sp2H 
homozygous embryos in the folate- and inositol-deficient group (FID) was 19 % greater 
than in the folate-deficient diet group however statistical analyses demonstrates that 
this difference is not significant (Fisher Exact; p = 0.060). These results suggest that 
inositol deficiency, in combination with folate deficiency, is a risk factor for exencephaly 
in Sp2H homozygous mutant embryos.
5.3.4 Analysing the development and size of splotch embryos
During collection of embryos, differences in size of embryos developing under varying 
dietary conditions were apparent (Figure 5.2). Thus, embryos from the folate-deficient 
diet group, were seen to be smaller than splotch embryos from the normal, bacterial 
folate-deficient and dietary folate-deficient groups.
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Figure 5.2. High magnification photographs of E10.5 splotch  embryos following dietary 
intervention. (A) Sp^/Sp™  embryo (30 somites) with an open posterior neuropore from the 
normal diet group (ND), (B) Sp2H/Sp2H embryo (30 somites) with exencephaly (solid arrow) and 
an open posterior neuropore from the folate deficient diet (FD) group, (C) Sp2H/Sp2H embryo (29 
somites) with an open posterior neuropore from the bacterial folate deficient diet (BFD) group 
and (D) Sp2H/Sp2H embryo (32 somites) with an open posterior neuropore from the dietary folate 
deficient diet (DFD) group. Dashed arrows indicate open posterior neuropore. Scale bar is 
equivalent to 1mm.
Thus, in addition to analysing embryos for NTDs, the developmental progression and  
size was also monitored by recording the number of somites an embryo had developed  
and by measuring the crown-rump length (Table 5.7). Som ites are  units of 
mesenchym al cells that arise in a periodic manner as the embryo grows and develops. 
Somitogenesis occurs within the same embryonic period of developm ent as  
neurulation, such that counting somites provides a simple approach to quantitate  
developm ental progression.
At E10.5, splotch embryos from the folate-deficient diet group were significantly sm aller 
(p < 0 .001 ) and developm ental^ retarded (p < 0 .001) than splotch em bryos from the  
normal diet group (Table 5.7). In comparison to the normal diet group, the bacterial 
and dietary folate deficient diet did not detrimentally affect em bryonic size or 
development (Table 5.7). Thus, both control diets appear to provide sufficient folate, 
either from the diet or from the gut bacteria, to enable normal growth and developm ent.
The folate- and inositol-deficient diet caused a significant decrease in embryonic size  
(p = 0 .001) and developm ent (p = 0.001) compared to embryos from the normal diet 
group. Moreover, in comparison to folate-deficient embryos, the folate- and inositol- 
deficient diet caused a significant decrease in the mean number of somites at E10.5, 
although the decrease in m ean crown rump length was not significant (p = 0 .07). This
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suggests that inositol deficiency, in addition to folate deficiency, further delayed 
development.
Diet Gestational
Age
n= Crown Rump Length 
(mm)
Number of somites
ND E10.5 80 3.97 ± 0 .0 6 29.3 ± 0.28
FD E10.5 82 2.78 ± 0.07** 23.5 ± 0.39**
BFD E10.5 26 4.36 ± 0.07 29.9 ± 0.70
DFD E10.5 18 4.08 ± 0.18 30.6 ± 1.28
FID E10.5 14 2.46 ± 0 .1 2 ** 20.1 ± 0.75****
ND E11.5 20 5.86 ± 0 .1 9 39.6 ± 1.07
FD E11.5 49 4.57 ± 0.11** 32.7 ± 0.48**
Table 5.7. Size and development of splotch  embryos following dietary intervention. All
genotypes were pooled for analysis. Values given as mean ± standard error of the mean. ** p < 
0.02 when compared to ND, m p < 0.001 when compared to FD (un-paired student t-test). FD, 
Folate-deficient Diet; ND, Normal Diet; BFD, Bacterial Folate-deficient Diet; DFD, Dietary 
Folate-deficient Diet; FID, Folate- and Inositol-deficient Diet.
To determine whether the Pax3 mutation summates with folate deficiency to affect 
embryonic size and development, the data was divided according to genotype for 
further analysis (Table 5.8). At E10.5, Sp2H/Sp2H embryos had significantly fewer
somites than heterozygous (p = 0.020) and wild-type (p = 0.025) embryos under
normal dietary conditions, yet the crown-rump length of embryos was comparable 
between genotypes (Table 5.8). Although Sp2H/Sp2H embryos had significantly fewer 
somites at E10.5 this finding is not consistently observed with the Sp2H colony (Greene, 
N., personal communication) and the biological relevance of this observation is unclear. 
The similar mean crown rump length of embryos of different genotypes suggests 
comparable growth. The size and development of Sp2H homozygous and
heterozygous embryos was indistinguishable from that of wild-type under folate-
deficient conditions (Table 5.8). Therefore, overall, there appears to be no interaction 
between diet and genotype to further affect the size and development of splotch 
embryos.
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Genotype Diet n= % cranial NTD Crown rump length 
(mm)
Number of 
somites
+/+ ND 13 0 49.3 ± 1.25 30.4 ± 0.27
Sp™/+ ND 53 0 48.1 ± 0.90 29.5 ± 0 .2 8
Sp2h/S p 2H ND 14 50 44.4 ±2 .31 27.6 ± 1.08*
+/+ FD 16 0 32.8 ± 1.55 23.6 ± 0 .8 0
Sp'H/+ FD 32 32 31.8 ± 1.00 22.5 ± 0.52
Sp2H/S p 2h FD 26 69 34.7 ± 1.07 22.9 ±0 .61
Sp'”/S p 'H FD 8 0 36.9 ± 1.44 23.6 ± 0 .8 9
S p '" /S p 'H FD 18 100 33.8 ± 1.45 22.5 ± 0 .8 3
Table 5.8. Size and development of E10.5 splotch embryos following dietary 
intervention: analysis by genotype. Values given as mean ± standard error of the mean. 
Mixed; embryos with normal and NTD phenotypes were pooled for analysis. FD, Folate-deficient 
Diet; ND, Normal Diet. * p < 0.05 when comparing wild-type to Sp2H/+  under normal dietary 
conditions (ND).
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Figure 5.3. Size and development of E10.5 Sp2H/Sp2H embryos from the folate deficient 
diet group (FD): analysis by phenotype. Values given as mean ± standard error of the mean.
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In order to determine whether folate deficiency causes NTDs in the smaller and more 
developmental^ delayed embryos, the size and development of exencephalic and 
normal homozygous embryos were compared (Table 5.8 and Figure 5.3). At E10.5, 
exencephalic Sp2H/Sp2H embryos from the folate-deficient diet group appeared to have 
a shorter mean crown rump length and fewer somites than unaffected Sp2H/Sp2H 
embryos from the folate-deficient diet group. However, statistical analyses using the 
student t-test demonstrated that this difference in size (p = 0.181) and development (p 
= 0.454) was not statistically significant. Thus, these results do not clarify whether the 
NTD is due to growth and developmental delay as a result of the folate deficient diet or 
if the NTD arises independent of the growth and developmental delay.
Later in gestation, at E11.5, splotch embryos from the folate-deficient diet group were 
significantly smaller (p < 0.001) and developmental^ (p< 0.001) retarded compared to 
embryos from the normal diet group, as at E10.5 (Table 5.7). There are two possible 
explanations which could explain the observed growth and developmental retardation; 
(i) the folate deficient embryos were growing and developing at a slower rate or, (ii) the 
folate deficient embryos grew at comparable rates during neurulation but were already 
behind in growth and development due to an event which happened prior to 
neurulation. To investigate this hypothesis the extent of growth and developmental 
retardation has been analysed at E10.5 and E11.5. At E10.5 (Table 5.7) splotch 
embryos from the normal diet group had developed approximately six more somites 
and were 5.8 mm longer than splotch embryos from the folate-deficient diet group. At 
E11.5 (Table 5.7) splotch embryos from the normal diet group had developed 
approximately seven more somites and were 6.9 mm longer than splotch embryos from 
the folate-deficient diet group. Thus, the extent of growth and developmental 
retardation appeared to be getting progressively worse with gestational age. Overall, 
this data suggests that the embryos from the folate-deficient diet group were growing 
and developing at a slower rate during the period of neural tube closure.
5.3.5 Effect of folic acid and thymidine supplementation on the incidence 
of NTDs in folate deficient splotch embryos
To determine the potential for prevention of cranial NTDs by supplemental folic acid 
(FA) and thymidine (THY), dams fed the folate-deficient diet were treated with FA 
(FD+FA) or THY (FD+THY) at E7.5, E8.5, E9.5 and E10.5 by intra-peritoneal injection. 
The dams were then sacrificed at E11.5 and the embryos collected for analysis. The 
incidence of cranial NTDs in Sp2H/Sp2H embryos following supplementation with FA was
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48% compared to 100% in untreated folate-deficient embryos (Table 5.9). Thus, 
supplemental folic acid caused a significant decrease in the incidence of NTDs.
The incidence of cranial NTDs in Sp2H/Sp2H embryos following supplementation with 
thymidine was 86% compared to 100% in untreated folate-deficient Sp2H homozygous 
embryos. Thus, treatment with thymidine did not significantly reduce the incidence of 
cranial NTDs (Table 5.9). However it became apparent that thymidine treatment 
reduced the severity of the cranial NTDs such that there was only a small opening 
visible at E11.5 (Figure 5.4).
Supplement No.
em bryos
+/+ Sp2H/+ S p "7 S p '"
n cNTD n cNTD n cNTD
ND 22 7 0 (0 ) 7 0 (0 ) 8 4 (5 0 )
FD 27 6 0 (0 ) 16 2 (13 ) 5 5 (100 )
FD+FA 70 15 0 (0 ) 32 0 (0 ) 23 11 (48)*
FD+THY 36 9 0 (0 ) 20 0 (0 ) 7 6 (8 6 )
Table 5.9. Incidence of NTD in fo late-defic ient E11.5 splotch  embryos following dietary 
supplem entation with folic acid or thym idine. Data are presented as number of embryos 
with percentage in each treatment group in parentheses. cNTD; cranial neural tube defect 
(exencephaly). * p < 0.05 when compared to FD (Fishers Exact). FD, Folate-deficient Diet; ND, 
Normal Diet; FD+FA, Folate-deficient Diet + FA; FD+THY, Folate-deficient Diet + THY.
Figure 5.4. High m agnification photographs (x1.25) of an E11.5 Sp2H/S p 2H embryo, (35 
somites) from the folate-deficient diet group supplem ented with thym idine (FD+THY).
Arrow highlights the small opening in the cranial neural tube. Scale bar is equivalent to 1mm at 
x2.0 magnification.
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Analysis of size and developmental progression of these embryos demonstrated that, 
although FA reduces the incidence of NTD, there is no improvement in the size or 
development compared to un-supplemented folate-deficient embryos (Table 5.10). In 
contrast, THY significantly increased the size and developmental progression of the 
treated embryos in comparison to un-supplemented folate-deficient (FD) embryos. 
Thus, improving growth and development may assist closure (see figure 5.4) but it 
does not appear sufficient to prevent NTDs.
Supplement Gestational
Age
No. embryos Crown Rump 
Length (mm)
Number of somites
ND E11.5 22 6.49 ± 0.11 40.8 ± 0.40
FD E11.5 18 4.52 ± 0.14 32.6 ± 0.69
FD+FA E11.5 20 4.28 ± 0.09 31.2 ± 0.49
FD+THY E11.5 13 5.02 ± 0.01** 35.5 ± 0.31**
Table 5.10. Size and development of folate deficient splotch embryos following dietary 
supplementation with folic acid and thymidine. Values given as mean ± standard error of 
the mean. **p < 0.02 when compared to FD (Holm-Sidak). FD, Folate-deficient Diet; ND, 
Normal Diet; FD+FA, Folate-deficient Diet + FA; FD+THY, Folate-deficient Diet + THY.
5.3.6 Investigating the relationship between embryonic growth and 
development following maternal dietary intervention.
To attempt to understand further how the folate-deficient diet is affecting embryonic 
growth and development at E10.5 and E11.5, embryos that had developed under 
folate-deficient and normal dietary conditions were analysed for protein content and 
number of somites, as a measure of growth and developmental progression, 
respectively. A graphical plot of protein content against somite number of each embryo 
(Figure 5.5), illustrates that the relationship between growth and development is 
unaffected by maternal diet. For example, a thirty somite embryo from the folate- 
deficient diet group had a similar protein content to a thirty somite embryo from the 
normal diet group. However, as shown in section 5.3.4, a thirty somite embryo from 
the folate-deficient diet group would be approximately a day older in gestation age 
(E11.5) than a thirty somite embryo from the normal diet group (E10.5). Thus 
collectively the results suggest that it is the relationship between growth/development 
and time (gestational age) which is perturbed by the folate-deficient diet.
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Figure 5.5. The relationship between embryonic growth (protein concentration) and 
development (somite number) for splotch embryos from the folate-deficient (FD) and 
normal (ND) diet groups. All genotypes were pooled together for analysis.
5.3.7 Development of L.Casei microbiological assay for the measurement 
of folate levels in neurulation-stage embryos
In order to study embryonic folate levels following maternal dietary intervention, the 
L.Casei microbiological assay was adapted to allow measurement of mono- and 
polyglutamylfolate levels in individual whole neurulation-stage embryos. Briefly, whole 
mouse embryos were sonicated to produce a homogeneous solution suitable for 
analysis. Aliquots from the homogenised solution then needed to be diluted to be 
within the read-out range of an assay. Folates are unstable and require antioxidants 
when extracted and assayed from tissues, and sodium ascorbate was therefore used 
as the diluent. The pH of the sodium ascorbate solution was also predicted to inhibit 
the activity of endogenous conjugase enzymes (Pfeiffer and Gregory, III, 1996) that 
may be present in the embryo, thereby preventing deconjugation and enabling 
monoglutamylfolate levels to be measured.
To determine polyglutamylfolate levels, an aliquot of embryo homogenate was 
incubated with conjugase extract (partially purified rat serum) and diluted with ascorbic 
acid to achieve optimal pH for the reaction (Pfeiffer and Gregory, 1996). The
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conjugase enzyme removes the glutamate chain to form assayable monoglutamates 
from the polyglutamates. Therefore, when this sample is analysed the result is the 
summation of the monoglutamyl- and polyglutamylfolate embryonic content. In order to 
calculate the polyglutamylfolate levels, the monoglutmylfolate level (measured in the 
absence of conjugase) is then subtracted.
To ensure that sonicating the embryo was a suitable method for production of a 
completely homogenised uniform solution, all ten aliquots from a single embryo sample 
were analysed in parallel to determine if there was any significant variation between 
aliquots (Figure 5.6). Statistical analysis by ANOVA indicated that the fluctuations in 
folate content between the aliquots were insignificant (p = 0.438). The mean folate 
content was 7.52 pg of folate per well with a standard deviation of 0.35 pg of folate per 
well. The coefficient of variation (CV%) was equal to 4.60%. Hence, sonicating the 
embryo was found to be a suitable procedure to produce a uniform solution for the 
analysis of folate.
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Figure 5.6. Variation  in m onoglutam ylfolate content between sample aliquots. An E10.5 
non-mutant CD-1 embryo was homogenised in 100 pi and separated into ten 10 pi aliquots for 
analysis.
To establish whether the assay was suitable to analyse polyglutamylfolate levels, in 
addition to monoglutamylfolate, in mouse embryos, an E9.5 CD1 mouse embryo was 
treated with the conjugase extract for varying time intervals (as described in section
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2.10.3). Incubation with conjugase over time resulted in an increasing concentration of 
measurable folate with time (Figure 5.7) since the polyglutamylfolates present in the 
embryo sample were being progressively de-conjugated to assayable 
monoglutamylfolates. After 30 min a plateau was reached when presumably all 
polyglutamylfolates present had been de-conjugated to monoglutamylfolates. The 
conjugase extract (partially purified rat serum) was dialysed to remove all small 
molecules including folate and analysis of extract alone confirmed that there was no 
detectable folate present in the serum. Analysis of the same embryo sample using the 
monoglutamylfolate analysis conditions (stated in section 2.10.3) revealed that the 
concentration of monoglutamylfolate was 19.8 ng folate / mg protein. This is similar to 
the concentration found at the initial time point (zero) using the polyglutamylfolate 
analysis conditions.
Of note, it is possible that neurulation-stage embryos endogenously express conjugase 
enzyme (gamma-glutamylhydrolase) which during the assay incubation period at 37 °C 
converts embryonic polyglutamylfolates to monoglutamylfolates. This would mean that 
the method used to quantify monoglutamylfolate levels may also detect some 
polygluatmylfolates that have been converted by the endogenous conjugase during the 
assay incubation, leading to a higher folate reading. Since little is known about the 
expression of the conjugase enzyme during embryonic development, nor the conditions 
at which it is active, it has been assumed that the conversion of polyglutamylfolates by 
endogenous conjugase is negligible. Furthermore, incubation with the exogenous 
conjugase extract from rat serum demonstrates higher folate readings than without, 
suggesting that if enodgneous conjugase was expressed during neurulation then the 
hydrolysis of polyglutamates during the incubation period is incomplete.
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Figure 5.7. Incubation with conjugase over tim e resulted in increasing concentrations of 
m easurable folate. An E9.5 CD1 mouse embryo sample was incubated with conjugase extract 
for increasing time periods. Aliquots were removed at intervals and assayed for folate content. 
Values are given as mean ± standard error of the mean.
Despite following a standardised protocol, some variation was observed within and 
between assays. This is because the bacteria are extremely sensitive to small 
changes in assay conditions, both between wells and plates and from day to day. This 
can be due to pipetting errors, variation in oven temperature, weighing errors, 
variations in the composition of all reagents and insufficient plate sealing, all of which 
can affect the growth of the bacteria. This can change the plot equation for the 
standard curve and/or the results obtained for a sample read-out. Although sufficient 
measures were taken to minimise these problems, variation still occurred and this 
needed to be monitored. To do this two quality control samples (pools of sonicated 
E9.5 and E10.5 CD1 embryos) were included in each assay and guidelines were in 
place for qualifying variation between sample results (see section 2.10.4). The graph 
below illustrates how the measured folate content varied in the E9.5 quality control 
between assays (Figure 5.8). If there was a large variation in both QC results from a 
single assay compared to other assays, the subsequent results for the analytical 
samples run on the same day were discarded (see section 2.10.5.4 for further details).
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Figure 5.8. Inter-day variation in measured total folate content of an E9.5 QC sample.
The QC was prepared as stated in section 2.10.4. The black line represents the mean, with the 
red lines representing 1xSD.
Since there was little data available concerning folate content in neurulation stage 
mouse embryos, it was decided to establish some basic parameters using the non­
mutant CD-1 mouse strain. Firstly, the variation within a litter was evaluated. 
Secondly, the effect of position of each embryo within the uterine horn on embryonic 
folate content was established. Thirdly, the relationship between monoglutamylfolate 
and polyglutamylfolate levels was investigated. To do this, monoglutamylfolate and 
total folate levels were assayed in each embryo from a non-mutant CD1 litter (Figure 
5.9). Embryonic folate levels were normalised to protein to adjust for variability in 
embryo size.
The results show that both the monoglutamylfolate and total folate concentration is 
highly variable within a single litter. This removes the need in later studies to cluster 
data from different litters for statistical analyses but emphasises the need for analysis 
of several embryos for a particular experimental condition. In the majority of embryos 
the total folate concentration was higher than the monoglutamylfolate concentration in 
each embryo. However, the embryos in position 13 and 15 had virtually equal 
concentrations of monoglutamylfolate and total folate, suggesting low levels of 
polyglutamylfolate. The mean ratio of monoglutamylfolate / total folate
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(monoglutamylfolate + polyglutamylfolate) is 0.70. Position within the uterus or 
distance from the uterine horn appeared to have no impact on the folate concentration.
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Figure 5.9. Monoglutamylfolate and total folate concentrations vary between embryos 
within a litter. The litter was collected an E9.5 from a wild-type CD-1 dam. The uterine 
position is numbered, starting with 1, from one end of the uterine horn going towards the uterine 
cervix and then back up the uterine hom in a sequential order.
5.3.8 Investigating embryonic folate levels following dietary intervention.
Once the L.casei microbiological assay had been adapted to measure embryonic 
folate, it was used to study folate levels in splotch embryos that developed under 
different dietary conditions. One approach to study the effects of all the different diets 
and supplements on embryonic folate levels would be to compare splotch embryos at 
the same gestational age. However, it must be appreciated that embryos from the FD 
and FID group are significantly smaller and developmental^ retarded compared to the 
ND group (section 5.3.4). Therefore, changes in folate content would simply reflect
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changes in size whereas, when normalised to protein, the FD embryos may appear to 
have a greater folate concentration because they are smaller and developmental^ 
retarded. Therefore, the total folate (monoglutamylfolate + polyglutamylfolate) content 
and concentration was determined in splotch embryos collected at E10.5-E11.5 and 
the data has been compared between embryos with the same number of somites 
(Table 5.11).
Diet n= Somite Range 
(average)
Total Folate Content 
(pg folate / embryo)
[Folate]
(ng folate /mg protein)
ND 6 22-26 (23.0) 5135 ± 305 42.6 ± 2.87
FD 9 22-26 (24.1) 4613 ± 177 35.5 ± 1.46"
FID 5 22-26 (23.4) 3743 ± 679 37.3 ± 10.2
FD+FA 11 22-26 (23.6) 5414 ± 511 50.3 ± 10.0
FID+FA 9 22-26 (23.8) 4955 ± 352 48.5 ± 3.35
ND 14 26-32 (30.1) 8857 ± 650 36.4 ± 3.14
FD 10 26-32 (29.6) 4647 ± 205 16.3 ± 4.55
BFD 14 26-32 (29.6) 6916 ± 317 23.3 ± 0.65
DFD 11 26-32 (28.7) 7347 ± 4 1 2 24.4 ± 1.34
Table 5.11. Embryonic folate levels in splotch embryos at the same developmental stage 
(the same number of somites). Folate values are given as mean ± standard error of the 
mean. * p < 0 .05 when compared to ND. FD, Folate-deficient Diet; ND, Normal Diet; BFD, 
Bacterial Folate-deficient Diet; DFD, Dietary Folate-deficient Diet; FID, Folate- and Inositol- 
deficient Diet, FD+FA, Folate-deficient Diet + FA, FID+FA, Folate- and Inositol-deficient Diet + 
FA.
In splotch embryos that have developed between 22 and 26 somites (Table 5.11), the 
folate content per embryo was lower in embryos from the folate-deficient diet than the 
normal diet group but the difference was not significant (p = 0.136). In contrast, the 
folate concentration per mg of protein was also significantly reduced (p = 0.03) by the 
folate-deficient diet. Inositol- and folate-deficiency (FID) had no further effect on 
embryonic folate content (p = 0.080) or concentration (p = 0.305), compared to folate 
deficiency alone (FD).
Maternal folic acid supplementation of splotch embryos in the folate-deficient diet group 
(FD+FA) caused an increase in total folate content of 801 pg and an increase in folate 
concentration of 14.8 ng folate / mg protein (Table 5.11). However statistical analysis
demonstrated that this change in embryonic folate content (p = 0.080) and 
concentration (p = 0.305) was not statistically significant compared to folate-deficient 
embryos. Similarly, maternal folic acid supplementation to embryos in the folate and 
inositol deficient diet (FID+FA) caused a non-significant increase in folate content and 
concentration of 342 pg/embryo (p = 0.192) and 13.0 ng folate/mg protein (p = 0.201), 
compared to offspring of the FID fed dams. The lack of statistical significance is most 
likely to be due to the variation of embryonic folate levels. This would suggest that the 
response of individual embryos to maternal supplementation varies, and this could 
explain why neural tube closure occurs in some embryos following supplementation but 
not in others.
To further study the effects of the bacterial and dietary folate-deficient diet, splotch 
embryos that had developed between 26 and 32 somites were also grouped for 
analysis (Table 5.11). At this later stage of neurulation, splotch embryos from the 
folate-deficient diet had a significantly reduced folate content (Holm-Sidak; p < 0.001) 
and folate concentration (p < 0.001) compared to embryos developing under normal 
diet conditions.
There were no significant differences in embryonic folate content and concentration 
between embryos from the bacterial or the dietary folate-deficient diet. However, the 
total folate content of embryos from the bacterial and the dietary folate-deficient diet 
groups was significantly lower (p = 0.001 and p = 0.03, respectively) than for the 
normal diet group and significantly greater (p = 0.001 and p < 0.001, respectively) than 
for the folate-deficient diet. Similarly, embryonic folate concentrations from the 
bacterial and the dietary folate-deficient diet groups were significantly lower (p < 0.001 
and p = 0.003, respectively) than for the normal diet group. Thus, embryonic folate 
levels for these two control diets are intermediate between the embryonic folate levels 
for the folate-deficient and the normal diet (Table 5.11). Overall, these results reveal 
that in order to have the maximum effect on embryonic folate status the diet needs to 
be deficient in both dietary and bacterial folate content.
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Figure 5.10. Mean total folate content (pg/embryo) and folate concentration (ng folate / 
mg protein) in splotch embryos that have developed between 26-32 somites following 
dietary intervention and supplementation: analysis by genotype. Each data point 
represents an individual embryo. ND, normal diet, FD, folate deficient diet.
Analysis of embryonic folate levels by genotype demonstrated that embryonic folate 
content and concentration are randomly distributed irrespective of genotype (Figure 
5.16). Hence, the Sp2H mutation has no apparent effect on embryonic folate status, 
under either normal or folate deficient dietary conditions. Thus, it appears to be a 
summation of the embryonic genotype and folate status which is responsible for the
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increased incidence of cranial NTDs among Pax3 deficient embryos when the diet is 
deficient of folate.
5.3.9 Detailed analysis of mono- and polyglutamylfolate levels with 
respect to developmental stage in splotch embryos
To illustrate how the embryonic monoglutamylfolate content and concentration change 
with development under different dietary conditions, the data was plotted against 
somite number (Figure 5.11). As expected, the total monoglutamylfolate content 
increases with development under normal dietary conditions, presumably since a larger 
and more developed embryo would have a greater folate content (Figure 5.11 A). Up to 
approximately the thirty somite stage, embryos from the FD and ND dietary groups 
have similar levels of monoglutamylfolate, but as development proceeds the 
monoglutamylfolate content fails to increase under folate-deficient conditions. Indeed 
in the FD group, the monoglutamylfolate content appears to decrease with 
development such that more developed embryos contain less folate. For statistical 
purposes, the data was analysed by linear regression (see section 5.2.3) and the 
gradients of the graph lines were found to be significantly different (p = 0.005).
When folate levels were normalised to protein content (Figure 5.11B), the embryonic 
monoglutamylfolate concentration was found to decrease with development under 
normal dietary conditions. Thus, there was less folate available per mg of tissue 
suggesting a rapid turnover of folate metabolites at this stage of development or 
insufficient regulation of folate to keep pace with the rapid growth. Under folate- 
deficient conditions, the embryonic monoglutamylfolate concentration also decreased 
with development but the rate of decrease (gradient of the graph line) is slightly 
greater. At some stages of development, for example when the embryos have 
developed 23 somites, embryos appear to have the same folate concentration 
irrespective of dietary conditions, whereas when comparing embryos with 30 or more 
somites, the embryos from the normal diet group seem to have a higher folate 
concentration compared to embryos from the folate-deficient diet group. Statistical 
analysis by linear regression (see section 5.2.3) demonstrates that the gradients of the 
two graphs are significantly different (p-value < 0.001).
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Figure 5.11. Comparison of monoglutamylfolate levels in splotch embryos between the 
folate-deficient (FD) and the normal diet (ND) group. The graphs show (A) 
monoglutamylfolate content per embryo (pg of folate / embryo) vs. somite number, and (B) 
embryonic monoglutamylfolate concentration (ng folate / mg protein) vs. somite number. • ,  
splotch embryos from the folate deficient group, • ,  splotch embryos from the normal diet group, 
Each data point represents an individual embryo (all splotch genotypes were pooled for 
analysis). Linear regression analysis demonstrates that the gradients of the graph lines are 
statistically different in 5.23.A (see section 5.2.3).
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Figure 5.12. C om parison o f polyglutam ylfolate levels in splotch  em bryos between the 
folate deficient (FD) and the norm al diet (ND) group. The graphs show (A) polyglutamylfolate 
content per embryo (pg of folate /  embryo) vs. somite number, and (B) embryonic 
polyglutamylfolate concentration (ng folate / mg protein) vs. somite number. • ,  splotch embryos 
from the folate deficient group, • ,  splotch embryos from the normal diet group, Each data point 
represents an individual splotch embryo (all splotch genotypes were pooled for analysis). 
Linear regression analysis demonstrates that the gradients of the graph lines are not statistically 
different (see section 5.2.3).
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It was next determined how the embryonic total polyglutamylfolate content and 
polyglutamylfolate concentration changes with somite number (developmental stage) 
(Figure 5.12). As expected, the polyglutamylfolate content of an embryo increased with 
developmental stage under normal dietary conditions such that larger embryos 
contained more folate (Figure 5.12A). Under folate-deficient conditions, it appears that 
the polyglutamylfolate content increases at a slower rate such that there is a smaller 
increase in polyglutamylfolate content with somite development compared to normal 
dietary conditions. However statistical analysis by linear regression demonstrates that 
the gradients of the graphs are not significantly different (p = 0.101). As for 
monoglutamylfolate concentrations, the polyglutamylfolate concentration also appears 
to decrease with development. Under folate-deficient conditions, the polyglutamyfolate 
concentration decreases with development at a slightly greater rate (Figure 5.12B) but 
the difference compared to the normal diet was not significant (p = 0.555).
If embryonic folate concentrations were to be compared for embryos at the same 
gestational age (Figure 5.11B and 5.12B) the data presented would show, due to the 
negative gradient of the graph line, that folate-deficient splotch embryos had a greater 
folate concentration than splotch embryos from the normal diet group. This is because 
folate-deficient embryos are developmentally retarded, such that they have less 
somites at a given gestational age.
5.3.10 Abundance of SAM and SAH in splotch embryos following 
dietary intervention
The effect of the maternal diets and supplements on the levels of SAM and SAH in 
neurulation-stage embryos was measured using the method described in chapter 3 
(also see Burren et al., 2006). Following dietary intervention and supplementation, a 
series of embryos from Sp2H/+ litters were collected, and levels of SAM and SAH were 
analysed in individual whole embryos. Levels were normalised to protein concentration 
and correlated with developmental stage (Table 5.12) to show the abundance of 
embryonic SAM and SAH, and the SAM/SAH ratio (Figure 5.13), in each dietary group.
In embryos at E10.5 and E11.5, SAM levels were typically 100-140 fold higher than 
SAH levels in splotch embryos. As gestation proceeded, the concentration of SAM did 
not significantly change (p = 0.887) whilst the concentration of SAH increased 
significantly (p = 0.012). Due to the increased abundance of SAH, the ratio of 
SAM/SAH was significantly lower at E11.5 than at E10.5 (p = 0.013).
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Maternal n= Age Somite SAM SAH Ratio
Treatment Number (nmoles/mg (nmoles/mg SAM/SAH
Group protein) protein)
ND 40 E10.5 29.7 ± 0.3 3.35 ± 0.26 0.024 ± 0.002 147 ± 6 .8
ND 14 E11.5 40.1 ± 0.64 3.28 ± 0.29 0.033 ± 0.0037** 111 ± 18.1**
FD 18 E11.5 29.6 ± 0.9 2.94 ± 0.23 0.050 ±0 .0 1 1 ** 96 ± 12.4**
FD+FA 29 E11.5 28.7 ± 0.7 3.29 ± 0.35 0.041 ± 0 .0 0 5 97 ± 14.2
FD+THY 13 E11.5 35.5 ± 0.3 3.58 ± 0.20 0.063 ±  0.004 59 ± 3.6**
Table 5.12. SAM and SAH abundance determined by LC-MS/MS in splotch embryos from 
each maternal treatment group. SAM and SAH were quantified in individual whole embryos. 
Values are given as mean (standard error of the mean. ND; Normal Diet, FD; Folate deficient 
Diet, FD+FA; Folate deficient Diet + Folic Acid; FD+THY; Folate deficient Diet + Thymidine. ** p 
< 0.02 when compared to ND at E10.5, ** p < 0.02 when compared to FD. All genotypes were 
pooled for analysis.
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Figure 5.13. SAM/SAH ratio in splotch embryos from each maternal treatment group.
Values are given as mean ± standard error of the mean. ** p < 0.02 when ND (E11.5) or FD 
compared to ND (E10.5), ** p < 0.02 when FD+THY compared to FD. All genotypes were 
pooled for analysis.
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When comparing splotch embryos at the same developmental stage (with the same 
mean number of somites) from the normal diet group to embryos from the folate- 
deficient diet, folate deficiency appeared to reduce the level of SAM but this reduction 
was not statistically significant, yet the level of SAH did significantly increase by two­
fold (p = 0.002). This slight decrease in SAM together with the increased SAH caused 
a significant decrease in the ratio of SAM/SAH (p < 0.001) in folate-deficient splotch 
embryos compared to splotch embryos developing under normal dietary conditions.
When comparing splotch embryos at the same gestational age (with different mean 
number of somites) from the normal diet and folate-deficient diet groups there was no 
significant difference in the level of SAM (p = 0.307) or SAH (p = 0.213). Similarly, the 
ratio of SAM/SAH, when comparing embryos at E11.5, was unchanged by folate 
deficiency (p = 0.417). Therefore despite folate-deficient splotch embryos being smaller 
and developmental^ retarded, the abundance of SAM and SAH was consistent with 
gestational age therefore the methylation potential was reduced at an earlier stage of 
embryonic development as defined by somite number.
Treatment of folate-deficient embryos with folic acid daily from E7.5-E10.5 (FD+FA) did 
not significantly affect the abundance of SAM (p = 0.472), SAH (p = 0.412) or the ratio 
of SAM/SAH (p = 0.934), when compared to folate-deficient embryos of the same 
gestational age. Treatment of folate-deficient embryos with thymidine daily from E7.5- 
E10.5 (FD+THY) caused a non-significant increase in SAM (p = 0.062) and a non­
significant increase in SAH (p = 0.334), when compared to folate-deficient embryos 
(FD) of the same gestational age. Overall this resulted in a significant decrease in the 
ratio of SAM/SAH (p = 0.0258) as the abundance of SAH increased to a greater extent 
than SAM. Thus, thymidine treated embryos have the lowest methylation potential 
(lowest ratio SAM/SAH) of all the maternal treatment groups.
To determine whether the splotch mutation had any effect on the methylation cycle, 
levels of SAM and SAH were compared in +/+, Sp2H/+ and Sp2H/  Sp2Hembryos from the 
normal diet group (Table 5.13). The results suggest that at E10.5 and E11.5 the Sp2H/+ 
embryos have a reduced concentration of SAM and subsequently, a reduced 
SAM/SAH ratio compared to +/+ and Sp2H/  Sp2H embryos. However, statistical analysis 
demonstrates that this is not significant at either embryonic day (ANOVA; p > 0.02). 
Thus, there was no apparent effect of splotch genotype on the abundance of SAM and 
SAH, or the ratio of SAM/SAH.
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Although the splotch genotype did not affect the abundance of SAM or SAH under 
normal dietary conditions, it is possible that the splotch genotype could further affect 
the abundance of SAM and SAH under folate-deficient conditions. To investigate this 
hypothesis, the abundance of SAM, SAH and the ratio of SAM/SAH in Sp2H/Sp2H 
embryos was analysed (Table 5.13). Overall, this revealed similar results to the 
analysis of all splotch genotypes pooled together (Table 5.13).
Genotype 
of embryo
Diet n= Age Somite
Number
SAM
(nmoles/ 
mg protein)
SAH
(nmoles/ 
mg protein)
Ratio
SAM/SAH
+/+ ND 5 E10.5 30.8 ± 0.4 3.59 ± 0.71 0.021 ± 0.005 183 ± 2 0 .4
SpJH/+ ND 29 E10.5 29.7 ± 0.3 3.28 ± 0.30 0.025 ± 0.002 137 ± 7 .4
S p'”/S p jM ND 6 E10.5 28.7 ± 0.6 3.44 ± 0.87 0.021 ± 0.005 168 ± 15.6**
+/+ ND 5 E11.5 40.2 ± 1.1 3.22 ± 0.23 0.031 ± 0.006 125 ± 33.7
Sp2H/+ ND 3 E11.5 39.3 ± 0.3 2.43 ± 0.02 0.027 ± 0.000 91 ± 0.7
S p'h/S p 'M ND 6 E11.5 40.5 ± 0.7 3.75 ± 0.34** 0.037 ± 0.004** 110 ± 15.3**
' !
S p'M/S p 'H FD 4 E11.5 31.5 ± 2.0 2.56 ±0 .31 0.030 ± 0.008 98 ± 17.6
S p'H/Sp"H FD+FA 12 E11.5 27.5 ± 1.2 3.30 ± 0.46 0.046 ± 0.011 87 ± 11.1
S p'M/S p JM FD+TH Y 2 E11.5 35.0 ± 0.0 2.73 ± 0.20 0.047 ± 0.017 66 ± 19.9
Table 5.13. SAM and SAH abundance determined by LC-MS/MS in +/+, Sp2W/+ and 
Sp2H/Sp2H embryos. SAM and SAH were quantified in individual whole embryos. Values are 
given as mean (standard error of the mean). ** p < 0.02 when compared to ND at E10.5. **p  < 
0.02 when compared to FD.
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5.4 Conclusion and Discussion
5.4.1 Folate deficiency affects maternal folate metabolism
Female Sp2H heterozygous mice fed the folate-deficient diet exhibited decreased whole 
blood folate and increased plasma homocysteine. The lowered maternal folate and the 
increase in homocysteine reported in this dietary study was consistent with previous 
results obtained in wild-type mice and rats fed similar folate deficient diets (Burgoon et 
al., 2002;Sohn et al., 2003). These changes in maternal folate and homocysteine, 
which can be rescued by folic acid, support the idea that the diets directly affect 
maternal folate metabolism.
5.4.2 Folate deficiency causes NTDs in Sp2H embryos
This study demonstrates that a lack of maternal folate uptake via the diet increased the 
incidence of exencephaly among Sp2H homozygotes and Sp2H heterozygotes, without 
affecting litter size or resorption rate. Previously, low incidences of NTDs in 
heterozygous splotch have been reported only when mice also harboured a mutation in 
one Nf1 allele, identifying Nf1 as a genetic modifier (Lakkis et al., 1999). Recent 
research by Li and colleagues using the splotch (Sp) mouse demonstrated that the 
incidence or severity of NTDs was not affected by a diet deficient in folic acid (Li et al., 
2006). In contrast, this study uses the folate-sensitive Sp2H mouse model in which 
NTDs have been previously shown to be rescued following folic acid supplementation 
(Fleming and Copp, 1998).
Other studies using folate-deficient diets (Burgoon et al., 2002;Heid et al., 1992) 
demonstrate that folate deficiency does not cause an increase in the incidence of NTDs 
in wild-type mice. Similarly, in this study, folate-deficient wild-type mice from Sp2H 
litters did not develop NTDs. The incidence of NTDs in wild type mice under normal 
breeding conditions is approximately 0.3-4.2 per 1000 embryos (Sakai, 1989). Thus, in 
order to detect the 14-27% fold increase in incidence demonstrated in mutant embryos 
in this study, it would be necessary to analyse a vast number of wild-type embryos. 
Therefore, the possibility that folate deficiency may cause NTDs in a very small 
percentage of wild-type embryos cannot be excluded.
Comparison of maternal folate levels in splotch compared to other strains suggests that 
maternal uptake of folate is not affected by Pax3 deficiency. Additionally, analysis by 
embryonic genotype shows that the genetic mutation in Pax3 does not affect 
embryonic folate levels, the abundance of SAM or SAH or, growth and development.
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Thus, it appears that the folate deficient diet affects folate metabolism and embryonic 
growth and development independent of Pax3 deficiency. However the alternative, 
that folate deficiency enhances the detrimental effect of Pax3 deficiency on neurulation, 
may be true. Since the mechanism underlying the neural tube defect in Sp2H 
homozygotes remains unclear, it is difficult to investigate this hypothesis. Overall, the 
etiology of NTDs in folate-deficient Sp2H embryos appears to be multifactorial in nature, 
possessing both genetic (Pax3 mutation) and environmental (dietary folate content) 
components.
5.4.3 Bacterial and dietary folate sources of folate need to be removed to 
induce effective folate deficiency
Research using radio-labelled precursors of bacterially synthesised folate has shown 
that at least 18% of the dietary folate requirement can be met by folate absorption 
across the large intestine (Asrar and O'Connor, 2005). For these reasons this study 
included an antibiotic in the diet to kill the gut bacteria which provide a major source of 
folate. Investigation of maternal biomarkers reveals that a diet deficient in both 
bacterial and dietary folate is required to have maximal effects on maternal folate and 
homocysteine. Also for folate deficiency to interact with the Sp2H mutation to increase 
the incidence of NTDs the diet needs to lack both forms of folate. The bacterial (BFD) 
and dietary folate deficient diets (DFD) did not detrimentally affect embryonic growth 
and development and had intermediate effects on embryonic folate status.
Burgoon et al. reported no differences in red blood cell folate, plasma folate, plasma 
homocysteine, resorptions or fetal weight between the normal breeding diet and the 
same diet with the antibiotic added. They conclude that the antibiotic could be 
removed, providing the mice remained on wire mesh floor to prevent coprophagy. 
Indeed it has been shown that fecal levels of folic acid can be 14-fold higher than that 
found in the diet (Ebino et al., 1988). Wire mesh cages were not used in this 
investigation, such that mice did have access to folate in their feces which presumably 
accounts for a proportion of the residual folate in dams and embryos. The fecal supply 
of folate may have been sufficient to prevent the poor reproductive outcome which was 
witnessed in other studies in which wire mesh flooring was utilised (Burgoon et al., 
2002;Heid et al., 1992) and enabled the incidence of NTDs to be assessed. 
Alternatively, discomfort to the mice caused by long term housing on wire mesh flooring 
may have increased the rate of resorptions.
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The folate deficient diet used by Li et al. in their study of folate deficiency in Sp mice 
did include an antibiotic, but not all of the dietary folate was removed (the “severely 
folic acid deficient diet” used contained 0.3 mg FA / kg diet) and it appears the mice 
were housed in normal breeding cages such that the dams had access to both dietary 
and fecal folate. Although it was shown that maternal homocysteine levels were 
significantly increased by the diet, my study demonstrates that changes in 
homocysteine do not necessarily predict a change in the incidence of NTD, as shown 
using the diet deficient in dietary folate (DFD). Thus, it is unclear whether the study by 
Li et al. induced folate deficiency to an extent which would be necessary to increase 
the incidence of NTDs in Sp embryos.
5.4.4 Folate deficiency causes retardation of embryonic growth and 
developmental progression
Overall, growth and developmental examinations revealed that splotch embryos from 
the folate-deficient diet group were growing and developing at a slower rate. Indeed 
evidence from this study appears to show that folate controls the rate of embryonic 
growth and development, yet the relationship between growth and development is 
unchanged. Therefore, when a folate-deficient embryo reaches the appropriate 
developmental stage at which neural tube closure occurs, the correct amount of cells 
should be present but the embryo would be older by gestational age. It is not yet fully 
understood if a disturbance of the time window in which neural tube closure occurs 
could affect the highly complex events, at the cellular, biochemical and molecular level, 
required for successful neurulation such as a dissociation between growth and correct 
gene expression.
An alternative explanation is that during neurulation embryos are growing and 
developing at the normal rate but they are delayed in growth and development due to 
an event which happened prior to neurulation. This raises the possibility of a critical 
period in early gestation when folate deficiency might retard growth and development, 
subsequently resulting in defective neurulation. However, the extent of growth and 
developmental retardation appears to be getting progressively worse with gestational 
age suggesting that this is not the case.
Embryonic growth and developmental delay caused by folate deficiency was shown to 
be independent of splotch genotype in this study. Copp and Fleming likewise 
demonstrated that the growth profile (DNA content plotted against somite number) of 
Sp2H homozygotes and heterozygotes was indistinguishable from that of wild type on a
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normal breeding diet (Fleming and Copp, 1998). Thus, it appears that Pax3 deficiency 
in Sp2H embryos does not affect embryonic growth or development. Research by 
Bennett and colleagues using Sp mice also demonstrated that under normal dietary 
conditions the overall growth, measured by somite number, does not differ between Sp 
genotypes during neural tube closure (Bennett et al., 1998). However a detailed 
evaluation of progression through neural tube closure in Sp embryos collected at 
several time-points during the period of neural tube closure revealed that there was a 
significant delay in the time taken to close the neural tube in both Sp/+ and Sp/Sp 
embryos (Bennett et al., 1998). Therefore, the increased incidence of cranial NTDs 
among splotch embryos could be explained by an extended delay in neural tube 
closure which is worsened by a lack of folate.
It remains to be fully established whether folate deficiency affects neurulation directly or 
indirectly via retardation of growth and development. The diets deficient in either 
bacterial (BFD) or dietary (DFD) folate, which did not detrimentally affect embryonic 
growth or development, failed to increase the incidence of NTD. However, analysis of 
size and developmental progression between affected and unaffected Sp2H 
homozygous embryos revealed that the smaller and developmental^ retarded embryos 
were not necessarily the ones affected by an NTD. This suggests that under these 
conditions, when growth and development is unaffected, other factors are important in 
the etiology of NTDs.
5.4.5 Folate deficiency affects embryonic one-carbon metabolism
None of the previous studies to date have measured embryonic folate levels following 
folate deficiency or supplementation. By adapting the L.casei microbiological folate 
assay, I was able to demonstrate that the folate content increases during neurulation 
but the concentration of folate (normalised to protein) decreases with development. 
The concentration of SAH was also found to increase during neurulation, causing a 
decrease in the SAM/SAH ratio. These findings suggest that after neurulation embryos 
have a reduced folate concentration and methylation potential, which is further reduced 
by the folate-deficient diet.
In folate-deficient embryos the rate of increase in embryonic folate content with 
development was lower than under normal dietary conditions, whereas the folate 
concentration (normalised to protein) decreased at a slightly greater rate. When 
comparing embryos with the same number of somites, the folate-deficient embryos had
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a lower mean folate content and concentration compared to the normal diet embryos 
such that during neural tube closure there would be less folate available.
Under folate-deficient conditions it seems as if embryonic growth and folate content 
have become unsynchronised such that the folates appear to be ‘diluted’ by more cells. 
This imbalance may be the cause of the reduced rate of embryonic growth and 
development. There are several potential outputs from the folate cycle which could 
affect embryonic growth and development including nucleotide synthesis and 
methylation. Analysis of methylation cycle metabolites revealed that the abundance of 
embryonic SAH was increased by the folate-deficient diet, resulting in a decrease in the 
SAM/SAH ratio. Increased SAH could potentially inhibit methyltransferases involved in 
the methylation of genes or proteins required for embryonic growth and development.
5.4.6 Possible mechanisms of folate-sensitive NTDs in splotch embryos
Mechanisms leading to cranial NTDs are not clear. Proposed mechanisms include 
faulty release of neural crest cells from the margins of the cranial neural folds (Copp et 
al., 2003) or imbalance of extracellular matrix components in the neural folds (Bennett 
et al., 1998). A further mechanism arose from an investigation which revealed that 
neuroepithelial cells in splotch (Sp) embryos undergo unscheduled apoptosis at the site 
of the neural tube prone to defects (Phelan et al., 1997). This led to a study whereby 
p53 deficiency, caused by either a genetic mutation or use of a chemical inhibitor, 
rescued not only apoptosis but also NTDs in Sp homozygous embryos, suggesting that 
Pax-3 regulates neural tube closure by inhibiting p53-dependent apoptosis (Pani et al., 
2002 ).
It is possible that all of the above proposed mechanisms could be worsened by growth 
and developmental delay caused by the folate-deficient diet. If an embryo is growth 
retarded and receives a genetic insult, it may not then be able to successfully repair 
itself or undergo ‘catch-up’ growth (Shum and Sadler, 1988). For example, if excess 
apoptosis does occur in splotch mice (Pani et al., 2002), the embryo may be able to 
undergo catch-up growth under normal dietary conditions to prevent the increased 
apoptosis from affecting neural tube closure. In contrast, under folate-deficient 
conditions, the lack of folate metabolites may prevent catch-up growth and thereby 
cause an increased incidence of NTD.
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5.4.7 How does folic acid rescue NTDs in folate-deficient splotch 
embryos?
A key outstanding question is how folic acid prevents NTDs. In this study I investigated 
possible mechanisms by which foiic acid prevents NTDs induced by folate deficiency, 
focussing on possible effects on growth or methylation. Maternal folic acid 
supplementation was found to increase maternal whole blood folate and reduce the 
incidence of NTDs in folate-deficient embryos. Whereas, maternal thymidine 
supplements did not reduce the incidence of NTDs in folate-deficient embryos, they 
apparently reduced the severity of the cranial defect. Interestingly, folic acid did not 
stimulate growth, whilst thymidine did stimulate growth. This suggests a possible 
protective effect of growth stimulation on the severity of the NTD, whereas folic acid 
may have had a localised effect on proliferation enabling cranial neural tube closure to 
occur successfully.
Embryonic metabolic analysis showed that folic acid supplements did not significantly 
affect embryonic folate status and there was no detectable change in the abundance of 
SAH or the SAM/SAH ratio. Confusingly, treatment with thymidine was found to 
decrease the methylation potential, which could be postulated to be due to scavenging 
of folate metabolites away from the methylation cycle, thereby causing a build-up of 
homocysteine which is converted to SAH. Perhaps inhibition of the methylation cycle 
counteracts the beneficial effect on embryonic growth and therefore, combined 
supplementation with thymidine and folic acid may have been a better preventative 
treatment. In summary, the data is not conclusive of either argument.
5.4.8 Summation of the effect of folate and inositol deficiency
A diet deficient in inositol as well as folate (FID) was found to increase the incidence of 
exencephaly to 95%-100% among Sp2H homozygotes, yet there was no further change 
in maternal and embryonic folate status compared to the folate deficient diet (FD). This 
indicates that inositol deficiency does not affect maternal or embryonic folate 
metabolism but there is an indirect interaction between inositol and folate metabolism 
to increase the risk of NTDs among Sp2H embryos. The folate and inositol deficient diet 
(FID) did not cause cranial NTDs in wild-type or Sp2H heterozygous embryos. Thus, 
the interaction between folate and inositol deficiency represents a summation of the 
effects of each deficiency to produce a disturbance of cranial neurulation in 
homozygous Sp2H embryos that is greater than with either deficiency alone.
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5.4.9 A mouse model of folate-responsive neural tube defects
In summary, the splotch mouse model described in the present study shows that folate 
deficiency causes developmental delays that may be related to increased incidence of 
neural tube defects. In this model reduced embryonic folate status and poor 
methylation capacity correlate with decreases in maternal folate and increases in 
homocysteine. This model also affords the opportunity to test the effects of 
supplemental vitamins to determine the potential for neural tube defect prevention.
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CHAPTER 6
Investigating the relationship between maternal dietary 
folate intake, embryonic one carbon metabolism and 
the incidence of neural tube defects in the curly tail
NTD mouse model
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6.1 Introduction
6.1.1 Folate resistant NTDs
The UK Medical Research Council trial demonstrated that folic acid prevented up to 
70% of recurrent NTDs (Wald et al., 1991). This result highlights the possibility that the 
remaining cases are resistant to folate. Indeed there have been reports of multiple 
NTD pregnancies within a single family despite high intake of folic acid (Cavalli and 
Copp, 2002; unpublished findings). This resistance to the prevention of NTDs by folic 
acid has been mirrored in several mutant mouse strains including the Ephrin A5, curly 
tail and Bent tail mouse models (Holmberg et al., 2000; Seller, 1994; Essien and 
Wannberg, 1993).
6.1.2 The curly tail NTD mouse model
The curly tail (ct) mutant mouse, originally identified in 1950, was first described by 
Hans Gruneburg (Gruneberg, 1954). Since then it has been maintained as a random 
bred closed colony whereby all individuals are assumed to be homozygous for the ct 
mutation. The ct mutant phenotype is incompletely penetrant and has variable 
expressivity, whereby 50% of homozygous embryos develop a curled tail which is 
accompanied with spina bifida in 10-20% of these embryos. A small proportion of curly 
tail embryos also develop exencephaly, yet relatively large variations in the frequency 
of this phenotype, ranging from 0-9%, have been reported (Van Straaten and Copp, 
2001 ).
The curly tail mutant mouse has been the focus of over 50 papers, despite the ct gene 
only recently being identified (Ting et al., 2003). The interest in this mouse model is in 
part due to its striking resemblance to human NTDs. Indeed, the curly tail mouse 
model was the first example of a closure failure during primary neurulation at the level 
often seen in human cases of spina bifida. Incomplete penetrance with major effect of 
genetic and environmental factors resembles multifactorial etiology of human NTDs. 
Also, there is increased alphafetoprotein (AFP) in the amniotic fluid (Adinolfi et al., 
1976) and maternal serum (Jensen et al., 1991), as demonstrated for anencephaly and 
spina bifida in humans. In addition several studies have shown that exencephaly is 
more common in females whilst males show a slight preponderance to spina bifida, as 
is seen in humans (Copp and Brook, 1989;Embury et al., 1979;Seller et al., 1979). 
Also, there is an association of spina bifida with hydrocephalus in ct embryos, as in 
humans (Van Straaten and Copp, 2001).
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The first sign of an abnormality in curly tail embryos is the reduced cell proliferation in 
the hindgut and notochord at the 27-29 somite stage (E10.5) (Copp et al., 1988a) and 
in the dorsal tailbud at E9.5 (Peeters et al., 1996). The growth imbalance causes a 
ventral curvature of the caudal axis which opposes closure of the neural tube and thus 
delays posterior neuropore closure (Brook et al., 1991). Delayed closure results in the 
curled tail phenotype, whereas a more prolonged delay prevents closure of the 
posterior neuropore leading to spina bifida. At the 27-29 somite stage, expression of 
RAR/3 in the hindgut and RARy in the tail bud is reduced (Chen et al., 1995). The 
expression of RAR/3 is known to play a key role in cell proliferation, and down- 
regulation of RAR/3 may therefore be responsible for the cell proliferation defect and 
the subsequent growth imbalance in caudal tissues.
6.1.3 Prevention of NTDs in curly tail
Treatment of curly tail embryos with folic acid or other folate derivatives was found to 
have no effect on the incidence of NTDs (Seller, 1994b). Methionine was also found to 
be ineffective at reducing the frequency of NTDs and methionine loading did not result 
in an aberrant rise in homocysteine (Seller, 1994b;Van Straaten et al., 1995). 
Furthermore, the deoxyuridine suppression test detected normal folate cycling in curly 
tail embryos (Fleming and Copp, 1998). Thus, the curly tail mouse has become known 
as a genetic model of “folate resistant” NTDs. It is believed to represent a possible 
paradigm for the sub-category of human NTDs which do not respond to folic acid (Van 
Straaten and Copp, 2001), estimated at around 30-50% (Wald et al., 2001).
Folate-resistant NTDs in the curly tail mouse can be prevented by inositol. A possible 
role for inositol in NTDs was first suggested by studies in which embryos were cultured 
in the absence of specific vitamins during cranial neurulation. Deficiency of inositol 
caused exencephaly, and among mouse strains tested, curly tail was particularly 
sensitive with 71% of embryos developing exencephaly (Cockroft et al., 1992). This 
study prompted Greene and Copp (1997) to test whether inositol might prevent spinal 
NTDs, and they showed a significant protective effect both in embryo culture and 
following maternal supplementation. Since myo-inositol treatment causes up- 
regulation of RAR/3 (Greene and Copp, 1997), it has been hypothesised that inositol 
rescues closure defects by promoting cell proliferation (Van Straaten and Copp, 2001). 
Future studies of cell proliferation in caudal tissues would provide further clarification.
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6.1.4 Genetics of curly tail
Genetic analysis has demonstrated that the ct mutation is semi-dominant since the 
curly tail phenotype is occasionally observed in heterozygous embryos (Gruneberg, 
1954), whilst the penetrance of the NTD phenotype is highly influenced by genetic 
background (Embury et al., 1979;Neumann et al., 1994). For example, crosses to 
other strains have resulted in low NTD frequencies (Neumann et al., 1994). Indeed, 
three modifier loci have been identified which affect the incidence of NTDs (Letts et al., 
1995;Neumann et al., 1994).
The lack of a wild-type control strain, and the fact that all mice in the curly tail colony 
are homozygous, poses potential difficulties in interpreting the results of research on 
curly tail NTDs. To overcome this problem, a partially congenic strain has been 
developed by successive backcrosses which is wild-type (SWR strain) throughout the 
mapped ct genetic region on chromosome 4 but shares more than 90% of its genetic 
background with the curly tail stock (G. Pavlovska and A.J. Copp, unpublished). The 
curly tail congenic mouse model (+/+cf) will be used as a control strain herein.
6.1.5 Investigating folate deficiency in curly tail
As described previously in chapter 5, folate-deficiency increased the incidence of 
exencephaly in folate-sensitive splotch embryos. It was originally hypothesised that 
folate deficiency would not affect the incidence of exencephaly among curly tail 
embryos, owing to the resistance of spina bifida in this model to the preventative 
effects of folic acid. However, unexpectedly this study demonstrates that induction of 
folate deficiency by dietary intervention does cause a high frequency of exencephaly in 
so-called “folate-resistant” curly tail embryos. Also, for the first time, dietary folate 
deficiency is shown to cause NTDs in wild-type congenic embryos and remarkably 
these folate-deficiency induced NTDs can be rescued with exogenous inositol. This 
study has used the analytical techniques described in chapter 5 to investigate the 
biochemical effects of the diets on folate and one-carbon metabolism in curly tail dams 
and their embryos. Overall, the findings of this study emphasise that folate deficiency 
increases the risk of cranial NTDs and suggest that inositol may be a possible therapy 
to use in conjunction with folic acid to prevent more cases of NTDs.
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6.2 Materials and Methods
6.2.1 Mouse diets
Female ct/ct and +/+cf mice were maintained on five different diets, as described in 
section 5.2.1, to test the effects of folate deficiency on developing embryos. To 
attempt to rescue the NTDs, pregnant mice on the folate deficient diet received an 
interperitoneal (i.p.) injection of 10 mg FA / kg body weight (FD+FA), 20 mg FA / kg 
body weight (FD++FA) or 400 mg myo-inositol (Ml) / kg body weight (FD+MI) at 
embryonic days E7.5, E8.5, E9.5 and E10.5 (Table 6.1).
Diet f a
1 (mg/kg)
Inositol
(g/kg)
SST
(mg/kg)
Supplements 
(per kg body weight)
Description
FD+FA ! X 1.9 10 10 or 20 mg folic acid Folate-deficient Diet + FA
FD+MI X 1.9 10 400 mg myo-inositol Folate-deficient Diet + Ml
Table 6.1. Details of the experimental diets fed to female curly  tail mice. Supplements 
were administered by i.p. injection at embryonic day E7.5, E8.5, E9.5 and E10.5.
6.2.2 Metabolite Analysis
Maternal blood was collected and plasma prepared as described in section 2.4. 
Maternal whole blood and embryonic folate concentrations were measured by the 
Lactobacillus casei microbiological assay using the method described in section 2.10.5. 
Total plasma homocysteine levels (free + protein-bound) were determined by the 
method described in section 2.4. Plasma homocysteine and whole blood folate were 
able to be measured in the same samples from a population of dams following 
optimisation of the blood collection method. Embryonic SAM and SAH were analysed 
in individual whole embryos as detailed in chapter 3.
6.2.3 Statistical Analysis
As described in section 5.2.3.
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6.3 Results
6.3.1 The effect of folate deficiency on maternal folate and homocysteine.
A  statistical com parison of w hole blood fo la te  and p lasm a hom ocysteine concentrations  
b etw een  ct/ct and + /+ cf dam s fed e ither diet (T ab le  6 .2 ) did not reveal any d ifferences  
b etw een  m o u se  strains indicating that the ct genetic  defect does not a ffect m aterna l 
uptake  of fo late  or m aternal hom ocyste ine m etabolism  com pared  to + /+ cr dam s.
Diet Mouse Whole Blood Folate (pg/ml) Plasma Homocysteine (pmol/L)
Model n= I Mean ± SEM n= Mean ± SEM
ND ct/ct 8 0.58 ± 0.05 7 3.53 ± 0.07
' +/+ cr 16 0.50 ± 0.03 5 3.54 ± 0.35
FD ct/ct 12 0.18 ± 0.03** 7 20.20 ± 5.32**
+/+c; 8 0.11 ± 0.02** 5 14.09 ± 4 .1 5 *
BFD ct/ct 9 ' 0.37 ± 0.01**“ 6 6.41 ± 0.46**
+/+:: 6 0.27 ± 0.07**“ 6 5.66 ± 0.08**
DFD ct/ct 10 0.19 ± 0.02** 4 13.91 ± 1.70**
+/+cr 9 ! 0.17 ± 0.02** 5 12.80 ± 3.15**
FID ’ ct/ct ~5 ! 0.11 ± 0.02**
+/+c? ~3 ' 0.09 ± 0 .0 2 ^
Table 6.2. Maternal whole blood folate and plasma homocysteine concentration 
following dietary intervention. Statistical analyses using the student t-test were between diet 
groups for each separate mouse model. FD, Folate-deficient Diet; ND, Normal Diet; BFD, 
Bacterial Folate-deficient Diet; DFD, Dietary Folate-deficient Diet; FID, Folate- and Inositol- 
deficient Diet. “  p-value < 0.02 when compared to FD group, * p-value < 0.05 when compared 
to ND group, ** p-value < 0.02 when compared to ND group.
Analysis of the effects of dietary intervention on maternal folate levels in each mouse 
model (ct/ct and +/+ct) did reveal significant changes (Table 6.2). After consumption of 
the folate-deficient diet for three consecutive weeks, ct/ct and +/+cr dams had a level 
only 22-31% of that in dams fed the normal diet (Table 6.2). Thus, whole blood folate 
levels were significantly reduced by the folate-deficient diet compared to the normal 
diet in both +/+ct (p < 0.001) and ct/ct (p < 0.001) dams. Similarly, +/+ct and ct/ct dams 
fed the dietary folate-deficient diet had a level only 33-34 % of that in dams fed the 
normal diet. In contrast, whole blood folate concentrations in the bacterial folate- 
deficient diet fed dams had only declined to 54-64% of that in dams fed the normal diet. 
Thus, the DFD reduced maternal folate to a lower level in both the ct/ct and +/+ct dams
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compared to the BFD. In ct/ct and +/+cf dams fed the folate and inositol deficient diet, 
the whole blood folate concentration was 18-19% of that in dams fed the normal diet. 
This was the lowest folate level of all the diets studied, yet statistical analysis revealed 
that inositol deficiency had no further detrimental effect on maternal folate levels 
compared to the folate-deficient diets.
Plasma homocysteine concentrations varied among the different diet groups for each 
mouse model, with the lowest levels in ct/ct and +/+cf dams fed the normal diet and 
highest levels in ct/ct and +/+cf dams fed the folate-deficient diet (Table 6.2). The ct/ct 
and +/+ct dams fed the dietary folate deficient diet and the bacterial folate deficient diet 
had intermediate homocysteine levels. Overall, as with the splotch mouse model, 
maternal biochemical analyses showed that the folate-deficient diet resulted in lowered 
maternal folate status and increased levels of homocysteine. Bacterial folate deficiency 
(BFD) was sufficient to affect maternal folate but not homocysteine levels. Dietary 
folate deficiency affected both blood folate and homocysteine but was not as effective 
as combined bacterial and dietary deficiency.
To illustrate the inverse relationship between folate and homocysteine in maternal 
mice, the blood collection method was optimised to ensure sufficient blood was 
collected from a population of ct/ct and +/+ct dams to enable the measurement of both 
whole blood folate and plasma homocysteine in a single sample. This direct 
comparison between folate and homocysteine levels for each dam sacrificed shows 
that the higher the plasma homocysteine concentration, the lower the whole blood 
folate concentration (Figure 6.1). It also demonstrates that the order of severity of each 
diet on maternal folate and homocysteine levels is FD, DFD, BFD and ND, with the 
highest homocysteine and lowest folate levels found in the FD dietary group.
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Figure 6.1. A d irect com parison o f w ho le  blood fo late and plasm a hom ocysteine levels in 
ct/ct and +/+cf dams fo llow ing dietary intervention. Each data point represents the folate 
and homocysteine level within a single blood sample collected from each dam sacrificed. FD, 
Folate-deficient Diet; ND, Normal Diet; BFD, Bacterial Folate-deficient Diet; DFD, Dietary 
Folate-deficient Diet.
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It is possible that ct/ct and +/+ct dams have a defect in folate metabolism or are unable 
to take up sufficient folate from the diet. To investigate this hypothesis maternal folate 
levels in ct/ct and +/+* dams were compared to Sp2H/+, a mutant strain previously 
shown to have no folate uptake defect (see section 5.3.1) and CD1 dams, a non­
mutant control strain assumed to have no folate-related defects. Unexpectedly, a 
comparison of maternal folate levels with Sp2H/+  and CD1 dams, revealed that whole 
blood folate concentrations in ct/ct and +/+ct dams were greater under normal dietary 
conditions (Figure 6.2). The increase in folate levels occurred in both ct/ct and +/+cf 
dams, which suggests the effect is due to the genetic background. However the 
biological significance of this finding is unclear, since under folate-deficient conditions 
the maternal folate levels were comparable between all strains (Figure 6.2).
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Figure 6.2. A com parison o f m aternal w hole blood folate levels between m ouse strains.
Values given as mean ± standard error of the mean. FD, Folate-deficient Diet; ND, Normal Diet. 
** p-value < 0.02 when compared to CD1 dams fed the normal diet (ND).
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6.3.2 The effect of folate deficiency on reproductive success
The mean number of implants per litter and the mean number of resorptions per litter 
(Table 6.3) in ct/ct dams compared to +/+ct dams were not significantly different, 
irrespective of dietary conditions (ANOVA analysis of all data groups and Holm-Sidak 
pair-wise analysis).
1 Mouse Model Diet ! No. of 
■ litters
I No. of total 
' implants
No. of implants 
per litter3
No. of resorptions 
per litter*3
ct/ct ND i 9 65 7.8 ± 0 .1 3 0.6 ± 0.17
FD i 1 4I
i  77 5.5 ± 0.53** 2.4 ± 0.43*
BFD i 6 ! 41 6.8 ± 0 .2 8 1.0 ± 0 .16”
DFD 5 33 6.8 ± 0 .2 8 2.3 ± 0 .1 7 **
+/+cr ND 7 45 6.8 ± 0.83 0.6 ± 0 .3 4
FD 7 30 4.0 ± 0.91** 2.3 ± 0.72**
BFD 4 21 5.3 ± 0.74 1.0 ± 0.17
DFD 4 ! 23 5.8 ±0 .31 2.0 ± 0 .3 8
Table 6.3. Resorption rates and number of implants in curly tail litters following dietary 
intervention. Implants were defined as visible sites of implantation either occupied by a viable 
embryo or where a resorption had occurred. Resorptions were defined as the absence of a 
viable embryo at a visible site of implantation. Values are given as mean value ± standard error 
of the mean. Statistical analyses were between diet groups for each separate mouse model. 
FD, Folate-deficient Diet; ND, Normal Diet; BFD, Bacterial Folate-deficient Diet; DFD, Dietary 
Folate-deficient Diet. ** p-value < 0.02 when compared to ND, * p-value < 0.05 when 
compared to ND, *’ p-value < 0.02 when compared to DFD.
Following dietary intervention it was apparent by observation that the folate deficient 
(FD) diet affected reproductive success in both mouse strains. Statistical analysis 
confirmed that the mean number of resorptions per litter under folate-deficient 
conditions was significantly greater than under normal dietary conditions in both ct/ct 
(Holm-Sidak; p < 0.001) and +/+cf (Holm-Sidak; p = 0.006) litters (Table 6.3). 
Correlating with this finding, the mean number of implants per litter under folate- 
deficient conditions was significantly decreased compared to normal dietary conditions 
in ct/ct litters (Holm-Sidak; p < 0.001) and +/+cf (Holm-Sidak; p = 0.004) (Table 6.3). To 
conclude, folate deficiency significantly affected reproductive success in both ct/ct and 
+/+ct litters. Since this effect was seen in both ct/ct and +/+ct mouse models it suggests
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that it is due to the closely similar genetic background, rather than an effect of the 
folate-deficient diet on all strains as reproductive success was unaffected in splotch 
litters (see section 5.3.2).
In both ct/ct and +/+cf, the dietary folate-deficient and the bacterial folate-deficient diets 
increased the number of implants per litter and decreased the number of resorptions 
per litter compared to the folate deficient diet (Table 6.3). However, the reproductive 
success was not as great as that recorded in the normal diet group. Statistical analysis 
demonstrates that the number of resorptions per ct/ct litter in the dietary folate-deficient 
diet was significantly less than for the normal diet (DFD vs. ND; Holm-Sidak p = 0.001) 
and, the bacterial folate-deficient diet (DFD vs. BFD; Holm-Sidak p = 0.004). The 
same trend was apparent in +/+cf litters but the results were not significant. Thus, it 
appears that the removal of folate from the diet had a worse effect on reproductive 
success than the addition of an antibiotic which eliminates bacterial sources of folate.
6.3.3 The effect of folate deficiency on the incidence of NTDs in curly tail 
embryos
The incidence of NTDs among both ct/ct and +/+cf litters at E10.5-E11.5 was noted 
following dietary intervention (Table 6.4). Unexpectedly, group-wise statistical analysis 
demonstrated that there was a significant effect of diet on the incidence of exencephaly 
in both ct/ct litters (Chi-square; p < 0.001) and +/+cf litters (Chi-square; p = 0.001).
The folate-deficient diet caused a significant increase in the incidence of exencephaly 
among ct/ct embryos, compared to ct/ct embryos in the normal diet group (Fishers 
Exact; p < 0.001). The folate-deficient diet also caused a significant number of +/+ct 
embryos to develop exencephaly, compared to +/+ct embryos from the normal diet 
group (Chi-square pair-wise; p < 0.001). In both ct/ct and +/+ct, the extent of increase 
in NTD incidence was approximately 30%.
The incidence of exencephaly among embryos from the dietary folate-deficient and the 
bacterial folate-deficient litters was lower than among the folate deficient litters for both 
ct/ct and +/+ct litters. With the exception of ct/ct embryos from the bacterial folate- 
deficient diet group, the incidence of exencephaly was greater among embryos from 
the dietary folate-deficient and the bacterial folate-deficient litters in comparison to 
embryos from the normal diet group. Statistical analysis demonstrated that among ct/ct 
embryos the rate of exencephaly on the bacterial folate-deficient diet was significantly 
lower than for the folate-deficient diet (BFD vs. FD; Chi-square pair-wise; p < 0.001)
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and, the d ietary fo late-defic ien t d iet (B F D  vs. D FD ; Fishers Exact; p = 0 .0 1 ). T h e  s am e  
trend w as ap p aren t in + /+ cf litters but the results w ere  not statistically significant. Thus, 
it ap p ears  that the  rem oval of fo la te  from  the  diet has a  g rea te r e ffect on th e  incidence  
of exen cep h a ly  than the addition o f antibiotic, which e lim inates bacterial sources of 
fo late.
Diet ct/ct +/+cr
n= EX n= EX
ND 48 9 (19) 42 0 (0 )
FD 74 42 (57)** 38 11 (2 9 )"
BFD 36 2 (6)**” 17 1 (6)
DFD 23 10 (44) 15 2 (1 3 )
Table 6.4. Incidence o f exencephaly (EX) in curly tail em bryos fo llow ing dietary  
in tervention. Data are presented as number of embryos with percentage in each treatment 
group in parentheses. Exencephaly is defined as failure of cranial neural tube closure in 
embryos that have completed embryonic turning and have 18 or more somites. This is based 
on the observation that cranial neural tube closure, in vivo, is completed by the 18 somite stage 
in ct/ct and +/+cf embryos in our laboratory. FD, Folate-deficient Diet; ND, Normal Diet; BFD, 
Bacterial Folate-deficient Diet; DFD, Dietary Folate-deficient Diet. Statistical analyses using the 
Chi-square or Fisher’s exact test were between diet groups for each separate mouse model. ** 
p-value < 0.02 when compared to ND, ** p-value < 0.02 when compared to FD, " p-value < 0.02 
when compared to DFD.
6.3.4 Analysing the development of curly tail embryos
A fter collecting litters from  th e  fo la te -d efic ien t diet groups, it b ecam e ap p aren t that the  
diet a ffected  the  size and d eve lo p m en ta l progression of both ct/ct and + /+ ct em bryos  
(F igure  6 .3 ). Fo late-defic ien t em bryos from  E 11 .5  litters resem bled  em bryos from  
norm al E 1 0 .5  litters. F urtherm ore , there  w as w ide variation in th e  s ize  and  
d eve lo p m en t of fo late-defic ien t em bryos within a litter. Thus, som e fo la te - deficient 
em bryos w e re  severe ly  growth and developm entally  restricted, w hile  others w e re  less  
affected . In the m ost severe ly  affected  em bryos, m orphological fea tu res  w ere  
indistinct, w hich m ay ind icate that the em bryo w as dying and w ould have  been  
resorbed if d eve lo p m en t w as allow ed  to continue.
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Figure 6.3. E11.5 curly tail embryos following dietary intervention. (A) ct/ct embryo (38 
somites) with a curled tail from the normal diet group (ND), (B) a typical litter of ct/ct embryos 
(10-32 somites) from the folate deficient diet (FD) group, (C) +/+* embryo (40 somites) with a 
normal, straight tail from the normal diet (ND) and (D) a typical litter of +/+* embryos (24-32 
somites) from the folate deficient diet (FD) group. Solid arrow indicates exencephaly, defined as 
persistently open cranial neural folds in an embryo with 18 or more somites. Scale bar is 
equivalent to 1mm.
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A direct comparison of embryos from the bacterial and dietary folate-deficient diet 
groups (Figure 6.4) clearly shows that the removal of dietary folate, as opposed to the 
removal of bacterial folate, had the greater effect on embryonic growth and 
developmental retardation.
Figure 6.4. E10.5 curly tail embryos from the bacterial folate deficient (BFD) and dietary 
folate deficient diet (DFD) groups. (A) ct/ct embryos and (B) +/+ct embryos from the bacterial 
folate deficient diet (BFD) group. (C) ct/ct embryos and (D) +/+ct embryos from the dietary folate 
deficient diet (DFD) group. Solid arrow indicates exencephaly. Scale bar is equivalent to 1 mm 
at x2.0 magnification.
In order to make quantitative comparisons of embryonic developmental progression 
and size, the number of somites and the crown-rump length were recorded for E10.5 
embryos (Table 6.5). Under normal dietary conditions (ND), the mean number of 
somites and crown-rump length was comparable between E10.5 ct/ct and +/+ct 
embryos. Similarly, under folate-deficient conditions, there was no significant 
difference in the mean number of somites and crown-rump length between E10.5 ct/ct 
compared to +/+ct embryos. Indeed developmental stage differences are not 
consistently observed between ct/ct and +/+* embryos (N. Greene, personal 
communication).
Group-wise statistical analysis demonstrated significant variation in the size and 
development of E10.5 embryos following dietary intervention (ANOVA; p < 0.001). At 
E10.5, ct/ct and +/+rt embryos from the folate-deficient diet group were significantly
182
smaller and developmentally retarded than ct/ct and +/+ct embryos from the normal diet 
group (Table 6.5). Folate deficient ct/ct and +/+cf embryos were also significantly 
smaller and developmentally retarded compared to ct/ct and +/+cf embryos from DFD 
and BFD litters (Table 6.5). Thus, the combined elimination of both dietary and 
bacterial forms of folate in the folate deficient (FD) diet has an acute effect on 
embryonic growth and development.
Diet n= Crown-rump length (mm) n= Number of somites
ct/c t
ND 31 3.84 ± 0.11** 24 31.3 ± 1.06**
f d 27 ' 2.17 ± 0.07** 34 19.5± 0.84**
BFD 34 3.73± 0.09** 34 28.4 ± 0.44**
DFD 13 ; 3.20 ± 0.18****
,
13 26.4 ± 0.87****
+ /+cr
ND 16 3.85 ± 0.12** 16 29.5 ± 0 .5 3 **
FD 14 2.19 ± 0.04** 10 15.9 ± 2.26**
BFD 8 3.47 ± 0.21** 8 26.9 ± 1.17**
DFD 7 3.90 ± 0.25** 7 28.9 ± 1.16**
Table 6.5. Development of E10.5 curly  ta il embryos following dietary intervention. Values 
given as mean ± standard error of the mean. FD, Folate-deficient Diet; ND, Normal Diet; BFD, 
Bacterial Folate-deficient Diet; DFD, Dietary Folate-deficient Diet. Statistical analyses using the 
Student t-test were between diet groups for each separate mouse model. ** p < 0.02 when 
compared to FD, ** p < 0.02 when compared to ND (Holm-Sidak).
The bacterial folate-deficient diet did not significantly affect embryonic growth and 
development compared to the normal diet group, in either ct/ct or +/+cf (Table 6.5). In 
comparison, E10.5 ct/ct embryos from the dietary folate-deficient diet group were 
significantly smaller and developmentally retarded compared to E10.5 ct/ct embryos 
from the normal diet group (Table 6.5). However, +/+cf embryos from the dietary folate- 
deficient diet group, were comparable in size and development to +/+cr embryos from 
the normal diet group (Table 6.5). Notably, the DFD diet also had a greater effect on 
the incidence of exencephaly in ct/ct embryos than in +/+ctembryos (Table 6.4).
6.3.5 The effect of folic acid and inositol supplementation on the 
incidence of NTD in folate deficient curly tail embryos.
The potential for NTD prevention of maternal supplemental folic acid (FA) and myo­
inositol (Ml) was tested in folate-deficient ct/ct and +/+cf embryos. Thus, dams fed the 
folate-deficient diet were treated with folic acid (at 10 or 20 mg/kg body weight) or myo­
inositol (at 400 mg/kg body weight) at E7.5, E8.5, E9.5 and E10.5 by i.p. injection. The 
dams were sacrificed at E11.5 or E13.5 and the embryos collected for analysis. A 
dose of 10 mg/kg body weight was chosen as this was found to prevent NTDs in 
splotch (Fleming and Copp, 1998).
In comparison to un-supplemented ct/ct embryos from the folate-deficient diet group 
(FD), low dose supplemental folic acid (10 mg/kg) did not reduce the incidence of 
exencephaly (Table 6.6). Doubling the dose of folic acid to 20 mg/kg did reduce the 
incidence of exencephaly in ct/ct embryos, but the change was not significant (p = 
0.523). The incidence of exencephaly among offspring of folate-deficient ct/ct dams 
supplemented with myo-inositol was higher than in unsupplemented folate-deficient 
litters but this was not statistically significant (Fishers Exact; p = 0.118, Table 6.6). 
Among folate deficient +/+ct embryos, the incidence of exencephaly following 
supplementation with 10 mg/kg folic acid was reduced but this was not significant 
(Fishers Exact; p = 0.303). Unexpectedly, none of the folate- deficient +/+cf embryos 
receiving myo-inositol supplementation developed NTDs (Fishers Exact; compared to 
FD, p = 0.011, compared to ND, p = 1.00).
Supplement ct/ct +/+c‘
n= EX n= EX
ND 61 9 (1 5 ) 42 0 (0 )
FD i 82 42 (52) 38 11 (29)
FD+FA (10 mg/kg) | 8 5 (63) 17 2 (1 2 )
FD+FA (20 mg/kg) ; 11
I
4 (3 6 ) -
FD+MI (400mg/kg)
! 7 6 (86) 18 0 (0)**
Table 6.6. Incidence of NTDs in folate deficient curly tail embryos following dietary 
supplementation with folic acid (FA) or myo-inositol (Ml). Data are presented as number of 
embryos with percentage in each treatment group in parentheses. ND; Normal Diet, FD; Folate 
deficient Diet, FD+FA; Folate deficient Diet + Folic Acid; FD+MI; Folate deficient Diet + Myo­
inositol. Embryos were treated at E7.5, 8.5, 9.5, 10.5 (AM) and collected at E10.5 (PM) or 
E 11.5. ** p < 0.02 when compared to FD.
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To determine if supplemental folic acid or myo-inositol reduced the developmental 
delay caused by folate-deficiency, the number of somites at E11.5 was recorded. At 
E11.5, ct/ct and +/+cr embryos from the folate-deficient diet group (FD) were 
significantly developmentally retarded (p<0.001 and p<0.001, respectively) compared 
to embryos from the normal diet group (ND), as at E10.5 (Table 6.7). Among both 
folate deficient ct/ct and +/+cf embryos, neither supplemental folic acid (FD+FA) nor 
myo-inositol (FD+MI) had a significant effect on embryonic development compared to 
unsupplemented folate deficient (FD) embryos.
: Diet ct/ct +/+cr
n= ; Number of somites n= Number of somites
ND 25 ! 41.0 ± 0.47 14 36.9 ± 1.37
FD 33 ' 27.7 ± 0.95** 17 27.6 ± 1.33**
FD+FA 17 ' 29.2 ± 2 .7 9 ** 8 27.8 ± 3.01**
FD+MI 6 25.8 ± 2.20** 13 30.3 ± 1.93**
Table 6.7. Developmental stage of folate deficient curly tail embryos at E11.5 following 
dietary supplementation with folic acid and myo-inositol. Values given as mean ± standard 
error of the mean. ND; Normal Diet, FD; Folate deficient Diet, FD+FA; Folate deficient Diet + 
Folic Acid; FD+MI; Folate deficient Diet + Myo-inositol. **p < 0.001 when compared to ND 
(Holm-Sidak). Of note when comparing somite matched embryos, folate-deficient embryos are 
of a younger gestational age.
At E13.5, exencephalic and curled tail phenotypes were observed in both folic acid and 
myo-inositol supplemented ct/ct embryos (Figure 6.5). It also became apparent that 
the folate-deficient diet was affecting eye development in exencephalic embryos. 
Thus, embryos appeared to have smaller eyes compared to litter mates, and moreover, 
in some cases one eye was more affected than the other eye. At E13.5, no neural tube 
defects were observed in myo-inositol supplemented folate-deficient +/+cr embryos 
(Figure 6.6). Eye defects were also apparent in supplemented and unsupplemented 
folate deficient +/+cf embryos. Hence, it appears the folate deficient diet is affecting 
eye development in both mouse strains.
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Figure 6.5. Folate-deficient E13.5 curly tail embryos supplemented with folic acid and 
myo-inositol. (A) Folate-deficient ct/ct embryos supplemented with folic acid (FD+FA) and (B) 
folate-deficient ct/ct embryos supplemented with myo-inositol (FD+MI). Solid arrow indicates 
the exencephaly. Scale bar is equivalent to 1 mm.
A B
Figure 6.6. Folate-deficient E13.5 congenic curly tail embryos supplemented with myo­
inositol. (A) right, and (B) left view of folate deficient +/+cf embryos supplemented with myo­
inositol (FD+MI). Scale bar is equivalent to 1 mm. Solid arrow indicates eye defects.
Mouse Model Diet No. of litters No. of embryos 
per litter
No. of resorptions 
per litter
ct/ct FD 6 0.75 ± 0.42 5.75 ± 1.28
FD+FA 3 5.33 ± 0.88 1.00 ±0 .5 8
FD+MI 5 2.20 ± 0.37 3.00 ± 1.22
+/+CT FD 4 0.33 ±0.21 5.50 ± 0.56
FD+FA 2 2.50 ± 1.50 1.00 ±0 .0 0
FD+MI 1 3.00 ± 0.00 0.00 ± 0.00
Table 6.8. Survival of curly tail embryos following dietary intervention. Resorptions were 
defined as the absence of a viable embryo at a visible site of implantation. Values are given as 
mean per litter ± standard error of the mean. FD; Folate deficient Diet, FD+FA; Folate deficient 
Diet + Folic Acid; FD+MI; Folate deficient Diet + Myo-inositol.
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Under normal dietary conditions +/+cr embryos survive into adulthood (N.Greene, 
personal communication). Likewise, since the ct gene mutation is not embryonic lethal, 
the majority of ct/ct embryos will survive until birth despite the presence of any NTDs. 
Following the collection of litters later in gestation, it became apparent that very few 
folate-deficient embryos were surviving past E13.5 (Table 6.8). The high number of 
visible resorptions suggested that embryos were dying around this stage of 
development (Table 6.8). Preliminary analysis of survival in supplemented litters 
suggests that both folic acid and myo-inositol both improved embryonic survival as 
shown by the increased mean number of live embryos at E13.5 and the reduction in 
the mean number of visible resorptions (Table 6.8). However, further work is required 
to clarify this finding.
6.3.6 Investigating the relationship between growth and development in 
curly tail embryos.
To attempt to understand further how the folate-deficient diet affected embryonic 
growth and development during neurulation, embryos that had developed under folate- 
deficient and normal dietary conditions were analysed for protein content and somite 
number, as a measure of growth and development, respectively. Upon observation 
there appears to be a disturbance of the relationship between growth and development 
for both ct/ct and +/+cr (Figure 6.11). Thus, folate-deficient ct/ct and +/+ct embryos 
appear to have a lower protein content compared to ct/ct and +/+cf embryos from the 
normal diet group with the same number of somites (Figure 6.11).
To investigate whether somite-matched folate-deficient embryos are growth retarded 
compared to embryos from the normal diet group, the mean growth (protein content) of 
embryos that had developed between 22-26 somites was compared (Table 6.9). 
Somite-matched folate-deficient ct/ct embryos had a lower protein content than ct/ct 
embryos from the normal diet (ND) group, however statistical analysis demonstrated 
that this difference was not significant (Student t-test; p = 0.422). A greater effect on 
growth was observed in the congenic wild-type strain, for which somite-matched folate 
deficient +/+c! embryos had statistically lower protein content than +/+cf embryos from 
the normal diet group (Student t-test; p < 0.001). Thus, folate deficient +/+ct embryos 
are smaller for both gestational age and developmental stage. This is in contrast to the 
splotch NTD mouse model where the folate deficient diet did not affect the relationship 
between growth and development such that embryos with the same number of somites 
had the same protein content.
187
A•  FD  
O ND O
o o
o
o  °
S  ,  ^ o
C °  •£  •
°  •  ^
Q[  „ ' °  O °
•  e
9 ° o e °  " ° -
•  o •
10 15 20 25 30 35
N um ber of somites
B
•  FD  
O ND
CD
E
c
0)
o
cl
o 
8 8 
•  •  •
o
°  8 8
o o
o
0
o
0
0 •
. * 8  * •
o
o
O o 
8
o
10 15 20 25 30 35
N um ber of somites
Figure 6.7. The relationship between em bryonic grow th (protein content) and 
developm ent (som ite num ber) for ct/ct (A) and +/+cf (B) em bryos from  the fo late deficient 
(FD) and norm al (ND) d iet groups. Each dot represents a single embryo.
188
Mouse Model Diet n= Mean number 
of somites
Protein Concentration 
(mg/ml)
ct/ct ND 14 28.4 3.47 ± 0.76
FD 10 29.1 2.69 ± 0.36
+ /+ - ND 19 29.7 3.05 ± 0 .1 9
FD 13 28.0 1.40 ± 0.08**
Table 6.9. A comparison of protein content between somite-matched ct/ct and +/+cf 
embryos following dietary intervention. Protein concentration was determined in 
homogenised embryos which had developed between 22-26 somites. Values are given as 
mean ± standard error of the mean. ND; Normal Diet, FD; Folate deficient Diet. ** p-value < 
0.02 when compared to ND. Of note, FD and ND embryos were of the same gestational age.
6.3.7 Investigating embryonic folate levels following dietary intervention.
As with the splotch mouse model (chapter 5), the total folate (monoglutamylfolate + 
polyglutamylfolate) content and concentration was determined in ct/ct and +/+cf 
embryos collected at E10.5-E11.5 and the data has been compared between embryos 
with the same number of somites.
Mouse
Model
Diet n= Somite Range 
(average)
Total Folate Content 
(pg folate / embryo)
[Folate]
(ng folate / mg 
protein)
ct/ct ND 10 26-32 (28.4) 8822 ± 1527 28.8 ± 3.20
FD 14 26-32 (29.1) 5065 ± 4 1 9 ** 23.4 ± 5.58
FD+FA 7 26-32 (28.1) 8877 ± 975* 56.0 ± 7 .9 1 **
+/+"•' ND 18 26-32 (29.8) 8244 ± 445 30.1 ± 3.31
FD 13 26-32 (28.0) 5184 ± 282* 37 3 ± 1 27
FD+FA 5 26-32 (28.8) 13675 ± 598**** 49 0 ± 9.18** 1
Table 6.10. Embryonic folate levels in ct/ct and +/+cr embryos at the same developmental 
stage (the same number of somites). Folate values are given as mean ± standard error of 
the mean. ND; Normal Diet, FD; Folate deficient Diet, FD+FA; Folate deficient Diet + Folic Acid. 
* p < 0.05 when compared to ND, ** p < 0.02 when compared to ND, * p < 0.05 when compared 
to FD, ** p < 0.02 when compared to FD. Of note when comparing somite matched embryos, 
folate-deficient embryos are of an older gestational age.
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In ct/ct embryos that had developed between 26 and 32 somites (Table 6.10), the 
folate-deficient diet caused a significant decrease in the folate content per embryo 
(Holm-Sidak; p = 0.007) compared to ct/ct embryos from the normal diet (ND) group. 
However, the folate concentration was not significantly affected by the folate-deficient 
diet (p = 0.719). Likewise, the folate-deficient diet significantly reduced the folate 
content (p = 0.05) in +/+cf embryos that had developed between 22 and 26 somites 
compared to +/+cf embryos developing under normal dietary (ND) conditions (Table 
6.10). The folate concentration in +/+cr embryos was also unaltered by the folate 
deficient diet (p = 0.128). Thus, it appears that the folate deficient diet restricts growth 
such that the embryo cannot grow or develop unless the required folate concentration 
is available.
Treating the folate-deficient ct/ct embryos with folic acid from E7.5 to E10.5 (FD+FA) 
led to a significant increase in folate concentration (p = 0.005). Additionally, folic acid 
treatment also significantly increased the folate content per embryo compared to folate- 
deficient embryos (p = 0.025) (Table 6.10). Treatment of folate-deficient +/+cf with folic 
acid from E7.5 to E10.5 led to a large, significant increase in folate content compared 
to +/+c? embryos from the folate-deficient diet group (p < 0.001) and the normal diet 
group (p < 0.001) (Table 6.10). There was also a significant increase in the folate 
concentration (p = 0.006) between supplemented (FD+FA) and +/+cf embryos from the 
normal diet group (ND). Thus, although folic acid supplementation did not affect 
embryonic development (number of somites; section 6.3.5), it did significantly increase 
the amount of folate per mg of protein, in both ct/ct and +/+cf embryos.
6.3.8 In-depth analysis of mono- and polyglutamylfolate levels in curly 
tail embryos
The previous section investigated how total folate levels differed between embryos of 
the same developmental stage. As described (section 1.4.1), total folate consists of 
two different forms; monoglutamylfolate and polyglutamylfolate. To illustrate how 
embryonic mono- and polyglutamylfolate content and, concentration change with 
development under different dietary conditions, the data was plotted against somite 
number (Figures 6.8 - 6.11).
In ct/ct embryos, as expected, the monoglutamylfolate content of an embryo increased 
as the embryo developed under normal dietary conditions, presumably since a larger 
and more developed embryo has a greater folate content (Figure 6.8A). Under folate- 
deficient conditions, the monoglutamylfolate content also increased with development
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but at a slower rate as shown by the shallower gradient of the linear regression plot. 
There was a wide variation in monoglutamylfolate content per embryo, for example 
some ct/ct embryos from the normal diet group had a monoglutamylfolate content 
similar to that of folate deficient ct/ct embryos and vice-versa. However, overall it 
appears that at all stages of development folate-deficient ct/ct embryos have a lower 
monoglutamylfolate content. Statistical analysis of the graphical data by linear 
regression (see section 5.2.3) demonstrated that the gradients of the graph lines were 
not significantly different (p = 0.390).
When folate levels were normalised to protein content (Figure 6.8B), the 
monoglutamylfolate concentration in ct/ct embryos was found to decrease with 
development under normal dietary conditions. Thus, there was less folate available per 
mg of tissue suggesting a rapid turnover of folate metabolites at this stage of 
development. Alternatively, rapid growth occurs which outpaces the rate of folate 
uptake. Under folate-deficient conditions, the embryonic monoglutamylfolate 
concentration also decreased with development but the gradient of the graph line was 
shallower, presumably due to the lower growth rate. At some stages of development, 
for example the 15-18 somite stage, ct/ct embryos from the normal diet group seem to 
have a higher folate concentration compared to ct/ct embryos from the folate-deficient 
diet group. In contrast, when comparing embryos with 25 or more somites, ct/ct 
embryos appear to have the same folate concentration irrespective of dietary 
conditions. Statistical analysis by linear regression demonstrated that the gradients of 
the graphs are not significantly different (p = 0.400)
It was next determined how the embryonic polyglutamylfolate content and 
polyglutamylfolate concentration changes with developmental progression (as indicated 
by somite number) among ct/ct embryos (Figure 6.9). As expected, the 
polyglutamylfolate content of ct/ct embryos increased with developmental stage under 
normal dietary conditions such that larger embryos contained more folate (Figure 
6.9A). Under folate-deficient conditions, the data points representing ct/ct embryos 
from the two dietary groups overlay and it is not possible to distinguish one group from 
another. However, the shallower gradient of the linear regression plot for the folate- 
deficient diet group appears to suggest that the polyglutamylfolate content is increasing 
at a slower rate such that there is a smaller increase in polyglutamylfolate content with 
somite development compared to normal dietary conditions. Statistical analysis by 
linear regression (see section 5.2.3) demonstrated that the gradients of the two graphs 
are significantly different (p-value = 0.010).
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Figure 6.8. Comparison of monoglutamylfolate levels in ct/ct embryos from the folate 
deficient (FD) and normal diet (ND) groups. The graphs show (A) monoglutamylfolate content 
per embryo (pg of folate/embryo) vs. somite number, and (B) embryonic monoglutamylfolate 
concentration (ng folate/mg protein) vs. somite number. • , ct/ct embryos from the folate 
deficient group; • ,  ct/ct embryos from the normal diet group, Each data point represents an 
individual embryo. The p-value represents the significance of the difference between slopes of 
the graph lines (see section 6.2.3).
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Figure 6.9. Comparison of polyglutamylfolate levels in ct/ct embryos from the folate 
deficient (FD) and the normal diet (ND) groups. The graphs show (A) polyglutamylfolate 
content per embryo (pg of folate/embryo) vs. somite number, and (B) embryonic 
polyglutamylfolate concentration (ng folate/mg protein) vs. somite number. • ,  ct/ct embryos 
from the folate deficient group; • , ct/ct embryos from the normal diet group, Each data point 
represents an individual embryo. The p-value represents the significance of the difference 
between slopes of the graph lines (see section 6.2.3).
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Under normal dietary conditions, the polyglutamylfolate concentration appears to 
remain constant with development among ct/ct embryos (Figure 6.9B) whilst under 
folate deficient dietary conditions, the polyglutamyfolate concentration decreases with 
development. Statistical analysis by linear regression showed that the difference 
between the gradients of these graphs is significant (p = 0.018). The 
polyglutamylfolate concentration in normal diet group ct/ct remains approximately IQ- 
20 ng/mg protein, perhaps at a concentration which is sufficient to enable embryonic 
growth and development. Unexpectedly, folate-deficient ct/ct embryos with between 
15-19 somites have a higher polyglutamylfolate concentration, compared to ct/ct 
embryos developing under normal dietary conditions. It is difficult to understand why 
ct/ct embryos have a greater polyglutamylfolate concentration under folate deficient 
dietary conditions. Possibly this represents a scavenging mechanism which enables 
ct/ct embryos to accumulate folate under limiting conditions. Also, somite-matched 
folate-deficient ct/ct embryos are older than normal diet ct/ct embryos therefore they 
would have had more time to accumulate folate stores.
Analysis of mono- and polyglutamylfolate in +/+cf embryos reveals identical patterns to 
those described in ct/ct embryos (Figure 6.10 and 6.11). Monoglutamylfolate content 
increases with development in both diets yet, at all stages of development folate- 
deficient +/+cf embryos have lower monoglutamylfolate content (Figure 6.10A). 
However, the gradients of the graph lines are not significantly different (p = 0.840). The 
monoglutamylfolate concentration decreases with development yet there is little 
variation between dietary groups (Figure 6.10B). Indeed, statistical analysis 
demonstrates that the gradients of the graph lines are not significantly different (p = 
0.743). The polyglutamylfolate content increases with development under normal 
dietary conditions, but increases at a slower rate in folate-deficient +/+ct embryos 
(Figure 6.11 A). The gradients of the graph lines were found to be significantly different 
(p = 0.010). Finally, the polyglutamylfolate concentration remains constant under 
normal dietary conditions, yet decreases with development under folate-deficient 
conditions due to the high polyglutamylfolate concentration in folate-deficient +/+ct 
embryos with 12-18 somites (Figure 6.11B). The difference in the gradients of the 
graph lines was highly significant (p < 0.001). The comparable relationships between 
folate and growth/development in ct/ct and +/+ct suggests that the ct mutation does not 
affect embryonic folate status.
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Figure 6.10. Comparison of monoglutamylfolate levels in +/+cf embryos from the folate 
deficient (FD) and normal diet (ND) groups. The graphs show (A) monoglutamylfolate content 
per embryo (pg of folate / embryo) vs. somite number, and (B) embryonic monoglutamylfolate 
concentration (ng folate / mg protein) vs. somite number. • ,  +/+cf embryos from the folate 
deficient group, • ,  +/+* embryos from the normal diet group, Each data point represents an 
individual embryo. The p-value represents the significance of the difference between slopes of 
the graph lines (see section 6.2.3).
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Figure 6.11. Comparison of polyglutamylfolate levels in +/+c< embryos from the folate 
deficient (FD) and normal diet (ND) groups. The graphs show (A) polyglutamylfolate content 
per embryo (pg of folate / embryo) vs. somite number, and (B) embryonic polyglutamylfolate 
concentration (ng folate / mg protein) vs. somite number. • , +/+cf embryos from the folate 
deficient group, • , +/+cf embryos from the normal diet group, Each data point represents an 
individual embryo. The p-value represents the significance of the difference between slopes of 
the graph lines (see section 6.2.3).
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Using the graphs it was then possible to compare mono- or polyglutamylfolate 
concentrations and content between embryos of the same gestational age, 
remembering that folate deficient embryos would have developed fewer somites. For 
example, when comparing embryos at E10.5, ct/ct and +/+ct embryos from the folate 
deficient (FD) diet group have developed approximately 16-20 somites, whilst ct/ct and 
+/+cf embryos from the normal diet (ND) group have developed approximately 30-31 
somites (Table 6.5). Thus the data presented would show (Figure 6.8A, 6.9A, 6.10A 
and 6.11A), due to the positive gradient of the graph line, that at the same gestational 
age ct/ct and +/+cf embryos from folate deficient diet group had a lower folate content 
than ct/ct and +/+cf embryos from normal diet group. Whereas, due to the negative 
gradients of the graph lines, at the same gestational age ct/ct and +/+ct embryos from 
folate deficient diet group had a higher folate concentration than ct/ct and +/+cf embryos 
from normal diet group of the same gestational age (Figure 6.8B, 6.9B, 6.1 OB and 
6.11B).
6.3.9 The abundance of SAM and SAH in curly tail embryos
The effect of different maternal diets and supplements on the levels of SAM and SAH 
in neurulation-stage embryos was measured using the method described in Chapter 3 
(also described in Burren et al., 2006). Following dietary intervention and 
supplementation, a series of embryos from both ct/ct and +/+ct litters were collected, 
and levels of SAM and SAH were analysed in individual whole embryos. Levels were 
normalised to protein concentration and correlated with developmental stage to show 
the abundance of embryonic SAM and SAH (Table 6.11), and the SAM/SAH ratio 
(Figure 6.12), in each dietary group.
SAM and SAH levels were quantified at E10.5 (24-32 somites) and E11.5 (38-42 
somites) in ct/ct and +/+cf embryos from the normal diet group and at E11.5 (22-34 
somites) in ct/ct and +/+cf embryos from the folate-deficient diet group. E11.5 embryos 
from the folate-deficient diet group are somite-matched to E10.5 embryos from the 
normal diet group. SAM and SAH levels were also analysed in E11.5 folate-deficient 
embryos treated with folic acid (19-34 somites) and myo-inositol (34-37 somites).
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Mouse
Model
Diet n= Age Somite
Number
SAM
(nmoles/mg
protein)
SAH
(nmoles/mg
protein)
Ratio
SAM/SAH
ct/ct ND 15 E10.5 29.5 ± 0.32 3.27 ± 0 .25“ 0.044 ± 0.004 76 ± 3.4“
ND 9 E11.5 39.8 ± 0.76 2.84 ± 0 .27“ 0.027 ± 0.003 119 ± 19.4
FD 16 E11.5 29.8 ± 1.40 5.18 ± 0.75 0.045 ± 0.012 195 ± 4 2 .7
FD+FA 9 E11.5 27.6 ± 0.80 2.98 ± 0.24“ 0.025 ± 0.004 152 ± 37.8
+/+cr ND 15 E10.5 29.2 ± 0.54 2.81 ± 0.18“ 0.031 ± 0 .002“ 93 ± 5 .4“
| ND1 8 E11.5 38.6 ± 0.86 1.98 ± 0 .08“ 0.025 ± 0 .001“ 79 ± 2 .8 “
I
FD 7 E11.5 32.6 ± 1.23 4.01 ± 0.47 0.116 ± 0.030 48 ± 10.7
FD+FA 5 E11.5 31.4 ± 0.87 2.44 ± 0 .16“ 0.029± 0.003“ 87 ± 5.9“
| i FD+MIi 5 E11.5 33.2 ± 1.93 2.38 ± 0 .16“ 0.030 ± 0 .008“ 104 ± 25 .6“
Table 6.11. SAM and SAH abundance determined by LC-MS/MS in curly tail embryos (all 
genotypes included) from each maternal treatment group. SAM and SAH were quantified in 
individual whole embryos. Values are given as mean ± standard error of the mean. ND; Normal 
Diet, FD; Folate deficient Diet, FD+FA; Folate deficient Diet + Folic Acid; FD+MI; Folate 
deficient Diet + Myo-lnositol. “  p < 0.02 when compared to FD.
In embryos at E10.5 and E11.5 under normal dietary conditions, SAM levels were 
typically 75-105 fold, and 80-90 fold higher than SAH levels in ct/ct and +/+ct embryos, 
respectively, at these stages of development. In ct/ct embryos, the concentration of 
SAM and SAH decreased as gestation progressed leading to an increase in the ratio of 
SAM/SAH since the concentration of SAH decreased by the greatest extent. In +/+cf 
embryos, the concentration of SAM and SAH also decreased as gestation proceeded, 
however this led to a decrease in the ratio of SAM/SAH since the concentration of SAM 
decreased to a greater extent compared to SAH.
When comparing ct/ct embryos from the normal diet group (ND) to embryos from the 
folate-deficient diet (FD) at the same developmental stage (with the same mean 
number of somites), the folate-deficient diet significantly increased the concentration of 
SAM (p = 0.007), yet the concentration of SAH remained unchanged. Overall, the 
increase in SAM caused a significant increase in the ratio of SAM/SAH (p = 0.005) in 
folate-deficient ct/ct embryos compared to ct/ct embryos developing under normal 
dietary conditions. Similarly, when comparing ct/ct embryos from the normal diet group 
(ND) to embryos from the folate-deficient diet (FD) at the same gestational age (with 
different mean number of somites), there was a significant increase in the 
concentration of SAM (p = 0.004) whilst there was no significant change in the
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concentration of SAH. The ratio of SAM/SAH, when comparing embryos of the same 
gestational age, appeared to be increased by the folate-deficient diet but this change 
was not significant. Thus, overall, the folate-deficient diet caused an increased 
concentration of SAM in ct/ct embryos. Treatment of folate-deficient ct/ct embryos with 
folic acid daily from E7.5-E10.5 (FD+FA) significantly decreased the concentration of 
SAM (p = 0.007) to near ND levels, when compared to folate-deficient embryos (FD) of 
the same gestational age.
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Figure 6.12. SAM/SAH ratio in ct/ct and +/+ct embryos from each maternal treatment 
group. Values are given as mean ± standard error of the mean. ** p < 0.02 when compared to 
FD.
When comparing +/+ct embryos from the normal diet group (E10.5) to embryos from the 
folate-deficient diet (E11.5) at the same developmental stage (with the same mean 
number of somites), the folate-deficient diet significantly increased the concentration of 
SAM (p<0.001) and SAH (p<0.001). Overall, the extent of change in the concentration 
of SAH was greatest, causing a significant decrease in the ratio of SAM/SAH (p < 
0.001) in folate deficient +/+ct embryos compared to +/+ct embryos developing under 
normal dietary conditions. Similarly, when comparing +/+cf embryos from the normal
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diet group (E11.5) to embryos from the folate-deficient diet (E11.5) at the same 
gestational age (with different mean number of somites), there was a significant 
decrease in SAM/SAH ratio due to a significant increase in the concentration of SAH (p 
< 0.001). To conclude, the folate-deficient diet caused a significant increase in the 
concentration of SAH in +/+cf embryos. Treatment of folate-deficient +/+ct embryos with 
folic acid daily from E7.5-E10.5 (FD+FA) significantly decreased the concentration of 
SAM (p < 0.001) and SAH (p < 0.001), when compared to folate-deficient embryos 
(FD) of the same gestational age, leading to an increase in the SAM/SAH ratio since 
the concentration of SAH was reduced by a greater extent. Similarly, treatment of 
folate-deficient +/+cf embryos with myo-inositol from E7.5-E10.5 (FD+MI) significantly 
increased the ratio of SAM/SAH, due to a significant decrease in the concentration of 
SAH (p < 0.001).
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6.4 Conclusions and Discussion
6.4.1 Folate deficiency affects maternal folate metabolism
The folate-deficient diet, which was deficient in both bacterial and dietary forms of 
folate, effectively changed maternal folate status, causing decreased whole blood 
folate levels and increased homocysteine in both ct/ct and +/+ct dams. Elimination of 
either bacterial folate or dietary folate alone reduced maternal folate and increased 
homocysteine, but not to the same extent as combined elimination of dietary and 
bacterial folate.
In this study an inverse relationship was apparent between maternal folate and 
homocysteine levels. Homocysteine and folate levels are usually inversely related and 
dietary supplementation with folate lowers homocysteine levels, restores normal folate 
levels (Daly et al., 2002) and reduces the risk for NTDs (Wald et al., 1991). In mice, a 
recent study by Ernest et al. also demonstrated an inverse relationship between folate 
and homocysteine levels in both wild-type and Crooked tail mutant embryos following 
dietary intervention (Ernest et al., 2006).
A comparison of folate levels with other available strains, such as the splotch NTD 
mouse model and the CD1 wild-type mouse strain, revealed that folate levels are 
higher in ct/ct and +/+cf dams. Furthermore, plasma homocysteine concentrations were 
also considerable higher in ct/ct and +/+cf than those measured in splotch dams, both 
under folate-deficient and normal dietary conditions (compare Table 5.2 and 6.2). Since 
elevated folate and homocysteine were recorded in both ct/ct and +/+ct dams this 
appears to suggest that the effect is due to the genetic background of the ct strain. 
Hyperhomocysteinemia has previously been demonstrated in ct/ct mice when 
compared to wild-type C57BI/6 mice, under both folate-deficient and normal dietary 
conditions (Tran et al., 2002). These authors also reported that homocysteine:cysteine 
ratios were comparable between ct/ct and C57BI/6 mice indicating that similar 
proportions of total homocysteine are metabolised through the transsulfation pathway 
to cysteine. Therefore, it is likely that the differences in homocysteine levels reflect 
differences in the remethylation cycle.
6.4.2 Folate deficiency causes NTDs in curly tail embryos
This study has shown that folate deficiency by maternal dietary intervention increases 
the incidence of exencephaly in curly tail embryos. This was unexpected since the 
curly tail mutant is well-known as a model of neural tube defects which are not
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preventable by folic acid (Seller, 1994b). Thus, it was presumed that folate deficiency 
would not affect the incidence of NTDs. It is important to note, however, that folic acid 
was administered to prevent spina bifida in curly tail embryos (Seller, 1994b) whilst in 
this study folate deficiency was shown to cause exencephaly. Another striking finding 
from this study was the occurrence of exencephaly in congenic embryos, +/+ct, which 
have a 95% similar genetic background to the curly tail mutant but are wild-type at the 
ct gene locus (Van Straaten and Copp, 2001). To date, the occurrence of NTDs in this 
control mouse strain has not been reported, however +/+ct embryos have a longer 
posterior neuropore compared to somite-matched wild type CD1 mouse embryos (Prof. 
Andrew J. Copp, personal communication).
Tran et al. investigated the incidence of NTDs among ct/ct embryos following dietary 
intervention (Tran et al., 2002). Four synthetic diets were used (a folate-deficient diet, 
a folate/choline-deficient diet, a folate-supplemented diet and a control diet) but none of 
these significantly affected the incidence of NTDs. However, it is unclear whether the 
folate-deficient diet used by Tran et al. effectively caused folate deficiency since 
changes in maternal folate and homocysteine were not reported. In addition, the 
minimum level of folic acid was 0.3 mg/kg and no antibiotic was added to eliminate 
bacterial folate. After eight weeks on the folate/choline-deficient diet homocysteine 
levels in ct/ct dams had increased twofold, in association with increased liver S- 
Adenosylhomocysteine and decreased SAM/SAH ratios. In contrast, in the present 
study, the folate-deficient diet resulted in four-fold and sixteen-fold increases in 
homocysteine level in ct/ct and +/+ct, respectively. The changes in homocysteine 
reported by Tran et al. could be due to the lack of choline in this diet as reducing 
dietary choline would further increase homocysteine abundance as less betaine would 
be available for the remethylation of homocysteine to methionine catalysed by BHMT. 
Nonetheless, their work suggests that altered homocysteine metabolism is present in 
ct/ct mice and could therefore contribute to the pathogenic mechanism of the ct defect.
The folate-deficient diet caused exencephaly in +/+ct embryos which are wild-type at 
the ct locus: +/+cf embryos have normal expression levels of the curly tail gene, 
believed to be Grhl3 (Ting et al., 2003). This implies that risk factors in the genetic 
background play a role in the susceptibility of cranial neural tube closure to folate- 
deficiency. Indeed, the presence of at least three modifier loci that influence the 
incidence of NTD have been demonstrated in the curly tail mice (Neumann et al., 
1994). In this study, aside from the increased SAM concentration in ct/ct embryos, all 
other metabolic effects induced by the folate deficient diet were comparable 
highlighting the important involvement of the genetic background on NTD risk.
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The risk of exencephaly in the SELH/Bc mouse inbred strain is determined by a 
combination of genes across about 3 loci and dietary content (Harris and Juriloff, 
2005;Juriloff et al., 2001). Thus, exencephaly seems to occur when the timing of 
cranial neural tube elevation is delayed beyond the critical threshold time due to multi­
factorial traits (Gunn et al., 1995;MacDonald et al., 1989). Perhaps ct background 
modifier genes affect the timing of cranial neural tube closure but not enough to cause 
the development of cranial NTDs under normal dietary conditions. Whereas under 
folate deficient conditions neural tube closure could be delayed beyond the critical 
threshold time causing exencephaly. This could be due to the embryonic growth and 
developmental retardation observed under folate deficient conditions. Significantly, 
that the incidence of exencephaly increased to the same extent in ct/ct and +/+ct 
embryos under folate deficient conditions indicating that the same underlying 
mechanism may be responsible.
6.4.3 Folate deficiency causes retardation of embryonic growth and 
developmental progression
As I found in the splotch mouse (Chapter 5), the folate-deficient diet retarded 
embryonic growth and development. However, in contrast to splotch, the fundamental 
relationship between growth and development was altered in curly tail such that 
embryonic growth was affected to a greater extent than developmental progression. 
Thus, ct/ct and +/+ct embryos from the folate-deficient group with a particular number of 
somites have a lower protein concentration than ct embryos from the normal diet 
group. This raises the possibility that the effect of folate deficiency in the ct/ct and +/+ct 
embryos reflects an effect of growth retardation as opposed to a specific defect in 
neurulation. Furthermore, the folate-deficient ct/ct and +/+ct dams appear to have a 
poor reproductive outcome again suggesting the folate-deficient diet may have caused 
severe growth retardation perhaps due to interaction with genetic risk factors in the ct 
background. It appears unlikely that there is generalised toxicity as the folate-deficient 
diet (FD) did not increase the incidence of neural tube defects in wild-type CD1 or 
folate-responsive cited-2 null embryos (personal communication, Dr. Nicholas Greene).
Previous studies of curly tail mice demonstrated that treatment with the DNA synthesis 
inhibitor, hydroxyurea, on embryonic day 8 increased the proportion of curly tail mice 
affected with exencephaly, whilst hydroxyurea reduced the incidence of NTDs when 
administered on day 9, mainly through a reduction of posterior neuropore defects 
(Seller and Perkins, 1983). Similar effects were also produced in curly tail mice with 
two other inhibitors of DNA synthesis; mitomycin C and 5-fluorouracil (Seller,
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1983;Seller and Perkins, 1986). Work by Copp et al. identified a cell-type specific cell 
proliferation abnormality that affects ct/ct embryos developing spinal NTDs but not their 
normally developing littermates (Copp et al., 1988a). In a subsequent study spinal 
NTDs in ct/ct embryos were prevented by growth retardation caused by food 
deprivation (Copp et al., 1988b). Thus, it appears that growth retardation exacerbates 
the incidence of exencephaly yet prevents the development of spinal NTDs in curly tail 
mice. It was not possible to study spinal neural tube closure in folate-deficient curly tail 
embryos due to poor reproductive success and survival. However, with further work it 
would be possible to study the effects of a less severe folate-deficient diet on spinal 
neurulation, such as the bacterial or dietary folate deficient diets.
6.4.4 Folate deficiency affects embryonic one-carbon metabolism
In this study, embryonic folate status was analysed in ct/ct and +/+ct embryos under 
normal and folate deficient dietary conditions. Mean folate content was reduced by the 
folate deficient diet in both ct/ct and +/+ct embryos that had developed between 26-32 
somites. In contrast, the folate concentration was unchanged yet folate-deficient 
embryos took longer to reach this developmental stage. This suggests that the total 
folate concentration needs to remain at a critical level to enable development to 
proceed. Therefore to maintain the critical embryonic folate concentration under folate 
limiting conditions, growth and development must be slowed. Treatment with 
exogenous folic acid dramatically increased the folate content and concentration, and 
reduced the incidence of cranial NTDs. However, improvement in embryonic growth 
and development was not detectable although this may become apparent later in 
development. Alternatively, a subtle effect on proliferation, perhaps in certain tissues, 
allowed neural tube closure to occur.
I found that mono- and polyglutamylfolate content increased with development. This 
was expected, since more developed embryos would be larger and therefore would be 
envisaged to contain more folate. Under normal dietary conditions the embryonic 
monoglutamylfolate concentration decreased with development, as seen in splotch 
embryos (chapter 5), indicating that at this stage of development the demand for 
monoglutamylfolate exceeds the supply. The same relationship was observed under 
folate-deficient conditions, however younger embryos had a lower monoglutamylfolate 
concentration compared to embryos from the normal diet such that the rate of decrease 
was less.
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Under normal dietary conditions, the polyglutamylfolate concentration remained 
constant as development proceeded. Thus, it seems that in order to meet the demand 
for biologically active polyglutamylfolates, monoglutamylfolates are being taken up into 
the cell, resulting in the observed decrease in monoglutamylfolate concentration with 
development. Under folate-deficient conditions, the polyglutamylfolate concentration 
decreases with development perhaps because there is less monoglutamylfolate 
available for uptake. However, confusingly, the polyglutamylfolate concentration is 
greater in folate-deficient embryos with 15-20 somites compared to embryos from the 
normal diet. This might represent a type of scavenging mechanism whereby the 
embryo, under folate limiting conditions, is able to store excess folate for future 
development. Uptake of folate by placental receptors might be more efficient when 
maternal folate concentrations are decreased (Antony, 2007). Alternatively, since 
folate deficient embryos took longer to develop, they would have had longer to uptake 
folate. However, it is not clear why development does not proceed in folate-deficient 
embryos despite the high polyglutamylfolate concentration.
In splotch and +/+ct embryos, the folate deficient diet (FD) led to a decrease in the ratio 
of SAM/SAH primarily due to high embryonic concentrations of SAH. Unexpectedly, in 
ct/ct embryos the response was reversed such that the SAM/SAH ratio increased due 
to high concentrations of SAM in folate deficient ct/ct embryos. To explore this 
difference further, work could be undertaken to analyse concentrations of SAM and 
SAH in younger embryos to determine the metabolic response as neurulation occurs. 
The analysis of SAM and SAH levels in E10.5 folate deficient ct/ct embryos may 
provide further insight, although embryos would need to be pooled due to their small 
size.
PCMT-null mice, which lack a protein methyltransferase enzyme required for protein 
repair, have a high SAM/SAH ratio (Kim et al., 1997). This raises the possibility that 
ct/ct mice may have a methylation defect whereby they are unable to utilise available 
methyl groups causing a build-up of SAM. In such a model, the build-up of SAM is 
envisaged to be minimal under normal dietary conditions whereas under folate deficient 
conditions the build-up of SAM becomes apparent. This could explain why folic acid 
treatment does not rescue NTDs in ct/ct embryos as exogenous folic acid may not 
rescue the methylation defect. Alternatively, this may suggest that folate-sensitive 
NTDs do not have defects in the methylation cycle.
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6.4.5 Alternative mechanisms underlying folate-sensitive NTDs in curly 
tail embryos
The evidence appears to suggest that growth and developmental retardation play a 
role in the mechanism underlying folate-sensitive NTDs in curly tail embryos. However, 
other possible mechanisms should also be considered. Reduced expression of RARp 
in the hindgut endoderm of affected ct/ct embryos correlates with decreased cell 
proliferation in this tissue (Chen et al., 1994). Administration of retinoic acid or inositol 
leads to an upregulation of RARfi expression in the hindgut endoderm. This is 
proposed to enhance cell proliferation in the hindgut and rescue spinal NTDs, although 
a causative link has not been proven (Chen et al., 1994;Greene and Copp, 1997). 
Further work analysing RARfi expression and cell proliferation in folate-deficient curly 
tail embryos could provide insight into the mechanism underlying folate-sensitive 
cranial NTDs. However, the mechanisms of closure in the cranial and caudal regions 
involve different developmental processes and the mechanism of NTD induction may 
differ (Copp, 2005). Despite this, the biochemical pathways of retinoic acid and 
homocysteine have some overlap, since homocysteine has been shown to disrupt 
conversion of retinal to the biologically active derivative, retinoic acid, in vitro. Limpach 
et al. proposed this as the mechanism of NTD induction by homocysteine in avian 
embryos (Limpach et al., 2000). Thus, higher levels of homocysteine in ct/ct and +/+ct 
mice could potentially affect NTD risk by blocking the synthesis of retinoic acid.
6.4.6 How does myo-inositol rescue cranial NTDs in +/+ct embryos?
The protective effect of inositol on spinal neurulation in ct/ct embryos depends on 
activation of protein kinase C (PKC), which stimulates cell proliferation in the hindgut 
(Cogram et al., 2004;Greene and Copp, 1997). Evidence suggests that neurulation 
does not depend on PKC activation, and defective closure in curly tail embryos is 
unlikely to result from a deficiency in specific PKC isoforms (Cogram et al., 2004). 
Rather exogenous inositol is thought to operate through the stimulation of the cell cycle 
that requires activation of specific PKC isoforms In particular, the activity of PKC 
isoforms pi and y are essential, whereas other isoforms (a, pll, 5, £) were found to be 
dispensable (Cogram et al., 2004). Over-expression of PKCpI has been shown to lead 
to increased proliferation of aortic endothelial cells (Rosales et al., 1998) and vascular 
smooth muscle cells (Yamamoto et al., 1998). Thus, if a similar effect is present in 
cranial tissues, activation of PKCpi by myo-inositol may increase cell proliferation and 
enable cranial neural tube closure to occur. Further studies are required to determine 
whether the protective action of inositol in folate deficient +/+ct involves stimulation of 
proliferation via the activation of PKC isoforms.
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In this study, myo-inositol treatment did not rescue cranial NTDs in folate deficient ct/ct 
embryos. Perhaps the unknown underlying mechanism could have been further 
disrupted due to combination of the ct mutation and the folate deficient diet, as 
indicated by the increased frequency of NTDs. Therefore, higher doses of m yo 
inositol, or the use of D-c/7/roinositol may be required especially since it has been 
proven that the prevention of NTDs in ct embryos by inositol is dose- and epimer- 
dependent (Cogram et al., 2002). Indeed, higher doses of folic acid were required to 
rescue folate deficiency in ct/ct embryos. Higher doses of myo-inositol, or the use of D- 
chiro-Inositol, may also prevent the severe and frequent NTDs observed in Grhl3-/- 
mice (Ting et al., 2003).
6.4.7 Summary
In humans, folic acid has been shown to be highly effective at preventing NTDs and 
sub-optimal folate status is a known risk factor for NTD. Although folic acid also has a 
preventative action in some mouse models, there are several models, including the 
curly tail mutant mouse, in which the NTDs are resistant to rescue by FA therapy. This 
has led to the term “folate-resistant” NTD. Here I show that folate deficiency by 
effective dietary intervention causes exencephaly in “folate-resistant” curly tail 
embryos. I also demonstrate for the first time that dietary folate deficiency causes 
NTDs in wild-type congenic embryos and show that these folate-deficient NTDs can be 
rescued by inositol. Our findings highlight that folate deficiency increases the risk of 
NTD and suggest that inositol may be a possible therapy to use in conjunction with folic 
acid to prevent more cases of NTDs.
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CHAPTER 7
Developing a quantitative method for the analysis of 
mvo-inositol in urine by liquid chromatography tandem
mass spectrometry.
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7.1 Introduction
7.1.1 Myo-Inositol
/Wyo-lnositol (Ml), a six-carbon sugar alcohol is the most abundant of the nine epimers 
of inositol in cells. As a constituent of living cells, inositol plays a important role in 
numerous biological functions. Free inositol is implicated in the control of cell volume 
and cell osmolarity (Kane et al., 1992). Inositol phosphates and their derivatives are 
involved in signalling pathways (Shears, 1998;Stuart et al., 1993), arachidonic acid 
metabolism, the modulation of membrane bound enzymes, mediation of 
transmembrane passage (Holub, 1986), cytoskeletal and endomembrane regulation 
(Dove and Michell, 2000) and insulin signalling (Alessi and Downes, 1998). In addition, 
many proteins are bound to the cell surface by a glycosylphosphatidylinositol (GPI) 
linkage (Brown and Waneck, 1992;Hooper, 1997;Low, 1989).
Human adults consume approximately 1 g of inositol per day in different biochemical 
forms (Holub, 1986). Free inositol is actively transported across the intestinal wall by a 
mechanism dependent on sodium and energy, a process that can be inhibited by 
glucose (Caspary and Crane, 1970;Scalera et al., 1991). Inositol is transported in 
blood plasma at a concentration of approximately 30 pM in healthy subjects (Clements 
and Diethelm, 1979). Circulating free inositol is taken up by most tissues by a 
membrane-associated sodium-dependent inositol co-transporter that is temperature- 
dependent, energy-dependent and saturable (Holub, 1986;Kane et al., 1992). Inositol 
penetrates the blood-brain barrier poorly (Spector, 1988;Spector and Lorenzo, 1975), 
such that a dose of 12 g for 7 days is needed to raise cerebrospinal fluid levels in 
human subjects by 70% (Levine et al., 1993). Several mammalian tissues such as the 
testes, mammary gland, brain, liver and kidney are able to synthesise inositol from 
glucose (Hooper, 1997). In particular, it is estimated that one kidney can synthesise 
approximately 2 g of inositol per day.
7.1.2 Prevention of neural tube defects by inositol
Considerable evidence has now accumulated to indicate the need and appropriateness 
of a clinical trial to assess whether inositol is capable of preventing FA-resistant NTDs 
in humans, as in mice. These several lines of evidence can be summarised as:
1. Inositol deficiency is the only ‘vitamin’ deficiency that leads to NTDs in mice 
(Cockroft, 1988;Cockroft et al., 1992).
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2. Significantly lower inositol concentration is present in the blood of mothers carrying 
NTD fetuses than in normal pregnancies (Groenen et al., 2003). The inositol:creatine 
ratio in the brain of hydrocephalic fetuses was found to be significantly lower than in 
normal fetuses (Kok et al., 2003). Hence, human NTDs may be associated with 
inositol deficiency.
3. Inositol supplementation of the NTD mutant mouse model curly tail during 
pregnancy, significantly reduces the frequency of NTDs (Cogram et al., 2002;Greene 
and Copp, 1997), a finding that has been replicated recently in another laboratory (Ting 
et al., 2003).
4. In a single case study, a woman took 0.5 g myo-inositol per day in the first trimester 
of her third pregnancy, after two previous pregnancies were terminated because of 
NTDs (she took FA in both). The third pregnancy was uneventful, and a normal baby 
was born (Cavalli and Copp, 2002). Since then four more women, all at high risk of 
NTD recurrence, have taken 0.5 g myo-inositol per day and gone on to have 
pregnancies without NTDs (Dr Pietro Cavalli, personal communication, 2005).
Inositol therapy appears safe during mouse pregnancy. Detailed pathological analysis 
of inositol-treated curly tail mice revealed no major fetal defects and no increase in fetal 
loss (Cogram et al., 2002). Treated pregnant females showed no adverse effects. 
Regarding the safety of inositol in human pregnancy, the mother who took inositol in a 
third pregnancy reported no side effects (Cavalli and Copp, 2002). Trials in adults for 
depressive pychiatric disorders (Levine et al., 1995), to improve insulin sensitivity in 
polycystic ovary syndrome (Nestler et al., 1999), and to ameliorate psoriasis in patients 
on lithium therapy (Allan et al., 2004) have all identified beneficial effects of inositol with 
no major side effects. In children, inositol has been used to treat autism (Levine et al., 
1997) and to reduce the severity of respiratory distress syndrome in premature babies 
(Hallman et al., 1992). Relatively high inositol doses have been used; up to 20 g per 
day in adults and 200 mg/kg in children. Inositol is a constituent of living cells, is 
widespread in many foods, and is an essential nutrient included in the culture medium 
of many cell lines. Thus, it seems unlikely that exogenous inositol therapy will pose a 
risk to the mother and/or embryo/fetus.
7.1.3 The PONTI (Prevention Of Neural Tube defects by Inositol) study
The PONTI study, a randomised, double blind clinical trial, has been set-up to compare 
(i) FA (folic acid) plus placebo, and (ii) FA plus Ml, for prevention of NTD recurrence.
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The aim is to evaluate the effectiveness of Ml in the context of co-administration with 
FA. Hence, a simple two-arm trial protocol has been adopted, in which all subjects 
receive identical FA supplementation at the ‘high dose’ level of 5 mg/day, typically used 
in pregnancies at risk of NTDs. The Ml dose level is set at 1 g/day. Placebo is used 
instead of Ml in the control group. Women are recruited into the trial who are planning 
a pregnancy and who have a history of one or more NTD pregnancies. 
Supplementation begins prior to conception and continues until the 12th week of 
pregnancy. Pregnancy outcome is determined by second trimester ultrasound 
scanning plus follow up of term pregnancies. Compliance is to be monitored by the 
collection of urine samples prior to trial entry, 2 weeks after trial entry and following 
conception at the first antenatal clinic.
7.1.4 Monitoring compliance
The kidneys play a major role in the regulation of plasma inositol concentration; 
besides being able to synthesise inositol, they are the primary sites of clearance. The 
kidney is the only organ containing inositol oxygenase, the rate limiting enzyme in the 
catabolism of inositol (Bry and Hallman, 1991). Clearance of inositol by the human 
kidney was found to be 1 g/day, rising to 21 g/day in cases of hyperinositolaemia. 
Thus, it was expected that the concentration of Ml in urine would be within a detectable 
range and would be a good marker of physiological changes in Ml levels. Additionally, 
PONTI trial participants would be able to collect the urine sample themselves and post 
it to the laboratory for analysis, overcoming the need to arrange blood collection.
Methods for the quantitation of Ml in urine, plasma and tissue samples have been 
developed using gas chromatography/mass spectrometry (GC-MS) (Lee and Chung, 
2006;Tetsuo et al., 1999), LC-MS (Perello et al., 2004) and LC-MS/MS (Kindt et al., 
2004;Perello et al., 2004). It is also possible to measure Ml by enzymatic assay 
(Ashizawa et al., 2000;Kouzuma et al., 2001) or by magnetic resonance imaging 
(Srinivasan et al., 2004)). Initial investigations demonstrated that the LC-MS/MS 
method described by Kindt et al. (2004) is not applicable to samples which contain 
glucose due to suppression of the myo-inositol signal. Therefore, a new method has 
been developed for the quantitative analysis of Ml by LC-MS/MS which uses a HPLC to 
separate these two metabolites. This has been applied to urine but could potentially be 
used to analyse other tissue samples which contain high concentrations of glucose, 
such as serum. In particular, the specificity of the method has been thoroughly 
investigated since inositol has the same molecular weight as other common hexose 
monosaccharides. Furthermore, the LC method was tested for its ability to separate
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other inositol epimers, which the mass spectrometer is unable to differentiate due to 
identical SRM transitions.
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Figure 7.1. Flow chart of procedures for the PONTI Study.
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7.2 Materials and Methods
7.2.1 Materials
Readily available inositol epimers (myo-, alio-, muco-, D-chiro, L-chiro- scyllo-,), 
fructose, galactose, glucose and mannose were purchased from Sigma-Aldrich 
(Dorset, UK). The internal standard, [2H6]-myo-inositol (MID6), was purchased from 
Cambridge Isotope Laboratories, Inc. (MA, USA). Solvents and water were all of HPLC 
grade (Fisher Scientific UK Ltd., UK).
7.2.2 Preparation of samples
Urine samples were purified by passing 1 ml of sample through an anion-exchange 
resin (16 mm x 5 mm pre-filled columns packed with 0.2 g of AG 1-X8 resin, Biorad). 
The column was then washed with 2 ml of distilled water and the eluted sample was 
diluted to a total volume of 5 ml prior to analysis. Sample injection volume was 40 pi.
7.2.3 Calibration and quantification
In order to quantify endogenous levels of Ml, the “calibration curve method” was 
implemented using Ml calibrators made up in a matrix of water and urine (see section 
2.12.2). To analyse urinary Ml, calibrators containing 2.5, 5, 10, 25, 50 and 100 pM of 
Ml were utilised.
7.2.4 LC-MS/MS Method
Ml was separated from other sugars with the same molecular weight on a 
SUPELCOGEL Pb (300 x 7.8 mm; 5 pm) column heated to 60 °C. The HPLC protocol 
consisted of an isocratic gradient of 95 % dH20  (HPLC grade): 5% acetonitrile over a 
40 min period. This column does not tolerate high organic content and care must 
therefore be taken to keep the mobile phase content of acetonitrile less than 10% and 
the column must not come into contact with methanol. The mass spectrometer (see 
section 2.12) was operating in negative-ion mode using the following settings: capillary 
3.75 kV, cone voltage 19 V, collision energy 19 V, cone gas flow rate 90 L/hr and 
desolvation gas flow rate 900 L/hr.
7.3 Results
7.3.1 Mass Spectra
A greater signal to noise ratio was apparent following the direct infusion of Ml and [2H6]- 
Ml into the MS/MS in negative ion mode, compared to positive ion mode. Thus MS/MS 
conditions were optimised for the predicted [M-H]* deprotonated molecule of m/z 178.8 
for Ml and m/z 184.9 for 2H6-MI (Figure 7.2). Of note, the [2H6]-MI internal standard is 
deuterated on the carbon backbone, therefore the deprotonated molecule corresponds 
to a loss of a hydrogen ([M-H]*) as opposed to a loss of deuterium ([M-D]*). Product ion 
spectra for Ml and [2H6]-MI yielded specific fragment ions of m/z 86.4 and 88.5, 
respectively (Figure 7.2). Although the most abundant product ion for Ml and [2H6]-MI 
were m/z 160.8 and 166.8, respectively, further analysis of this reaction (178.8 -> 
160.8) in urine samples demonstrated poor signal intensity, peak shape and 
reproducibility compared to the more specific reaction (178.8 -> 86.4). Thus, the final 
SRM transitions were as follows: Ml, 178.8 -> 86.4; [2H6]-MI, 184.9 88.5.
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Figure 7.2. Negative ion spectra of [M-H]* used for quantification. Molecular ions were at 
m/z 178.8 for Ml (A) and 184.9 for [2H6]-MI (B). The MS/M S conditions were optimised to favour 
the transition to major product ions at m/z 86.4 (A) and 88.5 (B).
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Since other common endogenous hexose monosaccharides have the same molecular 
weight as Ml, the specificity of the tandem mass spectrometer and selectivity of the 
HPLC method was investigated. To do this, MS/MS conditions in negative ion mode 
were optimised for the expected [M-H]' deprotonated molecular ions of m/z 179.0, 
178.8, 178.8 and 178.8 for glucose, galactose, fructose and mannose, respectively. 
Observed experimental results matched the theoretical masses (Figure 7.3). Product 
ion spectra for glucose, galactose, fructose and mannose yielded specific abundant 
fragments of m/z 88.8, 88.3, 88.3 and 88.3, respectively (Figure 7.3). The final SRM 
transitions for the five monosaccharides were; glucose, 179.0 -> 88.8; galactose 178.8 
88.3; fructose 178.8 -> 88.3; mannose 178.8 -> 88.3. Although galactose, fructose 
and mannose have identical molecular ions to Ml, the product ion of m/z 88.3 was not 
apparent in the product ion spectra for Ml. This demonstrates that tandem mass 
spectrometry is able to specifically analyse metabolites with the same molecular weight 
due to variations in fragmentation patterns.
Ml tut 'Ml«ij 1 *^*, X “*
» . , IS
V. «  SC to T to to 'a  110 130 1JC 1« '40 <60 ':c t it 'to 300 io 30 «  SO to 7C 1C SC IOC no 130 1)0 •« 'SO 160 ro 00 '90 200
Figure 7.3. Negative ion spectra of [M-H]' used to analyse potentially interfering hexose 
monosaccharides. Precursor ions were at m/z 179.0 for glucose (A), 178.8 for galactose (B), 
178.8 for fructose (C) and 178.8 for mannose (D). The collision energy was optimised to favour 
the transition to major product ions at m/z 88.8 (A), 88.3 (B), 88.3 (C) and 88.3 (D).
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In addition to the myo- form, various other endogenous and synthetic epimers of 
inositol are known. The mass spectrometer was unable to selectively determine 
epimers owing to the identical molecular ions and fragmentation ions (Figure 7.4). 
Thus, in order to quantify each inositol epimer individually an HPLC method would be 
required to resolve these metabolites based on their unique physical and chemical 
properties.
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Figure 7.4. Negative ion spectra of [M-H]' of inositol epimers. Precursor ions were at m/z 
179.2 for alio-inositol (A), 179.2 for muco-inositol (B), 179.2 for L-c/?/ro-inositol (C) and 179.2 for 
scyllo-inositol (D) and 179.2 for Ml (E). For all inositol epimers, the major product ion was at 
m/z 86.8 (A, B, C, D). The MS/MS conditions were the same as those selected for myo-inositol 
(see section 7.2.6).
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7.3.2 Chromatography
Initially, the HPLC separation method recommended by Kindt et al. was tested using a 
Metachem (Varian) Polaris Amide (2.0 x 10 mm, 5 pm) column fitted with a MetaGuard 
Polaris guard column (Metaguard Amide 5 pm, Varian) (Kindt et al., 2004). The mobile 
phase consisted of 5 mM ammonium acetate/acetonitrile (50:50, v/v) delivered at a flow 
rate of 0.2 ml/min. Final chromatographic retention times for Ml and [2H6]-MI were 
between 1.8 and 2 min. Using an aqueous standard, no significant interference was 
observed from glucose at the selected SRM for Ml (178.8 > 86.4) presumably due to 
differences in m/z of precursor and product ions.
Although glucose did not interfere with the method for normal urine, glucose is present 
at high concentrations in many other biological fluids and is often found in urine of 
diabetics. Therefore to assess the general applicability of the method, the effect of co­
elution of glucose on the intensity of the Ml signal was investigated. Co-elution of 
glucose (at concentrations typically found in serum) significantly suppressed the 
intensity of the Ml signal by approximately seven orders of magnitude (Figure 7.5). 
Thus, in order to ensure this method could later be adapted for other biological fluids 
and tissues besides urine, further work was undertaken to identify a column capable of 
separating hexose monosaccharides, to avoid signal suppression by co-elution.
T im®
Figure 7.5. Suppression of myo-inositol by co-eluting glucose. (A) 10 pM myo-inositol 
aqueous standard, (B) 10 pM myo-inositol aqueous standard plus 5 mM glucose aqueous 
standard. Vertical axes are linked.
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Kindt et al. also developed a chiral separation method that was capable of resolving 
four inositol epimers (chi romuco-,  scyllo- and myo-) using 40 minute runs (Kindt et 
al., 2004). Since this column was able to resolve inositol isomers, it was tested for its 
ability to resolve glucose and Ml to attempt to overcome signal suppression by co­
elution. To minimise costs, a guard column was purchased (Chiral-AGP Guard 4.0 x 
10 mm; 5 pm, Chromtech). Retention times for Ml and glucose were identical (0.87 
min) using a mobile phase consisting of 5 mM ammonium acetate and acetonitrile 
(50:50, v/v; flow rate 0.2 ml/min). Subsequently, aqueous standards of Ml and glucose 
were sent to Chromtech and it was confirmed by the manufacturers that the Chiral- 
AGP 150 x 4 mm (5 pm) column was not capable of resolving glucose and Ml. Thus, 
the Chiral-AGP column cannot be used to accurately quantify Ml in samples with a high 
concentration of glucose.
Several alternative columns suitable for carbohydrate analysis were then considered. 
The SUPELCOGEL Pb (300 x 7.8 mm; 5 pm) column was selected as this column was 
reported to separate glucose and Ml (Bulletin 887B, Supelco Literature, Sigma-Aldrich). 
It was also reported that this column was able to resolve galactose, fructose and 
mannose from Ml, all of which have the same molecular mass. Analysis of aqueous 
standards confirmed that this column was capable of resolving Ml, glucose, galactose, 
fructose and mannose over a 40 minute run with acceptable chromatographic peak 
shape (Figure 7.6). Importantly, the elution time of glucose and Ml were well 
separated, by 13 minutes. The ability to resolve these metabolites overcomes potential 
problems of signal suppression by high concentrations of co-eluting hexose 
monosaccharides (Figure 7.6).
The specificity of the tandem mass spectrometer for analysis of Ml was also confirmed 
by analysing a mixture of glucose, galactose, fructose, mannose and Ml, at a 
concentration of 20 pM using the SRM channel (m/z 178.8 > 86.4) selected for Ml. The 
chromatograms demonstrated that this channel was clear of interference from the other 
hexoses (Figure 7.7). Thus, interference is minimised because the product ions are 
different between the pyranoside structure of glucose, galactose, fructose and 
mannose and the hexahydrocyclohexane structure of Ml (Figure 7.7).
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Figure 7.6. Comparison of retention times (min) of four potentially interfering 
monosaccharides with myo-inositol and the internal standard, using the optimal SRM 
channel for each molecule. LC-MS/MS chromatograms obtained in SRM mode (channel 
shown in top right hand corner of each chromatogram) using the SUPELCOGEL Pb (300 x 7.8 
mm; 5 pm) column. Representative chromatograms are shown for 20 pM aqueous standards. 
Vertical axes are linked.
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As demonstrated, tandem mass spectrometry alone, without chromatographic 
resolution, could not distinguish the various inositol epimers (Figure 7.3). To determine 
if the HPLC method was capable of resolving inositol epimers, a mixture of myo- and 
D-ch/ro-inositol was analysed by LC-MS/MS. As indicated on the selected-ion 
chromatogram, this HPLC column is able to resolve these two epimers by 
approximately two minutes (Figure 7.8.).
27.27
Figure 7.8. Elution profiles of myo- and D-c/)/ro-inositol on the SUPECLOGEL Pb (300 x
7.8 mm; 5 pm) column. The retention time of 10 pm D-chiro- inositol was 27.27 and the 
retention time of 10 pM myo-inositol aqueous standard was 29.67 min. SRM transition m/z 
179.2 86.8.
Elution profiles of L-chiro, alio-, muco- and scyllo-inositol were subsequently verified 
(Figure 7.9). Two ions were apparent for scyllo-inositol; a narrow chromatographic 
peak eluting at 26 min had the highest intensity and a second broad chromatographic 
peak was apparent at 41 min. For alio-inositol, a broad chromatographic peak eluted 
at 46 min and there was a small chromatographic peak at 26 min. A single ion was 
apparent for L-chiro- and muco- inositol at 33 and 34 min, respectively. Thus all 
epimers tested, apart from muco-, could be resolved from Ml by HPLC. Of note, both 
L-chiro- and D-c/i/ro-inositol co-eluted at 27-28 min (Figure 7.8 and 7.9), indicating that 
the HPLC column was not able to resolve chiral epimers.
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Figure 7.9. Elution profiles of inositol epimers. (A) Scyllo-Inositol, (B) A//o-lnositol, (C) L- 
chiro-inositol, (D) Muco-Inositol, (E) Myo-lnositol. In each case, 10 pM aqueous standards were 
used. SRM transition m/z 179.2 -> 86.8. Vertical axes are linked.
7.3.3 Sample Preparation
Samples were prepared using the method reported by Perello and colleagues (Perello 
et al., 2004) whereby the urine was passed through an anion-exchange resin which 
retains ionic compounds and elutes neutral metabolites such as myo-inositol. In 
extracted urine, a prominent ion was apparent eluting at 29 min which matched the 
retention time of the aqueous Ml standard (Figure 7.10). Several other earlier eluting 
ions were apparent in the extracted urine sample at low intensity using the SRM 
transitions for Ml. The retention times do not match the retention times of the inositol 
epimers tested. Perhaps these ions correspond to other inositol epimers that were not
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tested. Alternatively, Ml may be bound to other molecules which could alter the 
chromatography, yet the bond between these molecules may break in the ion source 
such that it appears as free Ml. Indeed inositol forms many derivatives with 
phosphates and sugars. Of note, when Ml is added to the urine prior to extraction the 
intensity of the ion at 29 min increased, whilst the intensity of the smaller ions did not 
change, thus confirming that the ion at 29 min corresponds to free Ml in urine.
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Figure 7.10. Analysis of m yo-inositol in a urine sample. (A) 20 pM Ml, (B) prepared urine 
sample comprising 1 ml of urine passed through an anion-exchange column (AG 1-X8) with an 
injection volume of 40 pi. Vertical axes are linked.
7.3.4 Linearity and Precision
The internal standard, [2H6]-MI, was used for the quantification of Ml. Calibration curves 
made up in dH20  and urine, were linear throughout a concentration range of 2.5-50 pM 
(Figure 7.11). The coefficient of linear correlation (r2) was 0.999 and 0.999 for myo­
inositol in aqueous and urine samples, respectively, thus demonstrating that the 
method developed was suitably linear for quantification purposes.
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Figure 7.11. Calibration curves of peak-area ratios plotted against myo-inositol 
concentration. Calibrators were made up in (A) dH20  and, (B) urine with 10 pmol/L of M ID6 
(internal standard) added to each sample. Ml data points correspond to 0, 2.5, 5, 10, 25 and 50 
pM. Each sample was run in triplicate (n=3).
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Preliminary experiments to determine the precision of the proposed LC-MS/MS method 
were performed with 2.5, 10 and 25 pM of Ml made up in dH20  and urine. All samples 
contained 10 uM of the internal standard, [€H3]-MI. Overall, intra-assay coefficients of 
variation (CVs) ranged from 1.33 to 4.92 % and inter-assay CVs ranged from 5.49 to
13.4 % for the analysis of Ml aqueous standards (Table 7.1). Intra-assay coefficients of 
variation (CVs) ranged from 6.95 to 14.1 % and inter-assay CVs ranged from 4.39 to
10.3 % for the analysis of Ml in urine.
Sample Spiked 
concentration 
added (pM)
Precision
Ml
Mean concentration 
(pM ±SD)
CV (%)
Aqueous 2.5 Intra-assay (n=8) 2.83 ± 0 .1 3 4.51
Aqueous 10 Intra-assay (n=8) 10.97 ± 0 .5 4 4.92
Aqueous 25 Intra-assay (n=8) 27.04 ± 0.36 1.33
Urine 2.5 Intra-assay (n=8) 2.81 ± 0.40 14.14
Urine 10 Intra-assay (n=8) 9.54 ± 0.66 6.95
Aqueous 2.5 Inter-assay (n=7) 2.72 ± 0.36 13.4
Aqueous 10 Inter-assay (n=7) 10.21 ± 0 .6 6 6.42
Aqueous 25 Inter-assay (n=6) 26.12 ± 1.43 5.49
Urine 10 Inter-assay (n=8) 10.21 ± 1 . 0 5 10.26
Urine 25 Inter-assay (n=8) 24.49 ± 1.08 4.39
Table 7.1. Inter- and Intra-assay precision of the LC-MS/MS method for aqueous and 
urine samples. The precision was determined by repeated assay of standard aqueous 
solutions and urine samples, spiked with 0, 2.5, 10 or 25 pM of myo-inositol. CV, coefficient of 
variation.
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7.4 Conclusion and Discussion
Evidence has accumulated to suggest that inositol, in combination with folic acid, may 
prevent more cases of NTDs than folic acid alone. Thus, the PONTI study has been 
set-up to evaluate the benefit of inositol for the prevention of recurrent NTDs. In order 
to monitor patient compliance the method developed in this chapter will be used to 
quantify Ml in urine. Liquid chromatography tandem mass spectrometry was the 
method of choice since it combines the specificity of tandem mass spectrometry with 
the selectivity of liquid chromatography providing enhanced sensitivity, accuracy and 
high throughput.
In this study, it has been demonstrated how tandem mass spectrometry is able to 
differentiate between molecules with the same molecular mass such as glucose, 
fructose, mannose and myo-inositol due to variations in product ion masses, which 
ultimately gives rise to different SRM transitions. Similarly, the LC-MS/MS method 
reported by Kindt et al. also demonstrated that myo-inositol and other hexose 
monosaccharides have different fragmentation patterns (Kindt et al., 2004). In 
contrast, Perrello et al. used LC-MS to quantify Ml by monitoring m/z = 198, which 
corresponds to the Ml adduct with ammonium cation, an abundant pseudo molecular 
ion (Perello et al., 2004). Unlike tandem mass spectrometry, LC-MS is unable to 
differentiate between metabolites with the same molecular weight.
Despite the specificity of tandem mass spectrometry, results from this study show that 
simultaneous elution of glucose with Ml considerably suppresses the signal for Ml by 
approximately seven orders of magnitude. Thus, in order to analyse Ml in tissue 
samples such as serum with a high concentration of glucose, an LC column would be 
required to separate the two metabolites. Monosaccharide analyses are a challenge 
for chromatography due to the diversity of compounds with chemical and physical 
properties only differing slightly. Hence, HPLC separations depend on differences in 
conformation, configuration and bonding. In resin-based SUPELCOGEL columns, 
carbohydrates elute in descending order of molecular size with monosaccharides last 
(Bulletin 887B, Supelco Literature, Sigma-Aldrich). The pores in the resins exclude 
polysaccharides and larger oligosaccharides, which elute first. Smaller di- and 
monosaccharides enter the pores, interact with the counter-ions and are more strongly 
retained. The lead-form resin in SUPELCOGEL Pb columns provides the highest 
resolution and best selectivity for monosaccharides. It was confirmed in this study that 
the SUPELCOGEL Pb column is capable of resolving glucose, galactose, fructose, 
mannose and Ml over a 40 min run time. Therefore these metabolites will enter the
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mass spectrometer at different times thereby overcoming signal suppression by co­
eluting metabolites.
The LC-MS method reported by Perello et al. also achieved successful resolution of Ml 
and glucose using an Aminex HPX-87C column (Perello et al., 2004). In contrast, the 
LC-MS/MS method developed by Kindt et al. to quantify Ml in rat brain tissue using LC- 
MS/MS did not resolve myo-inositol and glucose, although this may not be a problem in 
tissues were the concentration of glucose is minimal (Kindt et al., 2004). In healthy 
persons, urine glucose concentration is minimal, however, it can be present at high 
concentration in diabetics. Participants involved in the PONTI study may have 
undiagnosed diabetes which could interfere with the quantification of myo-inositol. 
More importantly, it is hoped that in the future this method could be adapted for other 
tissues such as serum and whole mouse embryos to aid other research projects.
Kindt et al. reported the use of a novel chiral LC-MS/MS method, using the Chiral-AGP 
column (ChromTech), to resolve myo-inositol from other endogenous inositol epimers 
including chiro-, muco- and scyllo-inositol (Kindt et al., 2004). Their analysis of rat 
brain homogenate revealed that myo-inositol was the only major inositol component 
present in this tissue. In the present study, the SUPELCOGEL Pb column used was 
able to resolve scyllo-, alio- and chiro-inositol from myo-inositol, but muco-inositol had 
the same retention time as myo-inositol. Furthermore the SUPELCOGEL Pb column 
used in this study is considerably cheaper than the Chiral-AGP column used by Kindt 
et al (Kindt et al., 2004). Published data on inositol epimers in urine concluded that the 
two major components are myo- and chiro-inositol (Kennington et al., 1990). However, 
the urine sample analysed in this study appeared to contain only myo-inositol although 
analysis of more urine samples is required.
In order to monitor Ml levels in urine, it will be necessary to determine creatinine 
concentration. Creatinine is a waste product of creatine and creatine phosphate, which 
are important energy stores in muscle. Creatinine is produced at a fairly constant rate 
by the body and is excreted from the body entirely by the kidneys. Thus, the 
measurement of creatinine in urine acts as an index of urinary excretion rate (Jackson, 
1966). This provides a means to normalise the concentration of metabolites in urine 
irrespective of how dilute or concentrated the urine sample is. Thus, Ml concentration 
will be expressed per mmol of creatinine. Creatinine will be quantified by LC-MS/MS 
using an established laboratory protocol (Dr. Kevin Mills, personal communication, 
2007).
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Further work is required to establish normal reference levels of Ml in urine and to 
determine how these levels change when single and repeated doses of Ml are 
administered. To monitor patient compliance in the PONTI study, it will be particularly 
important to assess how the 1g Ml tablets taken each day affect Ml concentrations in 
the urine of women before and during the first trimester of pregnancy. One study 
showed that the blood inositol concentration was not significantly different between 
non-pregnant and pregnant women in the first, second and third trimesters (Quirk and 
Bleadale, 1983). However, a more recent study involving a larger number of women 
demonstrated that concentrations of inositol do vary during pregnancy (Groenen et al., 
2005). Concentrations of inositol determined pre-conceptually were comparable to 
those determined at 6 weeks after last menstrual period. Later in the first trimester, the 
serum inositol concentration decreased, and then concentrations gradually increased 
after 21 weeks. Notably, inositol concentrations at 30 and 37 weeks of pregnancy were 
found to be significantly associated with birth weight.
In summary, the proposed LC-MS/MS method has been developed to specifically 
quantify Ml in urine. Initial analyses of intra- and inter-run precision demonstrated that 
the method was robust and reproducible, whilst water- and urine-based calibration 
curves were linear between 2.5 and 50 pM. With further work, this method will be used 
for monitoring patient compliance in the PONTI study and it could also potentially be 
used as a tool for investigating the prevention of NTDs in mouse models.
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CHAPTER 8
Final discussion
229
The overall aim of this thesis was to investigate metabolic effects in the cause and 
prevention of NTDs. In particular, the role of embryonic metabolism has been focussed 
upon as little is known about it, presumably due to the constraints of analytical 
methods. Thus, initially a method was developed to quantify S-adenosylmethionine 
(SAM) and S-adenosylhomocysteine (SAH) in neurulation-stage mouse (chapter 3). 
This method was then used to investigate the effect of methylation cycle intermediates 
and inhibitors, which are known to cause cranial NTDs, on the abundance of SAM and 
SAH (chapter 4). Exposure of non-mutant mouse embryos to methionine or the MAT 
inhibitors, cycloleucine and ethionine, resulted in increased SAH levels associated with 
a decreased SAM/SAH ratio. This could affect methylation of a wide range of 
biomolecules including DNA, proteins and lipids. Further studies are needed to 
investigate whether changes in SAM/SAH ratio are sufficient to induce changes in 
methylation.
Experiments carried out using whole embryo culture confirmed that the DNA 
methylation inhibitor, azacytidine, is a teratogen capable of causing cranial NTDs in 
non-mutant embryos (chapter 4). Subsequent analysis of these embryos revealed that 
azacytidine did not affect the abundance of SAM and SAH indicating that this inhibitor 
is acting downstream of the methylation and folate cycle. Thus, DNA methylation is of 
critical importance for neural tube closure and folic acid may prevent NTDs through the 
provision of methyl groups for DNA methylation patterns. Further experiments could 
investigate the effect of azacytidine on global and specific DNA methylation in cultured 
embryos. To investigate whether folic acid prevents NTDs through the provision of 
methyl groups, future studies could be undertaken to analyse the effects of 
supplementary folic acid on DNA methylation in folate-preventable NTD mouse models. 
Another approach would be to test whether folic acid is capable of preventing NTDs 
caused by exposure to azacytidine.
In order to establish whether intrinsic defects in methylation cycle metabolism in the 
embryo could be involved in determining susceptibility to NTDs, the abundance of SAM 
and SAH was quantified in human cell lines (chapter 4). The LC-MS/MS method was 
adapted for use with cell pellets and subsequently two different types of cell lines from 
NTD and control patients were analysed. The results showed that there was very little 
variation in the concentration of SAM and SAH between samples. To fully understand 
the role of one-carbon metabolism in the etiology of human NTDs, a large study is 
required linking changes in folate and methylation cycle metabolites with genotype.
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The role of folate deficiency in the cause of NTDs is not conclusive and experiments in 
this thesis have attempted to elucidate possible answers. Effective folate deficiency in 
three mouse models (splotch, curly tail and +/+cf) has been shown to increase the 
incidence of exencephaly (chapter 5 and 6, Figure 8.1). Previous dietary studies using 
non-mutant mouse models have shown that folate deficiency alone is not sufficient to 
cause NTD (Burgoon et al., 2002). Whereas, my study demonstrated that folate 
deficiency can increase the incidence of NTD in combination with a genetic 
disturbance. In splotch embryos, the combined effects of the Pax3 mutation and folate 
deficiency increases the incidence of NTDs. Whilst in curly tail and +/+cf embryos, 
modifier genes in the genetic background appear to summate with the folate deficiency 
to increase the incidence of NTDs. Of note, the expression of these modifier genes 
alone is not sufficient to cause NTDs.
One important finding from the folate deficiency studies (chapter 5 and 6, Figure 8.1) 
was that folate deficiency affects the growth and development of neurulation-stage 
embryos. Retardation of embryonic growth and development may therefore render an 
embryo more susceptible to the NTD phenotype caused by the underlying genetic 
mutation. The neuroepithelium and supporting mesenchymal cells that facilitate neural 
tube closure are rapidly proliferating cells that require high levels of folate to produce 
the required high levels of nucleotides in order to facilitate DNA replication. If 
neuroepithelial cells exhaust their internal supply of nucleotides, cellular replication will 
be slowed and the development of the neural folds retarded. Indeed previous studies 
have implicated a delay in the development of the neural folds with the formation of 
NTDs (Van Allen et al., 1993). Thus, prevention of NTDs by folic acid may involve 
stimulation of cell proliferation to overcome reduced cell proliferation or to counteract 
the increased cell death. To investigate whether folate deficiency increases the 
incidence of NTDs by retarding growth and development, analysis of cell proliferation 
and apoptosis in the neural tube is required.
Studies of maternal folate in human NTD cases have demonstrated that sub-optimal 
folate status is linked to NTD risk (reviewed in chapter 1). The data presented in this 
thesis shows how maternal folate is reduced and homocysteine is increased under 
folate deficient conditions (chapter 5 and 6, Figure 8.1). Maternal status does not 
predict that all embryos will develop NTDs, moreover, the risk of having a NTD affected 
pregnancy depends on the genotype of the embryo and the risk increases when folate 
is limiting. Studies combining polymorphic data with dietary intake in the first-trimester 
would be an interesting area in which to investigate how genetic and environmental 
factors interact to affect NTD risk in humans.
In order to understand the role of folic acid in preventing NTDs, it is useful to initially 
understand folate metabolism during neurulation. Analysis of intra- and extracellular 
folate levels was carried out in order to investigate how embryonic folate status 
changes as the neural tube is closing (chapter 5 and 6). Analysis of 
monoglutamylfolate (extracellular folate) in all mouse models suggests that the demand 
for monoglutamylfolate during neurulation exceeds placental uptake such that 
monoglutamylfolate concentration decreases with development. Thus,
monoglutamylfolate is being gradually taken up into cells where a polyglutamate chain 
is added to aid cellular retention. Under normal dietary conditions, in splotch embryos 
the polyglutamylfolate concentration (intracellular folate) decreased with development 
whilst it remained constant in ct/ct and +/+cf. Under folate deficient conditions, the 
polyglutamylfolate concentration in splotch embryos was comparable to that in splotch 
embryos from the normal diet at all stages of development. High polyglutamylfolate 
concentrations were observed in ct/ct and +/+ct embryos which decreased with 
development to the same level as that observed under normal dietary conditions. The 
high polyglutamylfolate concentrations may indicate that the fetus can parasitize 
maternal folate stores for its own requirements even in the face of maternal folate 
deficiency. Indeed several studies have reported that folate deficiency leads to up- 
regulation of folate receptors (Antony, 2007).
To test how folate deficiency affects the methylation cycle, the abundance of SAM and 
SAH was analysed (chapter 5 and 6, Figure 8.1). In splotch and +/+ct embryos, folate 
deficiency resulted in increased concentrations of SAH and a decreased SAM/SAH 
ratio. It is not clear however whether this change in the abundance of SAH affected 
methylation reactions which in turn prevented closure of the neural tube. Elevated 
SAH itself may simply be a biomarker of a disturbed methylation cycle. The 
concentration of SAM was markedly high in ct/ct and was further increased under folate 
deficient conditions. It is unclear why the metabolic response differed in ct/ct embryos, 
perhaps it suggests that the ct mutation directly affects one-carbon metabolism.
ct/ct +/+rf splotch
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i }
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Figure 8.1 A summary of findings investigating folate deficiency in splotch, curly tail 
and +/+cf mouse models (chapters 5 and 6).
Further studies are required to investigate how folate deficiency affects methylation 
reactions. There are many possible methylation targets and it would be difficult to 
investigate each one individually. However, candidates could be suggested from 
previous evidence of a role in the process of neurulation. For example, as
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demonstrated in this thesis, exposure to the DNA methylation inhibitor, azacytidine, 
causes cranial neural tube defects thus DNA methylation poses an important area for 
further investigation. Whole embryo culture would be a useful tool in investigating how 
inhibitors of other methylation reactions affect neural tube closure, for example 
inhibition of protein methylation. Apart from changes in methylation, folate deficiency 
may also affect polyamine synthesis, as SAM is the precursor of this process. The 
effect of misregulation of polyamine synthesis on neural tube closure is currently 
unknown and is therefore an area of interest for further studies.
Treatment of folate deficient embryos with folic acid demonstrated how 
supplementation rescues maternal folate deficiency, arising from insufficient folate in 
the diet (chapter 5 and 6). This adds weight to the original hypothesis proposed by 
Smithells et al. to explain the prevention of neural tube defects by folic acid (Smithells 
et al., 1976). Nowadays an important area of research is the investigation of whether 
other agents besides folic acid, can help prevent neural tube defects in humans. 
Studies in the curly tail mouse have highlighted the role of inositol in the prevention of 
NTDs (Greene and Copp, 1997) and inositol deficiency has been shown to cause 
NTDs in non-mutant mice (Cockroft et al., 1992). Remarkably, the experiments carried 
out in this thesis show how inositol can prevent NTDs in folate deficient +/+cf embryos. 
This is the first time inositol has been shown to prevent NTDs in a wild-type mouse and 
provides further evidence for the need to test whether inositoi is capable of preventing 
human NTDs.
The final chapter of this thesis describes the implementation of a clinical trial to test the 
efficacy of inositol for the prevention of recurrent NTDs, in combination with folic acid. 
In order to monitor compliance I developed a LC-MS/MS method to quantify myo­
inositol in urine. The specificity of the method was tested and the column chosen is 
shown to be capable of separating myo-inositol from other potentially interfering 
monosaccharides. Further work is required to establish normal reference levels in 
urine collected from healthy adults. Furthermore, experiments need to be undertaken 
to determine how the urinary myo-inositol concentration changes after single and 
repeated doses of 1 g/day of myo-inositol before and during pregnancy. Adapting this 
method for the analysis of myo-inositol in neurulation stage embryos will provide a 
useful tool in investigating the metabolic effects of inositol treatment in the cause and 
prevention of NTDs
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